Methods and compositions for genome editing
Delivery vehicles with multiple payloads, including nucleases and recombinases, enhance genome editing efficiency by ensuring coordinated delivery of large sequences into cells, addressing inefficiencies in current methods.
Patent Information
- Application Number
- JP2024103605
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-06-14
- Filing Date
- 2024-06-27
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current genome editing methods are inefficient, particularly for in vivo delivery, due to a lack of effective delivery technologies.
The use of delivery vehicles comprising multiple payloads, including sequence-specific nucleases, targeted donor DNA, site-specific recombinases, and recombinase compositions, to facilitate the insertion of large nucleotide sequences into the genome, utilizing non-viral vehicles such as nanoparticles for efficient genome editing.
This approach enhances the efficiency of genome editing by ensuring that multiple payloads are delivered to the same cell with a 100-fold improvement over separate delivery, enabling the insertion of sequences up to 100 kbp, suitable for in vivo applications.
Smart Images

Figure 2024156658000001_ABST
Abstract
Description
[Technical Field]
[0001] cross reference This application claims the benefit of U.S. Provisional Patent Application No. 62 / 661,992, filed April 24, 2018, and U.S. Provisional Patent Application No. 62 / 685,240, filed June 14, 2018, which applications are incorporated herein by reference in their entireties.
[0002] Introduction Genome editing remains an inefficient method in many situations. Although there are many methods for site-specific gene editing, the translation to therapy is hindered by the insufficient delivery technology, especially when considering in vivo delivery. There is an important unmet need for compositions and methods for efficient genome editing. Summary of the Invention
[0003] Compositions and methods for genome editing using delivery vehicles with multiple payloads are provided. In some aspects, the methods comprise introducing a delivery vehicle into a cell, wherein the delivery vehicle comprises: (a) one or more sequence-specific nucleases that cleave the genome (e.g., meganucleases, homing endonucleases, zinc finger nucleases (ZFNs), TALENs, type I or type III CRISPR / Cas cleavage complexes, CRISPR / Cas effector proteins class 2 (RNA-guided CRISPR / Cas polypeptides (e.g., Cas9, CasX, CasY, Cpf1 (Ca)); (e.g., s12a), Cas13, MAD7), or one or more sequence-specific nucleases (herein (a) is referred to as a nuclease composition); (b) a first donor DNA comprising a nucleotide sequence to be inserted into the genome, where insertion of the nucleotide sequence provides a target sequence (e.g., an attP site) for a site-specific recombinase at an insertion site in the genome (herein (b) is referred to as a target donor composition); (c) a site-specific recombinase (e.g., ΦC31, ΦC31 RDF, Cre, FLP) (or a nucleic acid encoding the same), which recognizes the target sequence (herein (c) is referred to as a recombinase composition); and (d) a second donor DNA comprising a nucleotide sequence to be inserted into the genome as a result of recognition of the target sequence by the site-specific recombinase (herein (d) is referred to as an insert donor composition). A delivery vehicle comprising (a), (b), (c), and (d) facilitates the insertion of large sequences into a genome by insertion of one or more target sites for a site-specific recombinase, followed by recombinase-mediated insertion of a nucleotide sequence of interest. In some cases, the nucleotide sequence of interest to be inserted (from an Insert Donor composition) is 10 kilobase pairs (kbp) or larger (e.g., 15 kbp to 100 kbp, 30 kbp to 100 kbp, or 50 kbp to 100 kbp).
[0004] In some cases, insertion of the nucleotide sequence of the first donor DNA provides a first target sequence for the site-specific recombinase at a first site in the genome and a second target sequence for the site-specific recombinase at a second site in the genome (e.g., insertion of two attP sites). In some cases, the nuclease composition cleaves the genome at two locations, and the target donor composition includes two of the first donor DNAs, each of which includes the nucleotide sequence to be inserted into the genome, thereby providing a first target sequence for the site-specific recombinase at a first site in the genome and a second target sequence for the site-specific recombinase at a second site in the genome (e.g., insertion of two attP sites). In some cases, the second donor DNA includes two target sequences for the site-specific recombinase (e.g., attB sites), where the two target sequences flank the nucleotide sequence to be inserted into the genome.
[0005] Delivery vehicles can be introduced into / delivered to cells in vitro, ex vivo, or in vivo. One advantage of delivering multiple payloads as part of the same delivery vehicle (e.g., nanoparticles) is that the efficiency of each payload is not reduced. For example, if payload A and payload B are delivered in two separate packages / vehicles (package A and package B, respectively), the efficiency is multiplicative; for example, if package A and package B each have a transfection efficiency of 1%, the chance of delivering payload A and payload B to the same cell is 0.01% (1% x 1%). However, if payload A and payload B are both delivered as part of the same delivery vehicle, the chance of delivering payload A and payload B to the same cell is 1%, a 100-fold improvement over 0.01%.
[0006] Delivery vehicles can include, but are not limited to, non-viral vehicles, viral vehicles, nanoparticles (e.g., nanoparticles comprising a core comprising a targeting ligand and / or an anionic polymer composition, a cationic polymer composition, and a cationic polypeptide composition), liposomes, micelles, water-in-oil-in-water emulsion particles, oil-in-water emulsion micelle particles, multilamellar water-in-oil-in-water emulsion particles, targeting ligands conjugated to charged polymer polypeptide domains (e.g., peptide targeting ligands, where the targeting ligand binds to a cell surface protein and the charged polymer polypeptide domain condenses with a nucleic acid payload and / or electrostatically interacts with a protein payload), targeting ligands conjugated to payloads (e.g., peptide targeting ligands, where the targeting ligand binds to a cell surface protein), etc. In some cases, the payload is introduced into the cell as a deoxyribonucleoprotein complex and / or a ribo-deoxyribonucleoprotein complex.
[0007] The provided compositions and methods can be used for genome editing at any locus in any cell (e.g., in vivo, e.g., to engineer T cells). For example, a population of CD8+ T cells or a mixture of CD8+ and CD4+ T cells can be programmed to transiently or permanently express the appropriate TCRα / TCRβ pair of CDR1, CDR2, and / or CDR3 domains for antigen recognition.
[0008] The invention can best be understood from the following detailed description of the invention when reference is made to the accompanying drawings, in which: It is emphasized that, according to common practice, the drawings are not necessarily to scale. To the contrary, the drawings may be arbitrarily enlarged or reduced for the sake of clarity. The drawings include the following figures: [Brief explanation of the drawings]
[0009] [Figure 1]Figure 1 is a schematic diagram illustrating a method of the invention. In this example, two target sequences (e.g., attP sites) are inserted into a genome (using donor DNA from a target donor composition) after cleavage of the genome with a sequence-specific nuclease. Two target sequences (e.g., attB sites) are present on donor DNA from an insert donor composition, and two residual sites (e.g., attR sites) remain in the genome after insertion of the sequences from the donor DNA (from the insert donor composition) using a site-specific recombinase (e.g., ΦC31). [Figure 2] FIG. 2 is a schematic diagram illustrating a delivery vehicle, in this example, a type of nanoparticle. [Figure 3] 3 is a schematic diagram illustrating a delivery vehicle (in this example, a type of nanoparticle) that is multi-layered, having, from outside to inside, a surface coat (including an outer shell) layer, a second shed layer, an intermediate layer (including an additional payload), and a core (including the first payload) surrounded by a first shed layer. [Figure 4] Figure 4 (Panels A-B) is a schematic diagram showing an example of a targeting ligand configuration for the surface coating of a nanoparticle of the present invention. The illustrated delivery molecule comprises a targeting ligand conjugated to an anchor domain that electrostatically interacts with the decidual layer of the nanoparticle. Note that the targeting ligand can be conjugated at the N-terminus, C-terminus (left side of each panel), or internally (right side of each panel). Panel A includes a linker, while Panel B does not. [Figure 5A] Figure 5A is a schematic diagram illustrating a delivery vehicle (an example of a delivery molecule of the present invention). The targeting ligand can be conjugated at the N-terminus, C-terminus (left side of each panel), or internally (right side of each panel). This diagram shows a delivery molecule that includes a targeting ligand attached to a payload in addition to a linker. [Figure 5B]Figure 5B is a schematic diagram illustrating a delivery vehicle (an example of a constitutive delivery molecule of the present invention). The targeting ligand can be conjugated at the N-terminus, C-terminus (left side of each panel) or internally (right side of each panel). This diagram shows a delivery molecule without a linker but with a targeting ligand attached to a payload. [Figure 5C] Figure 5C is a schematic diagram illustrating a delivery vehicle (an example constituting a delivery molecule of the invention). The targeting ligand can be N- or C-terminally conjugated (left side of each panel) or internally conjugated (right side of each panel). The diagram shows a delivery molecule comprising a linker and targeting ligand attached to a polypeptide domain that is a charged polymer condensed with a nucleic acid payload (and / or interacting, e.g., electrostatically, with a protein payload). [Figure 5D] Figure 5D is a schematic diagram illustrating a delivery vehicle (an example constituting a delivery molecule of the invention). The targeting ligand can be N- or C-terminally conjugated (left side of each panel) or internally conjugated (right side of each panel). This figure shows a delivery molecule that does not have a linker but includes a targeting ligand attached to a polypeptide domain that is a charged polymer condensed with a nucleic acid payload (and / or interacting, e.g., electrostatically, with a protein payload). [Figure 6] Figure 6 shows examples of nuclear localization signal (NLS) molecules that can be used (e.g., as part of a nanoparticle, e.g., as an NLS-containing peptide; as part of / conjugated to an NLS-containing peptide, anionic polymer, cationic polymer, and / or cationic polypeptide, etc.). The figure is adapted from Kosugi et al., J Biol Chem. 2009 Jan 2;284(1):478-85 [Class 1, SEQ ID NO:201 to SEQ ID NO:221; Class 2, SEQ ID NO:222 to SEQ ID NO:224; Class 4, SEQ ID NO:225 to SEQ ID NO:230; Class 3, SEQ ID NO:231 to SEQ ID NO:245; Class 5, SEQ ID NO:246 to SEQ ID NO:264]. [Figure 7] FIG. 7 is a schematic diagram showing mouse hematopoietic cell lineages and markers identified on various cells within the lineages. [Figure 8] FIG. 8 is a schematic diagram showing human hematopoietic cell lineages and markers identified on various cells within the lineages. [Figure 9] FIG. 9 is a schematic diagram showing miRNAs that can be used to affect cell differentiation and / or proliferation. [Figure 10] FIG. 10 is a schematic diagram showing proteins that can be used to affect cell differentiation and / or proliferation. [Figure 11] FIG. 11 shows the average particle size of the nanoparticles for the compositions of Study A. [Figure 12] FIG. 12 shows the zeta potential of the nanoparticles for the composition of Study A. [Figure 13] FIG. 13 shows the polydispersity index of the nanoparticles for the compositions of Study A. [Figure 14] FIG. 14 shows a diagram illustrating the polydispersity index and stability of the nanoparticles for the composition of Study B. [Figure 15] FIG. 15 shows the average particle size of the nanoparticles for the composition of Study B. [Figure 16] FIG. 16 shows the zeta potential of the nanoparticles for the composition of Study B. [Figure 17] FIG. 17 shows the polydispersity index of the nanoparticles for the composition of Study B. [Figure 18] FIG. 18 shows a diagram illustrating the polydispersity index and stability of the nanoparticles for the composition of Study B. [Figure 19] FIG. 19 shows the particle size distribution of the nanoparticles for the composition of Study C. [Figure 20] FIG. 20 shows the zeta potential of the nanoparticles for the composition of Study C. [Figure 21] FIG. 21 shows the polydispersity index of the nanoparticles for the compositions of Study C. [Figure 22] FIG. 22 shows the polydispersity index and stability of the nanoparticles for the compositions of Study C. [Figure 23] FIG. 23 shows the fluorescence values obtained in the nanoparticle SYBR GOLD incorporation assay for the compositions of Study C. [Figure 24] FIG. 24 shows the characterization of RNP-H2B (minicore) particles. [Figure 25] FIG. 25 shows the characterization of RNP-H2B-PLE20:PDE20 (core) particles. [Figure 26] Figure 26 shows the serum stability of RNP-H2B-PLE20:PDE20 (core) particles. [Figure 27] FIG. 27 shows the polydispersity assessment for the ligand-modified particles after 1 day. [Figure 28] FIG. 28 shows the polydispersity assessment for the ligand-modified particles after 72 hours or 7 days. [Figure 29] Figure 29 shows cells, nuclei and nanoparticles measured with automated pipeline sampling. [Figure 30] FIG. 30 shows the changes in particle co-localization within cells up to 14.5 hours after various treatments. [Figure 31] Figure 31 shows the percentage of Cas9-eGFP cells up to 14.5 hours after various treatments. [Figure 32] Figure 32 shows particle incorporation into the nucleus up to 14.5 hours after various treatments. [Figure 33] Figure 33 shows the percentage of Cas9-eGFP cells up to 14.5 hours after various treatments. [Figure 34A] Figure 34A shows targeting of T cells and PBMCs in untreated samples. [Figure 34B] FIG. 34B shows human primary pan T cell data corresponding to FIG. 34A. [Figure 34C] Figure 34C shows human primary PBMC data corresponding to Figure 34A. [Figure 35A] FIG. 35A shows targeting of T cells and PBMCs in core particles. [Figure 35B]FIG. 35B shows human primary pan T cell data corresponding to FIG. 35A. [Figure 35C] Figure 35C shows human primary PBMC data corresponding to Figure 35A. [Figure 36A] Figure 36A shows targeting of T cells and PBMCs in samples treated with the ligand poly(L-arginine). [Figure 36B] FIG. 36B shows human primary pan T cell data corresponding to FIG. 36A. [Figure 36C] Figure 36C shows human primary PBMC data corresponding to Figure 36A. [Figure 37A] FIG. 37A shows targeting of T cells and PBMCs in a sample by the ligand CD3_CD3e_(4GS)2_9R_N_1. [Figure 37B] FIG. 37B shows human primary pan T cell data corresponding to FIG. 37A. [Figure 37C] Figure 37C shows human primary PBMC data corresponding to Figure 37A. [Figure 38A] FIG. 38A shows targeting of T cells and PBMCs in a sample by the ligand CD8_(4GS)2_9R_N. [Figure 38B] Figure 38B shows human primary pan T cell data corresponding to Figure 38A. [Figure 38C] Figure 38C shows human primary PBMC data corresponding to Figure 38A. [Figure 39A] Figure 39A shows the targeting of T cells and PBMCs in the sample by the ligand CD28_mCD80_(4GS)2_9R_N. [Figure 39B] FIG. 39B shows human primary pan T cell data corresponding to FIG. 39A. [Figure 39C] Figure 39C shows human primary PBMC data corresponding to Figure 39A. [Figure 40A] Figure 40A shows the targeting of T cells and PBMCs in the sample by the ligand CD28_mCD86_(4GS)2_9R_N. [Figure 40B]FIG. 40B shows human primary pan T cell data corresponding to FIG. 40A. [Figure 40C] Figure 40C shows human primary PBMC data corresponding to Figure 40A. [Figure 41A] FIG. 41A shows targeting of T cells and PBMCs in a sample by the ligand IL2R_mIL2_4GS_2_9R_N_1. [Figure 41B] FIG. 41B shows human primary pan T cell data corresponding to FIG. 41A. [Figure 41C] FIG. 41C shows human primary PBMC data corresponding to FIG. 41A. [Figure 42A] Figure 42A shows the targeting of T cells and PBMCs in a sample by the ligands CD3_CD3e_(4GS)2_9R_N_1 and CD8_(4GS)2_9R_N. [Figure 42B] Figure 42B shows human primary pan T cell data corresponding to Figure 42A. [Figure 42C] Figure 42C shows human primary PBMC data corresponding to Figure 42A. [Figure 43A] Figure 43A shows the targeting of T cells and PBMCs in a sample by the ligands CD3_CD3e_(4GS)2_9R_N_1 and CD28_mCD80_(4GS)2_9R_N. [Figure 43B] Figure 43B shows human primary pan T cell data corresponding to Figure 43A. [Figure 43C] Figure 43C shows human primary PBMC data corresponding to Figure 43A. [Figure 44A] Figure 44A shows the targeting of T cells and PBMCs in a sample by the ligands CD3_CD3e_(4GS)2_9R_N_1 and CD28_mCD86_(4GS)2_9R_N. [Figure 44B] Figure 44B shows human primary pan T cell data corresponding to Figure 44A. [Figure 44C] Figure 44C shows human primary PBMC data corresponding to Figure 44A. [Figure 45A]Figure 45A shows targeting of T cells and PBMCs in a sample by the ligands CD3_CD3e_(4GS)2_9R_N_1 and IL2R_mIL2_4GS_2_9R_N_1. [Figure 45B] Figure 45B shows human primary pan T cell data corresponding to Figure 45A. [Figure 45C] Figure 45C shows human primary PBMC data corresponding to Figure 45A. [Figure 46A] Figure 46A shows targeting of T cells and PBMCs in samples by the ligands CD3_CD3e_(4GS)2_9R_N_1 and poly(L-arginine); n=10. [Figure 46B] Figure 46B shows human primary pan T cell data corresponding to Figure 46A. [Figure 46C] Figure 46C shows human primary PBMC data corresponding to Figure 46A. [Figure 47A] Figure 47A shows the targeting of T cells and PBMCs in a sample by the ligands CD28_mCD80_(4GS)2_9R_N and CD28_mCD86_(4GS)2_9R_N. [Figure 47B] Figure 47B shows human primary pan T cell data corresponding to Figure 47A. [Figure 47C] Figure 47C shows human primary PBMC data corresponding to Figure 47A. [Figure 48A] Figure 48A shows targeting of T cells and PBMCs in a sample by the ligands CD3_CD3e_(4GS)2_9R_N_1, CD28_mCD86_(4GS)2_9R_N and CD8_4GS_2_9R_N_1. [Figure 48B] Figure 48B shows human primary pan T cell data corresponding to Figure 48A. [Figure 48C] Figure 48C shows human primary PBMC data corresponding to Figure 48A. [Figure 49A]Figure 49A shows targeting of T cells and PBMCs in a sample by the ligands CD3_CD3e_(4GS)2_9R_N_1, CD8_4GS_2_9R_N_1 and IL2R_mIL2_4GS_2_9R_N_1. [Figure 49B] Figure 49B shows human primary pan T cell data corresponding to Figure 49A. [Figure 49C] Figure 49C shows human primary PBMC data corresponding to Figure 49A. [Figure 50A] Figure 50A shows targeting of T cells and PBMCs in a sample by the ligands CD3_CD3e_(4GS)2_9R_N_1, CD28_mCD80_(4GS)2_9R_N and CD8_4GS_2_9R_N_1. [Figure 50B] Figure 50B shows human primary pan T cell data corresponding to Figure 50A. [Figure 50C] Figure 50C shows human primary PBMC data corresponding to Figure 50A. [Figure 51A] Figure 51A shows targeting of T cells and PBMCs in a sample by CD3_CD3e_(4GS)2_9R_N_1, CD28_mCD86_(4GS)2_9R_N and CD28_mCD80_(4GS_)2_9R_N_1. [Figure 51B] FIG. 51B shows human primary pan T cell data corresponding to FIG. 51A. [Figure 51C] Figure 51C shows human primary PBMC data corresponding to Figure 51A. [Figure 52A] Figure 52A shows targeting of T cells and PBMCs in a sample by ligands CD8_4GS_2_9R_N_1, CD28_mCD80_(4GS)2_9R_N and CD28_mCD86_(4GS)2_9R_N. [Figure 52B] Figure 52B shows human primary pan T cell data corresponding to Figure 52A. [Figure 52C] Figure 52C shows human primary PBMC data corresponding to Figure 52A. [Figure 53A]Figure 53A shows targeting of T cells and PBMCs in a sample by ligands CD8_4GS_2_9R_N_1, CD28_mCD80_(4GS)2_9R_N and IL2R_mIL2_4GS_2_9R_N_1. [Figure 53B] Figure 53B shows human primary pan T cell data corresponding to Figure 53A. [Figure 53C] Figure 53C shows human primary PBMC data corresponding to Figure 53A. [Figure 54A] Figure 54A shows targeting of T cells and PBMCs in a sample by ligands CD8_4GS_2_9R_N_1, CD28_mCD86_(4GS)2_9R_N, IL2R_mIL2_4GS_2_9R_N_1. [Figure 54B] Figure 54B shows human primary pan T cell data corresponding to Figure 54A. [Figure 54C] Figure 54C shows human primary PBMC data corresponding to Figure 54A. [Figure 55] Figure 55 shows image analysis, pan T cell flow analysis and PBMC flow analysis of samples with different ligands. [Figure 56] FIG. 56 shows image analysis, pan T cell flow analysis, and PBMC flow analysis for samples with a different ligand set than the ligand set in FIG. [Figure 57] Figure 57 shows a general outline of nanoparticle synthesis, which involves the addition of a payload, cationic / anionic peptide, and ligand, in any order. Examples of peptides, payloads, and ligands are also shown, which may vary in the number of bases and may include D / L isomers. [Figure 58A] Figure 58A shows the amounts of PLR50, buffer, and RNP added stepwise to each nanoparticle. [Figure 58B] FIG. 58B shows the amounts of PLR50, buffer, and RNP added stepwise to each nanoparticle (continued). [Figure 58C] Figure 58C shows the amounts of DNA, PLR50, and buffer added stepwise to each nanoparticle. [Figure 58D]Figure 58D shows the amounts of DNA, PLR50, and buffer added stepwise to each nanoparticle (continued). [Figure 58E] Figure 58E shows the nanoparticle well ID (the location in the 96-well plate where nanoparticles are synthesized and their size, zeta potential, and SYBR fluorescence are measured) and its conversion to the nanoparticle ID (96-well cell transfection plate) shown in Figure 61I. [Figure 59A] Figure 59A shows the particle size of nanoparticles synthesized in 2C.1.1.1. Particle size was measured in triplicate using a Wyatt Mobius Zeta Potential and DLS Detector. Size is shown as the mean hydrodynamic diameter (nm) ± standard deviation in a heat map associated with the nanoparticle 96-well ID. [Figure 59B] Figure 59B shows the zeta potential of nanoparticles synthesized in 2C.1.1.1. The zeta potential of the particles was measured in triplicate using a Wyatt Mobius Zeta Potential and DLS Detector. The zeta potential is shown as the mean zeta potential (mV) ± standard deviation in a heat map associated with the nanoparticle 96-well ID. [Figure 59C] Figure 59C shows the average (overnight) aggregation index for each particle by SYBR fluorescence assay. The aggregation index was calculated as [(fluorescence of target well - fluorescence of free DNA) / fluorescence of free DNA] x 100 and is shown as the average aggregation index ± standard deviation in a heat map associated with the nanoparticle 96-well ID. Fully aggregated nanoparticles are highly shielded and weakly fluorescent, and therefore have a negative aggregation index. [Figure 60A] Figure 60A shows the plate layout for transfection into HEK293-GFP cells. Nanoparticles were dosed at 20uL and 10uL on duplicate plates. Row B (gold highlighting) shows the charge ratio for layer 1, row C (orange highlighting) shows the charge ratio for the outer layer, green highlighting shows the CRISPRMAX transfection control, and gray highlighting shows the Lipofectamine 3000 transfection control. The DNA mix contains single-stranded deoxynucleotides and φC31 expression and donor plasmids. [Figure 60B] Figure 60B shows the results of flow analysis at 5 days post-transfection by measuring GFP and Alexa647 (nanoparticle) fluorescence. Live cells were gated based on FSC / SSC scatter, and the percentage of GFP- and nanoparticle+ cells are shown for the live cell gate. The lipofection control produces robust results, but no significant GFP knockdown is observed in the nanoparticle wells. The 20 μL dose of nanoparticles results in a significant nanoparticle signal at day 5, whereas the 10 μL dose does not. RFP expression was observed only in the lipofection control with tag-RFP plasmid: 20% RFP+ of live cells, well C11 (data not shown). Flow analysis at 10 and 14 days post-transfection showed that the nanoparticle group no longer showed nanoparticle Alexa647 signal, no GFP knockdown, and no RFP expression. In the plasmid lipofection control, RFP expression decreased over time (7% RFP+ at day 10, 2% RFP+ at day 14), whereas GFP knockdown in the CRISPRMAX controls (B10, C10) remained constant, consistent with the heritability of the gene edit. [Figure 60C] Figure 60C shows the results of genomic analysis 5 days post-transfection of the RNP+DNA mix lipofection control (well C10) showing editing of the GFP locus (25% knockdown) and homology-directed repair (knock-in) with attP single-stranded deoxyoligonucleotides (6%) using Synthego ICE knock-in analysis of Sanger sequencing data. [Figure 61A] FIG. 61A shows the amounts of PLR50, buffer, and RNP added stepwise to each nanoparticle. [Figure 61B] FIG. 61B shows the amounts of PLR50, buffer, and RNP added stepwise to each nanoparticle (continued). [Figure 61C] Figure 61C shows the amounts of DNA, ligand mix, ALEXA-647 nanoparticle label, and buffer added stepwise to each nanoparticle. [Figure 61D]FIG. 61D shows the amounts of PLR50, buffer, and RNP added stepwise to each nanoparticle (continued). [Figure 61E] Figure 61E shows the nanoparticle well ID (the location in the 96-well plate where nanoparticles are synthesized and where size, zeta potential, and SYBR fluorescence are measured) and its conversion to the nanoparticle ID (96-well cell transfection plate) shown in Figure 61I. [Figure 61F] Figure 61F shows the particle size of nanoparticles synthesized in 2C.2.1.1. Particle size was measured in triplicate using a Wyatt Mobius Zeta Potential and DLS Detector. Size is shown as the mean hydrodynamic diameter (nm) ± standard deviation in a heat map associated with the nanoparticle 96-well ID. [Figure 61G] Figure 61G shows the zeta potential of nanoparticles synthesized in 2C.2.1.1. The zeta potential of the particles was measured in triplicate using a Wyatt Mobius Zeta Potential and DLS Detector. The zeta potential is shown as the mean zeta potential (mV) ± standard deviation in a heat map associated with the nanoparticle 96-well ID. [Figure 61H] Figure 61H shows the average (overnight) condensation index for each particle by SYBR fluorescence assay. The condensation index was calculated as [(fluorescence of target well - fluorescence of free DNA) / fluorescence of free DNA] x 100 and is shown as the average condensation index ± standard deviation in a heat map associated with the nanoparticle 96-well ID. Fully condensed nanoparticles are highly shielded and weakly fluorescent, and therefore have a negative condensation index. [Figure 61I]Figure 61I shows the plate layout for transfection into stimulated PBMCs. Nanoparticles were administered at 10 uL per well containing 60,000 stimulated PBMCs. Row B (gold highlighting) indicates the charge ratio of layer 1, and row C (orange highlighting) indicates the charge ratio of the outer layer. Wells highlighted in green (B12(G)12 and G11) are nucleofection controls. NP18, NP39, and NP25 were the best-performing nanoparticle groups in terms of gene editing efficiency (TCR knockdown: 6%, 5%, and Sanger sequencing efficiency: 5%, respectively). Bold samples indicate cleavage values of >1% at the TCR locus as determined by Sanger sequencing. [Figure 61J] Figure 61J shows cell viability (% live cells) of transfected cells as measured by flow cytometry. After washing the overnight transfected nanoparticles with PBS, stimulated PBMCs were collected for flow analysis on day 1. Cell viability was assayed by Annexin V staining. Well E6 had an error. [Figure 61K] Figure 61K shows cell viability (% dead / apoptotic cells) of transfected cells measured by flow cytometry. After washing the overnight transfected nanoparticles with PBS, stimulated PBMCs were collected for flow analysis on day 1. Cell viability was assayed by Annexin V staining. Well E6 contained apoptotic and dead cells. Well E6 contained error bars. [Figure 61L]Figure 61L shows the cellular uptake of various nanoparticle formulations (AF647- / nanoparticle+ and EGFP- / Cas9+). After overnight transfection and washing with PBS, stimulated PBMCs were harvested for flow analysis on day 1. The percentages of GFP+ and nanoparticle+ cells in the live cell gate (Annexin V negative) for GFP (Cas9-GFP) and Alexa647 (nanoparticle) fluorescence are shown. The nanoparticle signal (Alexa647) in T cells was significantly lower than in HEK-293 cells, suggesting that rapid degradation of the AF647-conjugated endosomal escape peptide results in the most efficient intracellular Cas9 RNP delivery. Nearly all traces of nanoparticle+ (1-2%) coincided with the highest Cas9-GFP signal. >95% of cells were positive for CD3 staining (not shown), indicating that CD3 / CD28 stimulation resulted in selective T cell proliferation. [Figure 61M] Figure 61M shows flow analysis of TCR expression 4 days after transfection. Nucleofection wells with RNPs ± single-stranded deoxyoligonucleotides have robust TCR knockdown, whereas all-component nucleofection (F12) and nanoparticle wells do not. No nanoparticle signal (Alexa647 or Cas9-GFP) is observed, and only the RFP-based plasmid nucleofection control wells (G12) show RFP expression in 10% of live cells (data not shown). [Figure 61N] Figure 61N shows flow analysis of TCR expression at day 14 post-transfection. No nanoparticle signal (Alexa647 or Cas9-GFP) or RFP expression was observed, even from the plasmid nucleofection controls. [Figure 61O]Figure 61O shows ICE scores from Sanger sequencing data at day 14 for the TRAC locus. High ICE scores indicate robust editing in nucleofection samples as well as TCR knockdown by flow analysis. Three nanoparticles (boxed) showed low TCR editing with the Synthego ICE platform. None of the samples showed homology-directed repair (knock-in) with attP single-stranded deoxyoligonucleotides. [Figure 61P] Figure 61P shows the results of Sanger sequencing. In studies conducted prior to Experiment 2C.1.2.1, the core was further optimized to provide high nanoparticle uptake efficiency and intracellular release kinetics. Experiment 2C.1.2.1 further included varying ratios of histone fragments, PLR10, PLR50, NLS-modified histones, and / or endosomal escape-NLS peptides, as well as varying values of the PLE to PDE ratio. Prior to decoration with targeting ligands, various nanoparticle cores were evaluated for their biological performance (cellular uptake, intracellular retention over time, viability, and gene editing) in an initial set of screens intended to optimize the nanoparticle cores for rapid versus sustained intracellular release. [Figure 61Q] Figure 61Q shows the results of Sanger sequencing 14 days after transfection. In studies conducted prior to Experiment 2C.1.2.1, the cores were further optimized to provide high nanoparticle uptake efficiency and intracellular release kinetics. Prior to decoration with targeting ligands, various nanoparticle cores were evaluated for their biological performance (cellular uptake, intracellular retention over time, viability, and gene editing) in an initial set of screens intended to optimize the nanoparticle cores for rapid versus sustained intracellular release. [Figure 62A] FIG. 62A shows the amount of cationic peptide and buffer added in step 1 to each nanoparticle. [Figure 62B] Figure 62B shows the amount of RNP, DNA, or DNA+PLE / PDE added to each nanoparticle in step 2. The nanoparticles were incubated for 10 minutes at this stage. [Figure 62C] Figure 62C shows the amount of RNP, DNA, or DNA+PLE / PDE added to each nanoparticle in step 3. The nanoparticles were incubated for an additional 10 minutes at this stage. [Figure 62D] Figure 62D shows the amount of cationic peptide, nanoparticle ALEXA-647 label, and buffer added to each nanoparticle in step 3. The nanoparticles were incubated for an additional 10 minutes at this stage. [Figure 62E] Figure 62E shows the nanoparticle well ID (the location in the 96-well plate where nanoparticles are synthesized and where size, zeta potential, and SYBR fluorescence are measured) and its conversion to the nanoparticle ID (96-well cell transfection plate) shown in Figure 61I. [Figure 62F] Figure 62F shows an example calculation of the volume of cationic polypeptide required to achieve a charge ratio of 10 from a 0.1% stock solution. [Figure 62G] Figure 62G shows an example calculation of the volume of cationic polypeptide required to achieve a charge ratio of 4 from a 0.1% stock solution. [Figure 62H] Figure 62H shows the particle size of nanoparticles synthesized in 2C.1.2.1. Particle size was measured in triplicate using a Wyatt Mobius Zeta Potential and DLS Detector. Size is shown as the mean hydrodynamic diameter (nm) ± standard deviation in a heat map associated with the nanoparticle 96-well ID. [Figure 62I] Figure 62I shows the zeta potential of nanoparticles synthesized in 2C.1.2.1. The zeta potential of the particles was measured in triplicate using a Wyatt Mobius Zeta Potential and DLS Detector. The zeta potential is shown as the mean zeta potential (mV) ± standard deviation in a heat map associated with the nanoparticle 96-well ID. [Figure 62J]Figure 62J shows the average (overnight) condensation index for each particle by SYBR fluorescence assay. The condensation index was calculated as [(fluorescence of target well - fluorescence of free DNA) / fluorescence of free DNA] x 100 and is shown as the average condensation index ± standard deviation in a heat map associated with the nanoparticle 96-well ID. Fully condensed nanoparticles are highly shielded and weakly fluorescent, and therefore have a negative condensation index. [Figure 62K] Figure 62K shows the nanoparticle transfection layout into HEK293-GFP cells. Yellow highlighting indicates a single dose (10 μl) of the corresponding nanoparticles shown in Figures 62A-62E, and blue highlighting indicates a double dose (20 μl) of the corresponding nanoparticles shown in Figures 62A-62E. Green highlighting indicates the CRISPRMAX transfection control, and gray highlighting indicates the Lipofectamine 3000 transfection control. The DNA mix contains single-stranded deoxynucleotides, φC31 expression, and donor plasmids. [Figure 62L] Figure 62L shows the results of flow analysis 3 days after transfection by measuring Alexa647 fluorescence (nanoparticle signal). Live cells were gated based on FSC / SSC scatter, and the percentage of nanoparticles+ in the live cell gate is shown. [Figure 62M] Figure 62M shows the results of flow analysis 3 days after transfection by measuring GFP fluorescence. Live cells were gated based on FSC / SSC scatter, and the percentage of GFP- in the live cell gate is shown. RFP expression was observed only in the lipofection control with tag-RFP plasmid: 51% RFP+ of live cells in well B6 (data not shown). [Figure 62N] Figure 62N shows a plot of flow analysis of GFP and Alexa647 (nanoparticles) at day 3 for selected nanoparticle-transfected samples from 2C.1.2.1 (HEK293-GFP) showing GFP knockdown in Figure 62F. The live cell gate (based on FSC / SSC) is shown. The reduction in GFP expression with and without nanoparticle signal indicates rapid degradation of the nanoparticle peptide shell and release of the RNP payload. [Figure 62O] Figure 62O shows the results of flow analysis 3 days post-transfection by measuring GFP fluorescence and Alexa647 fluorescence (nanoparticle signal). Live cells were gated based on FSC / SSC scatter, and the percentage is shown for the live cell gate. Wells highlighted in green are the top hits for % GFP- (shown in 62F), and wells highlighted in pink are the top hits for % nanoparticle+ (shown in 62E). [Figure 62P] Figure 62P shows contrast-enhanced images (top left, bottom left; see ImageJ Script) and associated threshold maps (top right, bottom right) of AF647-labeled nanoparticles transfected into HEK293-GFP cells, corresponding to well E5 in 2C.1.2.1. Bright green areas represent GFP- regions with high nanoparticle-induced fluorescence, while red areas represent GFP+ regions with no nanoparticle-induced fluorescence. Nanoparticle fluorescence was detected with a BioTek Cytation 5 Texas Red Filter Cube (product number 1225102). Colocalization studies and comparison with flow cytometry results using AF647 (Cy5 channel) showed that nanoparticle+ pixels were indistinguishable from RFP+ pixels. These threshold maps were used to determine the Pearson coefficient, M1 and M2 coefficients, and overlap coefficient for each well location. [Figure 62Q] Figure 62Q shows a Costes threshold map applied to AF647-labeled nanoparticles transfected into HEK293-GFP cells, corresponding to well E5 made 6 days post-transfection and corresponding to Figure 62P. Bright green areas represent GFP- regions with high nanoparticle-induced fluorescence, while red areas indicate GFP+ regions where nanoparticle-induced fluorescence is absent. [Figure 62R] Figure 62R shows representative data corresponding to segmentation and Costes threshold maps, as well as automatic thresholding by the imaging script, for well E5, generated 6 days post-transfection. These threshold maps were used to determine the Pearson coefficient, M1 and M2 coefficients, and overlap coefficient at each well location. [Figure 62S] Figure 62S shows representative data corresponding to the automated generation of threshold maps for well B6 (RFP plasmid-only positive control) and automated thresholding by the imaging script. These threshold maps were used to determine the Pearson coefficient, M1 and M2 coefficients, and overlap coefficient for each position in the other wells. Identification of the Texas Red channel (RFP+) in the absence of the Cy5 channel (nanoparticle-) and the visibility of RFP+ as a nanoparticle+ indicator were used to set the thresholds for comparing other wells. [Figure 62T] Figure 62T shows an overlap image of RFP and DAPI. Well B5 has no RFP insert (seen in the RFP plasmid lipofectamine control in B6) and shows no Texas Red channel. Wells E8, E9, and F9 (nanoparticle group) show highly visible nanoparticle uptake, with certain wells (e.g., E5) showing Mander coefficients of M1 = 0.01 (fraction of GFP+ overlapping with nanoparticle+) vs. M2 = 0.907 (fraction of nanoparticle+ overlapping with GFP+). This indicates a strong relationship between particle uptake and lack of GFP expression. [Figure 62U]Figure 62U shows nanoparticle uptake and GFP knockdown at day 3 for 2C.1.2.1. In this figure, samples are sorted by the percentage of GFP- (B4–E4, descending order) and the percentage of nanoparticle+ (E7–F5, ascending order). Notably, in the highest-performing nanoparticle uptake group, the percentage of nanoparticle+ viable cells is similar on days 3 and 6. This suggests that various components of the particles efficiently enter cells but do not efficiently release their payload or reach the appropriate compartment, and that these nanoparticles may have sustained release kinetics. The top-performing GFP knockdown particles at day 3 showed a decrease in relative knockdown efficiency by day 6. Particle degradation is modeled by Δ(percent nanoparticle+ at day 3 (%) - percent nanoparticle+ at day 6 (%)). Gene editing efficiency, which accounts for the toxicity of nanoparticle+ edited cells, is modeled by Δ(percent GFP- at day 6 (%) - percent GFP- at day 3 (%)). Comparison of these two ratios allows for the establishment of optimal "core nanoparticles" for subsequent coating with targeting ligands, balancing the percentage of nanoparticle+ cells on day 3 with the percentage of GFP- cells on day 6. Based on these selection criteria, NP13, NP15, NP06, and NP14 (black squares) are top candidate nanoparticles for further ligand-targeting layering and optimization of intracellular targeting versus intracellular release efficiency. Figure 35A shows that "core particles" (according to the same definition, e.g., containing only anionic and / or cationic polypeptides without ligands) achieve uptake efficiencies comparable to the lowest performance in 2C.1.2.1 and 2C.2.1.1, where decoration with various targeting ligands enhances cellular uptake and delivery by CRISPR-Cas9 RNPs by more than 10-fold (Figures 30-56). [Figure 62V]Figure 62V shows nanoparticle uptake and GFP knockdown at day 6 for 2C.1.2.1. In this figure, samples are sorted by the percentage of GFP- (B4–E4, descending order) and the percentage of nanoparticle+ (E7–F5, ascending order). Notably, in the highest-performing nanoparticle uptake group, the percentage of nanoparticle+ viable cells is similar on days 3 and 6. This suggests that various components of the particles efficiently enter cells but do not efficiently release their payload or reach the appropriate compartment, and that these nanoparticles may have sustained release kinetics. The top-performing GFP knockdown particles at day 3 showed a decrease in relative knockdown efficiency by day 6. Particle degradation is modeled by Δ(percent nanoparticle+ at day 3 (%) - percent nanoparticle+ at day 6 (%)). Gene editing efficiency, which accounts for the toxicity of nanoparticle+ edited cells, is modeled by Δ(percent GFP- at day 6 (%) - percent GFP- at day 3 (%)). Comparison of these two ratios allows for the establishment of optimal "core nanoparticles" for subsequent coating with targeting ligands, balancing the percentage of nanoparticle+ cells on day 3 with the percentage of GFP- cells on day 6. Based on these selection criteria, NP13, NP15, NP06, and NP14 (black squares) are top candidate nanoparticles for further ligand-targeting layering and optimization of intracellular targeting versus intracellular release efficiency. Figure 35A shows that "core particles" (according to the same definition, e.g., containing only anionic and / or cationic polypeptides without ligands) achieve uptake efficiencies comparable to the lowest performance in 2C.1.2.1 and 2C.2.1.1, where decoration with various targeting ligands enhances cellular uptake and delivery by CRISPR-Cas9 RNPs by more than 10-fold (Figures 30-56). [Figure 62W]Figure 62W shows top-performing GFP knockdown particles at day 3 and top-performing uptake particles at day 6. Notably, in the top-performing nanoparticle uptake group, the proportion of nanoparticle + viable cells was similar on days 3 and 6, and GFP − cells appear to rely on rapid nanoparticle metabolism, whereas nanoparticles exhibiting low toxicity and high uptake rates exhibit low payload activity. This suggests that various components of the particles efficiently enter cells but do not efficiently release their payload or reach the appropriate compartment, and that these nanoparticles may have sustained release kinetics with limited toxicity. Certain addition and formulation orders may also disrupt gRNA-Cas9 activity due to strong electrostatic interactions. Top-performing GFP knockdown particles at day 3 exhibited a decline in relative knockdown efficiency by day 6. Samples E7, E4, F7, and E5 (closed squares) showed increased gene editing efficiency from day 3 to day 6 and had the highest ratio of edited cells to nanoparticle+ cells among all formulations in study 2C.1.2.1. [Figure 62X]Figure 62X shows nanoparticle+ viable cells (percentage of total viable cells containing nanoparticles) on days 3 and 6. The order of incorporation, addition of PDE / PLE, PLR10, PLR50, and / or histone-derived fragments, and transfection efficiency of 4 / 5-component nanoparticles are shown for various formulations. E8 NP17 achieved high transfection efficiency at 50% the dose of G8 NP17, suggesting that optimizing intracellular trafficking could increase nanoparticle+ cell numbers. Further optimization of the aggregation index, zeta potential, and ligand coating could result in improved cell specificity and intracellular release efficiency, as evidenced by the best performance of formulations approximately 10% below the global maximum aggregation index in the nanoparticle+ viable cell to GFP-edited viable cell ratio (Figures 62B-62C) and in further formulation studies of RNP-only delivery systems (Figures 11-56). Figure 35A shows that "core particles" (e.g., containing only anionic and / or cationic polypeptides without ligands) achieve uptake efficiencies comparable to the lowest performance in 2C.1.2.1 and 2C.2.1.1, whereas decoration with various targeting ligands enhances cellular uptake and delivery by CRISPR-Cas9 RNPs by over 10-fold (Figures 30-56). The creation of nanoparticles well below the global maximum condensation index, including multiple ratios of histone-derived sequences and PLE and / or PDE, allows for the rational selection of optimized targeting ligands and nanoparticle surface chemistries that balance intracellular trafficking and release potential. [Figure 62Y]Figure 62Y shows a comparison of nanoparticle+ viable cells (percentage of total viable cells that contain nanoparticles, are GFP-, or both) at days 3 and 6, as defined by the filled squares in Figures 62M-62O. These particles exhibited an increase in viable GFP- cells after transfection when comparing the two time points, suggesting delayed or prolonged release of the nanoparticle payload. Additionally, the frequency of viable GFP- cells was similar to the transfection efficiency, suggesting efficient intracellular release, degradation of the nanoparticle+AF647 fluorophore, and subsequent payload activity. The cores of these nanoparticles are ideal templates for further layering of targeting ligands, as shown in Figures 30-56. DETAILED DESCRIPTION OF THE INVENTION
[0010] As summarized above, compositions and methods for genome editing using delivery vehicles with multiple payloads are provided. In some aspects, the methods of the present invention comprise introducing a delivery vehicle into a cell, wherein the delivery vehicle (a) is capable of cleaving the genome with one or more sequence-specific nucleases (e.g., meganucleases, homing endonucleases, zinc finger nucleases (ZFNs), TALENs, type I or type III CRISPR / Cas cleavage complexes, CRISPR / Cas effector proteins class 2 (RNA-guided CRISPR / Cas polypeptides (e.g., Cas9, CasX, CasY, Cpf1 (Ca)), or other CRISPR / Cas polypeptides) or CRISPR / Cas polypeptides (e.g., Cas9, CasX, CasY, Cpf1 (Ca)), or other ... (s12a), Cas13, MAD7, etc.), or one or more sequence-specific nucleases (herein (a) is referred to as a nuclease composition); (b) a first donor DNA comprising a nucleotide sequence to be inserted into the genome, where insertion of the nucleotide sequence provides a target sequence (e.g., an attP site) for a site-specific recombinase at an insertion site in the genome (herein (b) is referred to as a target donor composition); (c) a site-specific recombinase (e.g., ΦC31, ΦC31 RDF, Cre, FLP) (or a nucleic acid encoding the same), which recognizes the target sequence (herein (c) is referred to as a recombinase composition); and (d) a payload comprising a second donor DNA comprising a nucleotide sequence to be inserted into the genome as a result of recognition of the target sequence by the site-specific recombinase (herein (d) is referred to as an insert donor composition).
[0011] Before the present methods and compositions are described, it is to be understood that this invention is not limited to the particular methods or compositions described herein, as such may, of course, vary. It is also to be understood that the scope of the present invention will be limited only by the claims, and that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
[0012] Where a range of values is presented, it is understood that each intervening value, to the tenth of the unit of the lower limit, between the upper and lower limits of that range is also specifically disclosed, unless the context clearly dictates otherwise. Each subrange between any stated values, or intervening value within a stated range, and any other stated or intervening value within that stated range, is encompassed within the invention. The upper and lower limits of these subranges may independently be included within or excluded from the range, and each range where either limit is included within the subrange, neither limit is included within the subrange, or both limits are included within the subrange is also encompassed within the invention, subject to any specifically excluded limit within the stated range. When a stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
[0013] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, some possible and preferred methods and materials are described herein. All publications mentioned herein are incorporated by reference as if to disclose and describe the methods and / or materials in connection with which the publications are cited. In case of conflict, it is understood that the present disclosure supersedes any disclosure of the incorporated publication.
[0014] Those skilled in the art will appreciate that, upon reading this specification, each of the individual embodiments described and illustrated herein has distinct components and features which may be readily separated from, and readily combined with, the features of any of the other embodiments without departing from the spirit or scope of the invention. Any recited method may be carried out in the order of events recited, or in any other order which is logically possible.
[0015] Please note that, as used in this specification and the claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, a reference to "a cell" includes a plurality of such cells, a reference to "an endonuclease" includes one or more endonucleases and equivalents thereof known to those skilled in the art, and so forth. It is further noted that the claims may be drafted to exclude any element, e.g., any optional element. Accordingly, this statement is intended to be used as a predicate for the use of exclusionary terminology, e.g., "solely," "only," or a "negative" limitation, in connection with the recitation of claim elements.
[0016] The publications cited herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such publication. Further, the publication dates provided may be different from the actual publication dates which may need to be independently confirmed.
[0017] Methods and Compositions Methods and compositions for efficient genome editing are provided. In some aspects, the methods of the invention comprise introducing into a cell a delivery vehicle with a payload comprising: (a) one or more sequence-specific nucleases (or one or more nucleic acids encoding one or more sequence-specific nucleases [referred to herein as a nuclease composition]) that cleave the genome; (b) a first donor DNA [referred to herein as a target donor composition] that comprises a nucleotide sequence to be inserted into the genome, where insertion of the nucleotide sequence provides a target sequence (target site, e.g., an attP site) for a site-specific recombinase at the insertion site in the genome; (c) a site-specific recombinase (or a nucleic acid encoding the same) that recognizes the target sequence [referred to herein as a recombinase composition]; and (d) a second donor DNA [referred to herein as an insert donor composition] that comprises a nucleotide sequence of interest that is inserted into the genome as a result of recognition of the target sequence by the site-specific recombinase.
[0018] The nucleic acid encoding (a) a site-specific nuclease (also referred to herein as a sequence-specific nuclease) or (b) a site-specific recombinase may be a nucleic acid of interest, e.g., as the nucleic acid payload of a delivery vehicle, the nucleic acid may be linear or circular, a plasmid, a viral genome, RNA, etc. The term "nucleic acid" encompasses modified nucleic acids. In some cases, nucleic acid molecules may be mimetics and may include a modified sugar backbone, one or more modified internucleoside linkages (e.g., one or more phosphorothioate linkages and / or heteroatom internucleoside linkages), one or more modified bases, etc. (so long as the nucleic acid can be transcribed and / or translated into a protein).
[0019] I. Nuclease Compositions (Sequence-Specific Nucleases) The nuclease compositions of the present invention comprise one or more sequence-specific nucleases (also referred to herein as site-specific nucleases) or one or more nucleic acids encoding one or more sequence-specific nucleases. The site-specific nucleases of the present invention are site-specific nucleases that can introduce breaks (double-stranded or single-stranded) into genomic DNA in a sequence-specific manner. Some site-specific nucleases are engineered proteins (e.g., zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs)); in some cases, such proteins are used to generate nicks (single-stranded breaks) or as protein pairs that generate blunt or cohesive ends. In some cases, the site-specific nuclease is a site-specific nuclease that generates blunt double-stranded breaks (e.g., CRISPR / Cas effector protein class 2 (e.g., Cas9, CasX, CasY, Cpf1, Cas13, etc.)). In some cases, the site-specific nuclease is a site-specific nuclease (e.g., a CRISPR / Cas effector protein class 2 (e.g., Cas9)) that naturally generates a blunt single-strand break, but is mutated so that the protein is a nicase (cuts only one strand of DNA). A nicase protein, e.g., a mutant nicase Cas9, can be used to generate a single-strand break or to generate a cohesive end by using two guide RNAs that target opposite strands of the target DNA. Thus, in some cases, the methods of the invention include using a sequence-specific nicase (e.g., a CRISPR / Cas effector protein class 2 that is a nicase (e.g., Cas9 that is a nicase)) with two guide RNAs to generate a cohesive break at (at least) one of two genomic sites. In some cases, the methods of the invention involve using a sequence-specific nicase (e.g., a CRISPR / Cas effector protein class 2 that is a nicase (e.g., Cas9 that is a nicase)) with four guide RNAs to generate two cohesive cuts at two genomic sites.
[0020] Any convenient site-specific nuclease (e.g., a gene editing protein (e.g., any convenient programmable gene editing protein)) may be used. Examples of suitable programmable gene editing proteins include, but are not limited to, transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), type I or type III CRISPR / Cas effector proteins, and CRISPR / Cas RNA-guided polypeptide (effector) class 2 (e.g., Cas9, CasX, CasY, Cpf1, Cas13, MAD7, etc.). Examples of site-specific nucleases that may be used include transcription activator-like effector nucleases (TALENs); zinc finger nucleases (ZFNs); type I or type III CRISPR / Cas nucleases; CRISPR / Cas RNA-guided polypeptides (effector proteins), e.g. Cas9, CasX, CasY, Cpf1, Cas13, MAD7, etc.); meganucleases (e.g. I-SceI, I-CeuI, I-CreI, I-DmoI, I-ChuI, I-DirI, I-FlmuI, I-FlmuII, I-Anil, I-SceIV, I -CsmI, I-PanI, I-PanII, I-PanMI, I-SceII, I-PpoI, I-SceIII, I-LtrI, I-GpiI, I-GZeI, I -OnuI, I-HjeMI, I-MsoI, I-TevI, I-TevII, I-TevIII, PI-MleI, PI-MtuI, PI-PspI, PI-Tli I, PI-Tli II, PI-SceV, etc.), as well as homing endonucleases. Site-specific nucleases can be delivered to cells as proteins or as nucleic acids (RNA or DNA) encoding the proteins (as part of a delivery vehicle).
[0021] In some cases, the delivery vehicle is used to deliver a nucleic acid encoding a gene editing tool (i.e., a gene editing system, e.g., a site-specific cleavage system (e.g., a component of a programmable gene editing system)). For example, the nucleic acid payload may include one or more of: (i) a CRISPR / Cas guide RNA; (ii) DNA encoding the CRISPR / Cas guide RNA; (iii) DNA and / or RNA encoding a programmable gene-editing protein, such as a zinc finger protein (ZFP) (e.g., a zinc finger nuclease (ZFN)), a transcription activator-like effector (TALE) protein (e.g., fused to a nuclease (TALEN)), a type I or type III CRISPR / Cas nuclease and / or a CRISPR / Cas RNA-guided polypeptide (e.g., Cas9, CasX, CasY, Cpf1, Cas13, MAD7, etc.); (iv) DNA and / or RNA encoding a meganuclease; (v) DNA and / or RNA encoding a homing endonuclease; and (iv) a donor DNA molecule (the first and / or second donor DNAs of the invention).
[0022] In some cases, the delivery vehicles of the invention are used to deliver protein payloads, such as proteins, e.g., ZFNs, TALENs, Type I or Type III CRISPR / Cas nucleases and / or CRISPR / Cas RNA-guided polypeptides (e.g., Cas9, CasX, CasY, Cpf1, Cas13, MAD7, etc.), meganucleases, and homing endonucleases.
[0023] Depending on the nature of the system and the desired outcome, a gene editing system (e.g., a site-specific gene editing system, e.g., a programmable gene editing system) can include a single component (e.g., a ZFP, ZFN, TALE, TALEN, meganuclease, etc.) or multiple components. In some cases, a gene editing system includes at least two components. For example, in some cases, a gene editing system (e.g., a programmable gene editing system) includes (i) a nucleic acid of a donor DNA molecule; and (ii) a gene editing protein (e.g., a programmable gene editing protein, e.g., a ZFP, ZFN, TALE, TALEN, a DNA-guided polypeptide, e.g., Natronobacterium gregoryi Argonaute (NgAgo), a type I or type III CRISPR / Cas nuclease and / or a CRISPR / Cas RNA-guided polypeptide (e.g., Cas9, CasX, CasY, Cpf1, Cas13, MAD7, etc.), or a nucleic acid molecule (e.g., DNA or RNA, e.g., a plasmid or mRNA) encoding the gene editing protein. As another example, in some cases, a gene editing system (e.g., a programmable gene editing system) includes (i) a CRISPR / Cas guide RNA or DNA encoding the CRISPR / Cas guide RNA; and (ii) a CRISPR / Cas and a nucleic acid molecule (e.g., DNA or RNA, e.g., a plasmid or mRNA) encoding an RNA-guided polypeptide (e.g., Cas9, CasX, CasY, Cpf1, Cas13, MAD7, etc.) or an RNA-guided polypeptide. As another example, in some cases, a gene editing system (e.g., a programmable gene editing system) includes (i) an NgAgo-like guide DNA; and (ii) a DNA-guided polypeptide (e.g., NgAgo) or an nucleic acid molecule (e.g., DNA or RNA, e.g., a plasmid or mRNA) encoding the DNA-guided polypeptide.In some cases, a gene editing system (e.g., a programmable gene editing system) includes at least three components: (i) a donor DNA molecule; (ii) a CRISPR / Cas guide RNA or DNA encoding the CRISPR / Cas guide RNA; and (iii) a nucleic acid molecule (e.g., DNA or RNA, e.g., a plasmid or mRNA) encoding a CRISPR / Cas RNA-guided polypeptide (e.g., Cas9, CasX, CasY, or Cpfl) or an RNA-guided polypeptide. In some cases, a gene editing system (e.g., a programmable gene editing system) includes at least three components: (i) a donor DNA molecule; (ii) an NgAgo-like guide DNA or DNA encoding an NgAgo-like guide DNA; and (iii) a DNA-guided polypeptide (e.g., NgAgo) or a nucleic acid molecule (e.g., DNA or RNA, e.g., a plasmid or mRNA) encoding the DNA-guided polypeptide.
[0024] In some embodiments, the payload of the delivery vehicle comprises one or more gene editing tools. Herein, the term "gene editing tool" is used to refer to one or more components of a gene editing system. Thus, in some cases, the payload comprises a gene editing system, and in some cases, the payload comprises one or more components of the gene editing system (i.e., one or more gene editing tools). For example, the target cell may already contain one of the components of the gene editing system, and the user only needs the remaining components. In such cases, the payload of the nanoparticles of the present invention does not necessarily contain all of the components of a given gene editing system. Thus, in some cases, the payload comprises one or more gene editing tools.
[0025] By way of example, the target cell may already contain DNA or RNA encoding a gene-editing protein, such as a ZFP, a TALE, a DNA-guided polypeptide (e.g., NgAgo), a type I or type III CRISPR / Cas nuclease, and / or a CRISPR / Cas RNA-guided polypeptide (e.g., Cas9, CasX, CasY, Cpf1, Cas13, MAD7, etc.), and / or a protein, and thus the payload may comprise one or more of: (i) a donor DNA molecule; and (ii) a CRISPR / Cas guide RNA, or a DNA encoding the CRISPR / Cas guide RNA; or an NgAgo-like guide DNA. Similarly, the target cell may already contain a CRISPR / Cas guide RNA, and / or a DNA encoding the guide RNA, or an NgAgo-like guide DNA, and thus the payload may comprise one or more of: (i) a donor DNA molecule; and (ii) a CRISPR / Cas guide RNA, or a DNA encoding the guide RNA, or an NgAgo-like guide DNA. It may comprise one or more of an RNA-guided polypeptide (e.g., Cas9, CasX, CasY, Cpf1, Cas13, MAD7, etc.), or a nucleic acid molecule (e.g., DNA or RNA, e.g., a plasmid or mRNA) encoding an RNA-guided polypeptide; or a DNA-guided polypeptide (e.g., NgAgo), or a nucleic acid molecule encoding a DNA-guided polypeptide.
[0026] For more information regarding programmable gene editing tools (e.g., CRISPR / Cas RNA-guided proteins, e.g., Cas9, CasX, CasY, Cpf1 (Cas12a), and Cas13, zinc finger proteins, e.g., zinc finger nucleases, TALE proteins, e.g., TALENs, CRISPR / Cas guide RNAs, etc.), see, e.g., Dreier, et al., (2001) J Biol Chem 276:29466-78; Dreier, et al., (2000) J Mol Biol 303:489-502; Liu, et al., (2002) J Biol Chem 277:3850-6; Dreier, et al., (2005) J Biol Chem 280:35588-97; Jamieson, et al., (2003) Nature Rev Drug Disov 2:361-8;Durai, et al., (2005) Nucleic Acids Res 33:5978-90;Segal, (2002) Methods 26:76-83;Porteus and Carroll, (2005) Nat Biotechnol 23:967-73;Pabo, et al., (2001) Ann Rev Biochem 70:313-40;Wolfe, et al., (2000) Ann Rev Biophys Biomol Struct 29:183-212;Segal and Barbas, (2001) Curr Opin Biotechnol 12:632-7;Segal, et al., (2003) Biochemistry 42:2137-48;Beerli and Barbas, (2002) Nat Biotechnol 20:135-41;Carroll, et al., (2006) Nature Protocols 1:1329;Ordiz, et al., (2002) Proc Natl Acad Sci USA 99:13290-5;Guan, et al., (2002) Proc Natl Acad Sci USA 99:13296-301;Sanjana et al., Nature Protocols, 7:171-192 (2012);Zetsche et al, Cell. 2015 Oct 22;163(3):759-71;Makarova et al, Nat Rev Microbiol. 2015 Nov;13(11):722-36;Shmakov et al., Mol Cell. 2015 Nov 5;60(3):385-97;Jinek et al., Science. 2012 Aug 17;337(6096):816-21;Chylinski et al., RNA Biol. 2013 May;10(5):726-37;Ma et al., Biomed Res Int. 2013;2013:270805;Hou et al., Proc Natl Acad Sci US A. 2013 Sep 24;110(39):15644-9;Jinek et al., Elife. 2013;2:e00471;Pattanayak et al., Nat Biotechnol. 2013 Sep;31(9):839-43;Qi et al, Cell. 2013 Feb 28;152(5):1173-83;Wang et al., Cell. 2013 May 9;153(4):910-8;Auer et. al., Genome Res. 2013 Oct 31;Chen et. al., Nucleic Acids Res. 2013 Nov 1;41(20):e19;Cheng et. al., Cell Res. 2013 Oct;23(10):1163-71;Cho et. al., Genetics. 2013 Nov;195(3):1177-80;DiCarlo et al., Nucleic Acids Res. 2013 Apr;41(7):4336-43;Dickinson et. al., Nat Methods. 2013 Oct;10(10):1028-34;Ebina et. al., Sci Rep. 2013;3:2510;Fujii et. al, Nucleic Acids Res. 2013 Nov 1;41(20):e187;Hu et. al., Cell Res.2013 November; 23(11): 1322 - 5; Jiang et al., Nucleic Acids Res. 2013 November 1; 41(20): e188; Larson et al., Nat Protoc. 2013 November; 8(11): 2180 - 96; Mali et al., Nat Methods. 2013 October; 10(10): 957 - 63; Nakayama et al., al., Genesis. 2013 December; 51(12): 835 - 43; Ran et al., Nat Protoc. 2013 November; 8(11): 2281 - 308; Ran et al., Cell. 2013 September 12; 154(6): 1380 - 9; Upadhyay et al., G3 (Bethesda). 2013 December 9; 3(12): 2233 - 8; Walsh et al., Proc Natl Acad Sci U S A. 2013 September 24; 110(39): 15514 - 5; Xie et al., Mol Plant. 2013 October 9; Yang et al., Cell. 2013 September 12; 154(6): 1370 - 9; Briner et al., Mol Cell. 2014 October 23; 56(2): 333 - 9; Burstein et al., Nature. 2016 December 22 - Epub ahead of print; Gao et al., Nat Biotechnol. 2016 July 34(7): 768 - 73 and Shmakov et al., Nat Rev Microbiol.2017 Mar;15(3):169-182; and International Patent Applications WO2002099084; WO00 / 42219; WO02 / 42459; WO2003062455; WO03 / 080809; WO05 / 014791; WO05 / 084190; WO08 / 021207; WO09 / 042186; WO09 / 054985 and WO10 / 065123; U.S. Patent Application Publication Nos., 20030059767; 20030108880; 20140068797; 20140170753; 20140179006; 20140179770; 0140186843;20140186919;20140186958;20140189896;20140227787;20140234972;20140242664;20140242699;20140242700;20140242702;201 40248702;20140256046;20140273037;20140273226;20140273230;20140273231;20140273232;20140273233;20140273234;20140273235;201402 87938;20140295556;20140295557;20140298547;20140304853;20140309487;20140310828;20140310830;20140315985;20140335063;20140335620;20140342456;20140342457;20140342458;20140349400;20140349405;20140356867;20140356956;20140356958;20140356959;2014035752 3; 20140357530; 20140364333; 20140377868; 20150166983 and 20160208243; and U.S. Patent Nos. 6,140,466; 6,511,808; 6,453,242; 8,685,737; 8,906,616; 8,895,308; 8,889,418; 8,889,356; 8,871,445; 8,865,406; 8,795,965; 8,771,945 and 8,697,359, all of which are incorporated herein by reference in their entirety.
[0027] II. Target Donor Composition (First Donor DNA) The targeted donor compositions of the present invention include first donor DNA. The first donor DNA can be linear or circular and can be in any convenient format (e.g., plasmid, minicircle, linear, etc.). The donor DNA of the targeted donor composition can include one or more target sequences (target sites) that are inserted into a genome and then recognized (and utilized) by a site-specific recombinase. In some cases, the donor DNA of the targeted donor composition does not include a target site, but insertion of the donor DNA results in such a target site being present in the genome (e.g., a target site can be generated at the junction of the donor insert sequence and the genome, e.g., in some cases, the donor and genome have sticky ends).
[0028] The donor DNA of the target donor composition (first donor DNA) can be single-stranded or double-stranded.
[0029] In some cases, the base pairs of the second donor DNA (donor DNA of the insert donor composition) are 10 (bp) or more (e.g., 20 bp or more, 30 bp or more, 50 bp or more, 100 bp or more, 200 bp or more, 500 bp or more, 1,000 bp or more, 5,000 bp or more, 10,000 bp or more, 50,000 bp or more, or 75,000 bp or more). In other words, in some cases, the donor DNA of the present invention has 10 bp or more (e.g., 20 bp or more, 30 bp or more, 50 bp or more, 100 bp or more, 200 bp or more, 500 bp or more, 1,000 bp or more, 5,000 bp or more, 10,000 bp or more, 50,000 bp or more, or 75,000 bp or more).
[0030] In some cases, the base pairs (bp) of the second donor DNA of the present invention (donor DNA of the insert donor composition) may be a total of 10 bp to 150 kilobase pairs (kbp) [in the case of single strands, the units are nucleotides (nt) rather than "bp"] (e.g., 10 bp to 100 kbp, 70 kbp, 10 bp to 50 kbp, 10 bp to 40 kbp, 10 bp to 25 kbp, 10 bp to 15 kbp, 10 bp to 10 kbp, 10 bp to 1 kbp, 10 bp to 750 bp, 10 bp to 500 bp, 10 bp to 250 bp, 10 bp to 150 bp, 10 bp to 100 bp, 10 bp to 100 kbp, p~50bp, 18bp~150kbp, 18bp~100kbp, 18bp~70kbp, 18bp~50kbp, 18bp~40kbp, 18bp~25kbp, 18bp~15kbp, 18bp~10kbp, 18bp~1kbp, 18bp~750bp, 18bp~5 00bp, 18bp~250bp, 18bp~150bp, 25bp~150kbp, 25bp~100kbp, 25bp~70kbp, 25bp~50kbp, 25bp~40kbp, 25bp~25kbp, 25bp~15kbp, 25bp~10kbp, 25bp~1k bp, 25bp~750bp, 25bp~500bp, 25bp~250bp, 25bp~150bp, 50bp~150kbp, 50bp~100kbp, 50bp~70kbp, 50bp~50kbp, 50bp~40kbp, 50bp~25kbp, 50bp~15k bp, 50bp~10kbp, 50bp~1kbp, 50bp~750bp, 50bp~500bp, 50bp~250bp, 50bp~150bp, 100bp~150kbp, 100bp~100kbp, 100bp~70kbp, 100bp~50kbp, 100bp~ 40kbp, 100bp~25kbp, 100bp~15kbp, 100bp~10kbp, 100bp~1kbp, 100bp~750bp, 100bp~500bp, 100bp~250bp, 200bp~150kbp, 200bp~100kbp, 200bp~70k bp, 200bp~50kbp, 200bp~40kbp, 200bp~25kbp, 200bp~15kbp, 200bp~10kbp, 200bp~1kbp, 200bp~750bp, 200bp~500bp, 10kbp~150kbp, 10kbp~100kbp,In some cases, the first donor DNA of the present invention (donor DNA of the target donor composition) has a total length of 10 bp to 50 kbp. In some cases, the first donor DNA of the present invention (donor DNA of the target donor composition) has a total length of 10 bp to 10 kbp. In some cases, the first donor DNA of the present invention (donor DNA of the target donor composition) has a total length of 10 bp to 10 kbp. In some cases, the first donor DNA of the present invention (donor DNA of the target donor composition) has a total length of 50 kbp to 100 kbp. In some cases, the first donor DNA of the present invention (donor DNA of the target donor composition) has a total length of 10 bp to 10 kbp. In some cases, the first donor DNA of the present invention (donor DNA of the target donor composition) has a total length of 10 bp to 1 kbp. In some cases, the first donor DNA of the present invention (donor DNA of the target donor composition) has a total length of 20 bp to 50 kbp. In some cases, the first donor DNA of the present invention (donor DNA of the target donor composition) has a total length of 20 bp to 10 kbp. In some cases, the first donor DNA of the present invention (donor DNA of the target donor composition) has a total length of 20 bp to 1 kbp.
[0031] In some cases, the donor DNA includes one or more of a mimetic, a modified sugar backbone, a non-natural internucleoside linkage (e.g., one or more phosphorothioate and / or heteroatom internucleoside linkages), modified bases, and the like.
[0032] The nucleotide sequence of the donor DNA (first donor DNA) of the target donor composition to be inserted into the genome can be of any convenient length, for example, in some cases, the sequence is 10 base pairs (bp) or more (e.g., 20 bp or more, 30 bp or more, 50 bp or more, 100 bp or more, 200 bp or more, 500 bp or more, 1,000 bp or more, 5,000 bp or more, 10,000 bp or more, 50,000 bp or more, or 75,000 bp or more) in length (having a total of these base pairs). In other words, in some cases, the length of the nucleotide sequence of the donor DNA (first donor DNA) of the target donor composition to be inserted into the genome is 10 bp or more (e.g., 20 bp or more, 30 bp or more, 50 bp or more, 100 bp or more, 200 bp or more, 500 bp or more, 1,000 bp or more, 5,000 bp or more, 10,000 bp or more, 50,000 bp or more, or 75,000 bp or more).
[0033] In some cases, the nucleotide sequence of the donor DNA (first donor DNA) of the target donor composition to be inserted into the genome is between 10 base pairs (bp) and 150 kilobase pairs (kbp) in total [in nucleotides (nt), not "bp," if single-stranded] (e.g., 10 bp to 100 kbp, 70 kbp, 10 bp to 50 kbp, 10 bp to 40 kbp, 10 bp to 25 kbp, 10 bp to 15 kbp, 10 bp to 10 kbp, 10 bp to 1 kbp, 10 bp to 750 bp, 10 bp to 500 bp, 10 bp to 250 bp, 10 bp to 150 bp, 10 bp to 100 bp, 10bp~50bp, 18bp~150kbp, 18bp~100kbp, 18bp~70kbp, 18bp~50kbp, 18bp~40kbp, 18bp~25kbp, 18bp~15kbp, 18bp~10kbp, 18bp~1kbp, 18bp~750bp, 1 8bp~500bp, 18bp~250bp, 18bp~150bp, 25bp~150kbp, 25bp~100kbp, 25bp~70kbp, 25bp~50kbp, 25bp~40kbp, 25bp~25kbp, 25bp~15kbp, 25bp~10kbp, 25b p~1kbp, 25bp~750bp, 25bp~500bp, 25bp~250bp, 25bp~150bp, 50bp~150kbp, 50bp~100kbp, 50bp~70kbp, 50bp~50kbp, 50bp~40kbp, 50bp~25kbp, 50bp~ 15kbp, 50bp~10kbp, 50bp~1kbp, 50bp~750bp, 50bp~500bp, 50bp~250bp, 50bp~150bp, 100bp~150kbp, 100bp~100kbp, 100bp~70kbp, 100bp~50kbp, 100b p~40kbp, 100bp~25kbp, 100bp~15kbp, 100bp~10kbp, 100bp~1kbp, 100bp~750bp, 100bp~500bp, 100bp~250bp, 200bp~150kbp, 200bp~100kbp, 200bp~70 kbp, 200bp~50kbp, 200bp~40kbp, 200bp~25kbp, 200bp~15kbp, 200bp~10kbp, 200bp~1kbp, 200bp~750bp, 200bp~500bp, 10kbp~150kbp, 10kbp~100kbp,In some cases, the length of the nucleotide sequence of the donor DNA (first donor DNA) of the target donor composition to be inserted into the genome is 10 bp to 50 kbp in total. In some cases, the length of the nucleotide sequence of the donor DNA (first donor DNA) of the target donor composition to be inserted into the genome is 10 bp to 10 kbp in total. In some cases, the length of the nucleotide sequence of the donor DNA (first donor DNA) of the target donor composition to be inserted into the genome is 10 bp to 10 kbp in total. In some cases, the length of the nucleotide sequence of the donor DNA (first donor DNA) of the target donor composition to be inserted into the genome is 50 kbp to 100 kbp in total. In some cases, the length of the nucleotide sequence of the donor DNA (first donor DNA) of the target donor composition to be inserted into the genome is 10 bp to 10 kbp in total. In some cases, the length of the nucleotide sequence of the donor DNA (first donor DNA) of the target donor composition to be inserted into the genome is 10 bp to 1 kbp in total. In some cases, the length of the nucleotide sequence of the donor DNA (first donor DNA) of the target donor composition to be inserted into the genome is 20 bp to 50 kbp in total. In some cases, the nucleotide sequence of the donor DNA (first donor DNA) of the target donor composition to be inserted into the genome is 20 bp to 10 kbp in total. In some cases, the length of the nucleotide sequence of the donor DNA (first donor DNA) of the target donor composition to be inserted into the genome is 20 bp to 10 kbp in total.
[0034] In some embodiments, two target sites are inserted into the genome (to accommodate the insertion of a single nucleotide sequence of interest from a second donor DNA (insert donor composition), as described in more detail below). In other words, in some embodiments, insertion of the nucleotide sequence of the first donor DNA of the target donor composition results in a first target sequence for the site-specific recombinase at a first site in the genome, and a second target sequence for the site-specific recombinase at a second site in the genome, which can be achieved using any convenient method. For example, in some cases, the two target sites can be present on the same first donor DNA. In some cases, each of the two target sites is inserted into a separate first donor DNA within the genome, and thus in some cases the payload of a delivery vehicle of the invention may comprise two different first donor DNAs (e.g., in some cases this will require cleavage of the genome at two different sites using, for example, two different site-specific nucleases or a single CRISPR / Cas effector protein with at least two different guide RNAs that may be included as part of a nuclease composition).
[0035] After the two target sites are created / inserted into the genome (e.g., using one or two first donor DNAs and one or more site-specific nucleases (or one or more guide RNAs with CRISPR / Cas effector proteins)), the distance between the two target sites may be 1,000,000 base pairs (bp) or less (e.g., 500,000 bp or less, 100,000 bp or less, 50,000 bp or less, 10,000 bp or less, 1,000 bp or less, 750 bp or less, or 500 bp or less). In some cases, the distance between the two target sites is 100,000 bp or less. In some cases, the distance between the two sites is 50,000 bp or less. In some embodiments, the spacing between two target sites is between 5 and 1,000,000 base pairs (bp) (e.g., between 5 and 500,000, between 5 and 100,000, between 5 and 50,000, between 5 and 10,000, between 5 and 5,000, between 5 and 1,000, between 5 and 500, 10 and 1,000,000, between 10 and 500,000, between 10 and 100,000, between 10 and 50,000, between 10 and 1 0,000, 10-5,000, 10-1,000, 10-500, 50-1,000,000, 50-500,000, 50-100,000, 50-50,000, 50-10,000, 50-5,000, 50-1,000, 50-500, 100-1,000,000, 100-500,000, 100-100,000, 100 ~50,000, 100~10,000, 100~5,000, 100~1,000, 100~500, 300~1,000,000, 300~500,000, 300~100,000, 300~50,000, 300~10,000, 300~5,000, 300~1,000, 300~500, 500~1,000,000, 500 ~500,000, 500~100,000, 500~50,000, 500~10,000, 500~5,000, 500~1,000, 1,000~1,000,000, 1,000~500,000, 1,000~100,000, 1,000~50,000, 1,000~10,000, or 1,000~5,000 bp).
[0036] In some cases, the distance between the two target sites is 20 to 1,000,000 bp. In some cases, the distance between the two target sites is 20 to 500,000 bp. In some cases, the distance between the two target sites is 20 to 150,000 bp. In some cases, the distance between the two target sites is 20 to 50,000 bp. In some cases, the distance between the two target sites is 20 to 20,000 bp. In some cases, the distance between the two target sites is 20 to 15,000 bp. In some cases, the distance between the two target sites is 20 to 10,000 bp.
[0037] In some cases, the distance between the two target sites is 500 to 1,000,000 bp. In some cases, the distance between the two target sites is 500 to 500,000 bp. In some cases, the distance between the two target sites is 500 to 150,000 bp. In some cases, the distance between the two target sites is 500 to 50,000 bp. In some cases, the distance between the two target sites is 500 to 20,000 bp. In some cases, the distance between the two target sites is 500 to 15,000 bp. In some cases, the distance between the two target sites is 500 to 10,000 bp.
[0038] In some cases, the distance between the two target sites is 1,000 to 1,000,000 bp. In some cases, the distance between the two target sites is 1,000 to 500,000 bp. In some cases, the distance between the two target sites is 1,000 to 150,000 bp. In some cases, the distance between the two target sites is 1,000 to 50,000 bp. In some cases, the distance between the two target sites is 1,000 to 20,000 bp. In some cases, the distance between the two target sites is 1,000 to 15,000 bp. In some cases, the distance between the two target sites is 1,000 to 10,000 bp.
[0039] In some cases, the distance between the two target sites is 5,000 to 1,000,000 bp. In some cases, the distance between the two target sites is 5,000 to 500,000 bp. In some cases, the distance between the two target sites is 5,000 to 150,000 bp. In some cases, the distance between the two target sites is 5,000 to 50,000 bp. In some cases, the distance between the two target sites is 5,000 to 20,000 bp. In some cases, the distance between the two target sites is 5,000 to 15,000 bp. In some cases, the distance between the two target sites is 5,000 to 10,000 bp.
[0040] When the first donor DNA is double-stranded, each end of the donor DNA may independently have a 5' or 3' single-stranded overhang, or may be blunt-ended. For example, in some cases, both ends of the donor DNA have 5' overhangs. In some cases, both ends of the donor DNA have 3' overhangs. In some cases, one end of the donor DNA has a 5' overhang, while the other end has a 3' overhang. Each overhang can be any convenient length. In some cases, the length of each overhang, independently, is 2 to 200 nucleotides (nt) in length (e.g., 2 to 150, 2 to 100, 2 to 50, 2 to 25, 2 to 20, 2 to 15, 2 to 12, 2 to 10, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 3 to 150, 3 to 100, 3 to 50, 3 to 25, 3 to 20, 3 to 15, 3 to 12, 3 to 10, In some cases, the length of each overhang can be independently 2 to 20 nucleotides in length. In some cases, the length of each overhang can be independently 2 to 15 nucleotides in length. In some cases, the length of each overhang can be independently 2 to 15 nucleotides in length. In some cases, the length of each overhang can be independently 2 to 10 nucleotides in length. In some cases, the length of each overhang can be independently 2 to 7 nucleotides in length.
[0041] In some embodiments, the donor DNA has at least one adenylated 3' end.
[0042] Any convenient target site can be used (e.g., it can be contained within the nucleotide sequence of the first donor DNA to be inserted into the genome). In some cases, the target site is 15 bp (or nt) in length (e.g., 18 bp or more, 20 bp or more, 25 bp or more, or 30 bp or more). In some cases, the target site is 15-50 bp (or nt) in length (e.g., 15-45, 15-40, 15-35, 18-50, 18-45, 18-40, 18-35, 20-50, 20-45, 20-40, 20-35, 25-50, 25-45, 25-40, 25-35, 30-50, 30-45, 30-40, 30-35). Examples of target sites include, but are not limited to, LoxP (recognized by Cre), LoxP2722 (recognized by Cre), att (e.g., attB (ΦC31), attP (ΦC31), attL (ΦC31 RDF), attR (ΦC31 RDF), RS (recognized by R), gix (recognized by Gin)), see, e.g., U.S. Patent Nos. 9,902,970; 9,783,822; 9,233,174; 8,546,135; 8,399,254; 8,058,506; 7,670,823; and 5,888,732; all of which are incorporated by reference herein for their teachings regarding target sites and / or corresponding site-specific recombinases.
[0043] III. Recombinase Compositions (Site-Specific Recombinases) The recombinase compositions of the present invention comprise one or more sequence-specific recombinases (also referred to herein as site-specific recombinases), or one or more nucleic acids encoding one or more sequence-specific recombinases. The site-specific recombinases of the present invention are site-specific recombinases that can recognize one or more target sites (see above) in a genome (after insertion of a sequence from a first donor DNA) and one or more target sites in a second donor DNA (the donor DNA of the Insert Donor Composition), and catalyze the insertion of a sequence of interest from the second donor DNA into a genome. Several site-specific recombinases are known in the art, and any convenient site-specific recombinase can be used. Examples of site-specific recombinases include, but are not limited to, ΦC31, ΦC31 RDF, Cre, and FLP. Additionally, representative site-specific recombinases can include, but are not limited to, ΦC31, R4, TP901-1, ΦBT1, Bxb1, RV-1, AA118, U153, and ΦFC1 integrases.
[0044] IV. Insert Donor Composition (Second Donor DNA) The Insert Donor composition of the present invention includes a second donor DNA. The second donor DNA can be linear or circular and in any convenient format (e.g., plasmid, minicircle, linear, etc.). The donor DNA of the Insert Donor composition includes a nucleotide sequence of interest to be inserted into a genome by a site-specific recombinase. The donor DNA of the Insert Donor composition can be single-stranded or double-stranded, so long as the site-specific recombinase can catalyze the insertion of the sequence using the target site created during insertion of the sequence of the first donor DNA (of the target donor composition). Thus, the second donor DNA will typically include one or more target sites recognized by the site-specific recombinase (e.g., see the target sites described above with respect to the first donor DNA) to facilitate insertion of the sequence of interest into the genome. As known to those skilled in the art, in some cases, insertion of the second donor DNA may leave residual sequences in the genome. For example, if attB and attP target sites are used, attL and / or attR sequences may remain in the genome after insertion is complete.
[0045] In some cases, the second donor DNA (donor DNA of the Insert Donor composition) contains one target site. In some cases, the second donor DNA (donor DNA of the Insert Donor composition) contains one or more target sites (e.g., two or more target sites). In some cases, the second donor DNA (donor DNA of the Insert Donor composition) contains two target sites. In some cases, the nucleotide sequence of interest (the sequence to be inserted into the genome) is flanked by the two target sites (and in some cases, the two target sites are the same, i.e., the nucleotide sequence of interest is flanked by two copies of the same target site).
[0046] In some cases, the second donor DNA (donor DNA of the Insert Donor composition) is 10 base pairs (bp) or more in length (having a total of these base pairs) (e.g., 20 bp or more, 30 bp or more, 50 bp or more, 100 bp or more, 200 bp or more, 500 bp or more, 1,000 bp or more, 5,000 bp or more, 10,000 bp or more, 50,000 bp or more, or 75,000 bp or more). In other words, in some cases, the donor DNA of the present invention has 10 bp or more (e.g., 20 bp or more, 30 bp or more, 50 bp or more, 100 bp or more, 200 bp or more, 500 bp or more, 1,000 bp or more, 5,000 bp or more, 10,000 bp or more, 50,000 bp or more, or 75,000 bp or more).
[0047] In some cases, the second donor DNA of the present invention (donor DNA of the insert donor composition) has a total length of 10 base pairs (bp) to 150 kilobase pairs (kbp) [in the case of single strands, the length is measured in nucleotides (nt) rather than "bp"] (e.g., 10 bp to 100 kbp, 70 kbp, 10 bp to 50 kbp, 10 bp to 40 kbp, 10 bp to 25 kbp, 10 bp to 15 kbp, 10 bp to 10 kbp, 10 bp to 1 kbp, 10 bp to 750 bp, 10 bp to 500 bp, 10 bp to 250 bp, 10 bp to 150 bp, 10 bp to 100 bp, 10 bp to 50 bp). p, 18bp~150kbp, 18bp~100kbp, 18bp~70kbp, 18bp~50kbp, 18bp~40kbp, 18bp~25kbp, 18bp~15kbp, 18bp~10kbp, 18bp~1kbp, 18bp~750bp, 18bp~500bp, 1 8bp~250bp, 18bp~150bp, 25bp~150kbp, 25bp~100kbp, 25bp~70kbp, 25bp~50kbp, 25bp~40kbp, 25bp~25kbp, 25bp~15kbp, 25bp~10kbp, 25bp~1kbp, 25bp ~750bp, 25bp~500bp, 25bp~250bp, 25bp~150bp, 50bp~150kbp, 50bp~100kbp, 50bp~70kbp, 50bp~50kbp, 50bp~40kbp, 50bp~25kbp, 50bp~15kbp, 50bp~1 0kbp, 50bp~1kbp, 50bp~750bp, 50bp~500bp, 50bp~250bp, 50bp~150bp, 100bp~150kbp, 100bp~100kbp, 100bp~70kbp, 100bp~50kbp, 100bp~40kbp, 100b p~25kbp, 100bp~15kbp, 100bp~10kbp, 100bp~1kbp, 100bp~750bp, 100bp~500bp, 100bp~250bp, 200bp~150kbp, 200bp~100kbp, 200bp~70kbp, 200bp~50 kbp, 200bp~40kbp, 200bp~25kbp, 200bp~15kbp, 200bp~10kbp, 200bp~1kbp, 200bp~750bp, 200bp~500bp, 10kbp~150kbp, 10kbp~100kbp, 10kbp~70kbp,In some cases, the second donor DNA of the present invention (donor DNA of the insert donor composition) has a total length of 10 bp to 50 kbp. In some cases, the second donor DNA of the present invention (donor DNA of the insert donor composition) has a total length of 10 bp to 10 kbp. In some cases, the second donor DNA of the present invention (donor DNA of the insert donor composition) has a total length of 10 bp to 10 kbp. In some cases, the second donor DNA of the present invention (donor DNA of the insert donor composition) has a total length of 50 kbp to 100 kbp. In some cases, the second donor DNA of the present invention (donor DNA of the insert donor composition) has a total length of 10 bp to 10 kbp. In some cases, the second donor DNA of the present invention (donor DNA of the insert donor composition) has a total length of 10 bp to 1 kbp. In some cases, the second donor DNA of the present invention (donor DNA of the insert donor composition) has a total length of 20 bp to 50 kbp. In some cases, the second donor DNA of the present invention (donor DNA of the insert donor composition) has a total length of 20 bp to 10 kbp. In some cases, the second donor DNA of the present invention (donor DNA of the insert donor composition) has a total length of 20 bp to 1 kbp.
[0048] In some cases, the donor DNA includes one or more of a mimetic, a modified sugar backbone, a non-natural internucleoside linkage (e.g., one or more phosphorothioate and / or heteroatom internucleoside linkages), modified bases, and the like.
[0049] The nucleotide sequence of the donor DNA of the Insert Donor Composition (second donor DNA) to be inserted into the genome can be of any convenient length. For example, in some cases, the sequence is 10 base pairs (bp) or longer (e.g., 20 bp or longer, 30 bp or longer, 50 bp or longer, 100 bp or longer, 200 bp or longer, 500 bp or longer, 1,000 bp or longer, 5,000 bp or longer, 10,000 bp or longer, 50,000 bp or longer, or 75,000 bp or longer) in length (having a total of these base pairs). In other words, in some cases, the nucleotide sequence of the donor DNA of the insert donor composition (second donor DNA) that is inserted into the genome is 10 bp or more (e.g., 20 bp or more, 30 bp or more, 50 bp or more, 100 bp or more, 200 bp or more, 500 bp or more, 1,000 bp or more, 5,000 bp or more, 10,000 bp or more, 50,000 bp or more, or 75,000 bp or more).
[0050] In some cases, the length of the nucleotide sequence of the donor DNA of the Insert Donor Composition (second donor DNA) to be inserted into the genome is a total of 10 base pairs (bp) to 150 kilobase pairs (kbp) [in nucleotides (nt), not "bp," if single-stranded] (e.g., 10bp to 100kbp, 70kbp, 10bp to 50kbp, 10bp to 40kbp, 10bp to 25kbp, 10bp to 15kbp, 10bp to 10kbp, 10bp to 1kbp, 10bp to 750bp, 10bp to 500bp, 10bp to 250bp, 10bp to 150bp, 10bp~100bp, 10bp~50bp, 18bp~150kbp, 18bp~100kbp, 18bp~70kbp, 18bp~50kbp, 18bp~40kbp, 18bp~25kbp, 18bp~15kbp, 18bp~10kbp, 18bp~1kbp, 18b p~750bp, 18bp~500bp, 18bp~250bp, 18bp~150bp, 25bp~150kbp, 25bp~100kbp, 25bp~70kbp, 25bp~50kbp, 25bp~40kbp, 25bp~25kbp, 25bp~15kbp, 25bp ~10kbp, 25bp~1kbp, 25bp~750bp, 25bp~500bp, 25bp~250bp, 25bp~150bp, 50bp~150kbp, 50bp~100kbp, 50bp~70kbp, 50bp~50kbp, 50bp~40kbp, 50bp~2 5kbp, 50bp~15kbp, 50bp~10kbp, 50bp~1kbp, 50bp~750bp, 50bp~500bp, 50bp~250bp, 50bp~150bp, 100bp~150kbp, 100bp~100kbp, 100bp~70kbp, 100bp ~50kbp, 100bp~40kbp, 100bp~25kbp, 100bp~15kbp, 100bp~10kbp, 100bp~1kbp, 100bp~750bp, 100bp~500bp, 100bp~250bp, 200bp~150kbp, 200bp~100 kbp, 200bp~70kbp, 200bp~50kbp, 200bp~40kbp, 200bp~25kbp, 200bp~15kbp, 200bp~10kbp, 200bp~1kbp, 200bp~750bp, 200bp~500bp, 10kbp~150kbp,The length of the donor DNA (second donor DNA) of the insert donor composition to be inserted into the genome is 10 kbp to 50 kbp in total. In some cases, the length of the donor DNA (second donor DNA) of the insert donor composition to be inserted into the genome is 10 kbp to 100 kbp in total. In some cases, the length of the donor DNA (second donor DNA) of the insert donor composition to be inserted into the genome is 10 kbp to 10 kbp in total. In some cases, the length of the donor DNA (second donor DNA) of the insert donor composition to be inserted into the genome is 50 kbp to 100 kbp in total. In some cases, the length of the nucleotide sequence of the donor DNA of the insert donor composition (second donor DNA) to be inserted into the genome is 10 bp to 10 kbp in total. In some cases, the length of the nucleotide sequence of the donor DNA of the insert donor composition (second donor DNA) to be inserted into the genome is 10 bp to 1 kbp in total. In some cases, the length of the nucleotide sequence of the donor DNA of the insert donor composition (second donor DNA) to be inserted into the genome is 20 bp to 50 kbp in total. In some cases, the length of the nucleotide sequence of the donor DNA of the insert donor composition (second donor DNA) to be inserted into the genome is 20 bp to 10 kbp in total. In some cases, the length of the nucleotide sequence of the donor DNA of the insert donor composition (second donor DNA) to be inserted into the genome is 20 bp to 1 kbp in total.
[0051] In some embodiments, the donor DNA has at least one adenylated 3' end.
[0052] In some aspects, insertion of the nucleotide sequence of the second donor DNA into the genome results in operable linkage of the inserted sequence with an endogenous promoter (e.g., (i) a T cell-specific promoter; (ii) a CD3 promoter; (iii) a CD28 promoter; (iv) a stem cell-specific promoter; (v) a somatic cell-specific promoter; and (vi) a promoter for T cell receptor (TCR) α, β, γ, or δ). In some cases, the nucleotide sequence of the Insert Donor Composition that is inserted comprises a sequence encoding a protein operably linked to a promoter (e.g., (i) a T cell-specific promoter; (ii) a CD3 promoter; (iii) a CD28 promoter; (iv) a stem cell-specific promoter; (v) a somatic cell-specific promoter; and (vi) a promoter for T cell receptor (TCR) α, β, γ, or δ).
[0053] In some embodiments, the nucleotide sequence inserted into the genome (of the second donor DNA) encodes a protein. Any convenient protein may be encoded (examples include, but are not limited to, a T cell receptor (TCR) protein; the CDR1, CDR2, or CDR3 region of a T cell receptor (TCR) protein; a chimeric antigen receptor (CAR); a membrane-bound, extracellularly displayed cell-specific targeting ligand; or a reporter protein (e.g., a fluorescent protein, such as GFP, RFP, CFP, YFP, and far-red-fluorescent, near-infrared-fluorescent fluorescent proteins). In some embodiments, the nucleotide sequence inserted into the genome (of the second donor DNA) encodes a multivalent (e.g., heteromultivalent) surface receptor (e.g., in some cases, when T cells are the target cells). Any convenient multivalent receptor may be used; non-limiting examples include bispecific or trispecific CARs and / or TCRs, or other affinity tags on immune cells. Such insertion will cause the receptor to be expressed in the targeted cells. In some cases, multivalency is achieved by inserting separate receptors, where the inserted receptors function as an OR gate (one or the other induces activation) or an AND gate (signaling by the receptor is costimulatory; homovalent binding will not activate / stimulate the cell, e.g., targeted T cell).The protein (e.g., CAR, TCR, multivalent surface receptor) encoded by the inserted DNA may be any of the following: CD3, CD28, CD90, CD45f, CD34, CD80, CD86, CD19, CD20, CD22, CD3 epsilon, CD3γ, CD3δ; the constant regions of TCRα, TCRβ, TCRγ, and / or TCRδ; 4-1BB, OX40, OX40L, CD62L, ARP5, CCR5, CCR7, CCR10, CXCR3, CXCR4, CD94 / NKG2, The antibodies may be selected to bind to (e.g., function to target cells (e.g., T cells) to) one or more targets selected from NKG2A, NKG2B, NKG2C, NKG2E, NKG2H, NKG2D, NKG2F, NKp44, NKp46, NKp30, DNAM, XCR1, XCL1, XCL2, ILT, LIR, Ly49, IL-2, IL-7, IL-10, IL-12, IL-15, IL-18, TNFα, IFNγ, TGF-β, and α5β1.
[0054] In some cases, the inserted nucleotide sequence encodes a receptor in which the target targeted by (the receptor binds to) the receptor is specific to the individual's disease (e.g., cancer / tumor). In some cases, the inserted nucleotide sequence encodes a heteromultivalent receptor in which the combination of targets targeted by the heteromultivalent receptor is specific to the individual's disease (e.g., cancer / tumor). As one example, an individual's cancer (e.g., tumor, e.g., via biopsy) can be sequenced (e.g., by nucleic acid sequencing, proteomics, metabolomics, etc.) to identify antigens of the diseased cells that can be targets (e.g., antigens that are overexpressed in or unique to the tumor compared to the individual's control cells), and a nucleotide sequence encoding a receptor (e.g., a heteromultivalent receptor) that binds to one or more of these targets (e.g., 2 or more, 3 or more, 5 or more, 10 or more, 15 or more, or about 20) can be inserted into an immune cell (e.g., an NK cell, B cell, T cell, e.g., using a CAR or TCR) such that the immune cell specifically targets the individual's diseased cells (e.g., tumor cells). In this manner, the inserted nucleotide sequence (of the second donor DNA) can be therapeutically responsive (in the sense that the encoded receptor (e.g., heteropolyvalent receptor) can be designed after receiving unique insights into the patient's proteomics, genomics, or metabolomics (e.g., via sequencing)) to generate a highly avid and specific immune system response. In this manner, immune cells (e.g., NK cells, B cells, T cells, etc.) can be genome-edited to express receptors, e.g., CAR and / or TCR proteins (e.g., heteropolyvalent forms), designed to be effective against an individual's specific disease (e.g., cancer). In some cases, regulatory T cells can be endowed with similar avidity for autoimmune-affected tissues following therapeutic intervention.
[0055] In some cases, the nucleotide sequence of the second donor DNA to be inserted into the genome comprises a nucleotide sequence encoding an intronless protein, in some cases the intronless nucleotide sequence encodes all or a portion of a TCR protein.
[0056] In some embodiments, more than one delivery vehicle can be introduced into a target cell. For example, in some cases, the methods of the present invention include introducing a first and a second of the delivery vehicles into a cell, wherein the nucleotide sequence of the second donor DNA of the first delivery vehicle inserted into the genome encodes a T cell receptor (TCR) α or δ subunit, and the nucleotide sequence of the second donor DNA of the second delivery vehicle inserted into the genome encodes a TCR β or γ subunit. In some cases, the methods of the present invention include introducing a first and a second of the delivery vehicles into a cell, wherein the nucleotide sequence of the second donor DNA of the first delivery vehicle inserted into the genome encodes a constant region of a T cell receptor (TCR) α or δ subunit, and the nucleotide sequence of the second donor DNA of the second delivery vehicle inserted into the genome encodes a constant region of a TCR β or γ subunit.
[0057] In some cases, the methods of the invention include introducing a first and a second of the delivery vehicles into a cell, wherein the nucleotide sequence of the second donor DNA of the first delivery vehicle is inserted within a nucleotide sequence that functions as a promoter for a T cell receptor (TCR) α or δ subunit, and the nucleotide sequence of the second donor DNA of the second delivery vehicle is inserted within a nucleotide sequence that functions as a promoter for a TCR β or γ subunit. For more information regarding TCR proteins and CDRs, see, e.g., Dash et al., Nature. 2017 Jul 6;547(7661):89-93. Epub 2017 Jun 21 and Glanville et al., Nature. 2017 Jul 6;547(7661):94-98. Epub 2017 Jun 21.
[0058] In some cases, the methods of the invention include introducing a first and a second of the delivery vehicles into a cell, wherein the nucleotide sequence of the second donor DNA of the first delivery vehicle that is inserted into the genome encodes a T cell receptor (TCR) α or γ subunit, and the nucleotide sequence of the second donor DNA of the second delivery vehicle that is inserted into the genome encodes a TCR β or δ subunit. In some cases, the methods of the invention include introducing a first and a second of the delivery vehicles into a cell, wherein the nucleotide sequence of the second donor DNA of the first delivery vehicle that is inserted into the genome encodes a constant region of a T cell receptor (TCR) α or δ subunit, and the nucleotide sequence of the second donor DNA of the second delivery vehicle that is inserted into the genome encodes a constant region of a TCR β or γ subunit. In some cases, the methods of the invention include introducing a first and a second of the delivery vehicles into a cell, wherein the nucleotide sequence of the second donor DNA of the first delivery vehicle is inserted within a nucleotide sequence that functions as a promoter for a T cell receptor (TCR) α or γ subunit, and the nucleotide sequence of the second donor DNA of the second delivery vehicle is inserted within a nucleotide sequence that functions as a promoter for a TCR β or δ subunit. For more information regarding TCR proteins and CDRs, see, e.g., Dash et al., Nature. 2017 Jul 6;547(7661):89-93. Epub 2017 Jun 21 and Glanville et al., Nature. 2017 Jul 6;547(7661):94-98. Epub 2017 Jun 21.
[0059] Delivery Vehicle / Payload In some embodiments, the compositions of the invention (nuclease composition, target donor composition, recombinase composition, and / or insert donor composition) are delivered to cells as payloads of the same delivery vehicle. For example, in some cases, (i) the first donor DNA of the invention; (ii) one or more sequence-specific nucleases (e.g., meganucleases, homing endonucleases, zinc finger nucleases, TALENs, CRISPR / Cas effector proteins) (or additional nucleic acids encoding one or more sequence-specific nucleases); (iii) a site-specific recombinase; and (iv) the second donor DNA are payloads of the same delivery vehicle. In some such cases, the payloads combine together to form one or more: a ribonucleoprotein complex (e.g., a complex comprising a protein and RNA, e.g., a CRISPR / Cas effector protein and a guide RNA), a deoxyribonucleoprotein complex (e.g., a complex comprising DNA and a protein), and / or a ribo-deoxyribonucleoprotein complex (e.g., a complex comprising a protein, DNA, and RNA).
[0060] Delivery vehicles may include, but are not limited to, non-viral vehicles, viral vehicles, nanoparticles (e.g., nanoparticles comprising a targeting ligand and / or a core comprising an anionic polymer composition, a cationic polymer composition, and a cationic polypeptide composition), liposomes, micelles, water-in-oil-in-water emulsion particles, oil-in-water emulsion micelle particles, multilamellar water-in-oil-in-water emulsion particles, targeting ligands conjugated to charged polymer polypeptide domains (e.g., peptide targeting ligands, where the targeting ligand binds to a cell surface protein and the charged polymer polypeptide domain condenses with a nucleic acid payload and / or electrostatically interacts with a protein payload), and targeting ligands conjugated to payloads (e.g., peptide targeting ligands), where the targeting ligand binds to a cell surface protein.
[0061] In some cases, the delivery vehicle is a water-in-oil-in-water emulsion particle. In some cases, the delivery vehicle is an oil-in-water emulsion micelle particle. In some cases, the delivery vehicle is a multilamellar water-in-oil-in-water emulsion particle. In some cases, the delivery vehicle is a multilamellar particle. In some cases, the delivery vehicle is a DNA origami nanobot. In any of the above cases, the payload (nucleic acid and / or protein) can be located inside the particle by covalent bonding, by being bound as a nucleic acid complement, or by being located within the aqueous phase of the particle. In some cases, the delivery vehicle includes a targeting ligand, such as a targeting ligand coated on a water-in-oil-in-water emulsion particle, an oil-in-water emulsion micelle particle, a multilamellar water-in-oil-in-water emulsion particle, a multilamellar particle, or a DNA origami nanobot (described in detail elsewhere in this specification). In some cases, the delivery vehicle has a metal particle core, and the payload (e.g., donor DNA and / or a site-specific nuclease (or a nucleic acid encoding the same)) can be conjugated (covalently bound) to the metal core.
[0062] nanoparticles The nanoparticles of the present invention comprise a payload, which may be made from nucleic acids and / or proteins. For example, in some cases, the nanoparticles of the present invention are used to deliver nucleic acid payloads (e.g., DNA and / or RNA). In some cases, the core of the nanoparticle comprises the payload. In some such cases, the core of the nanoparticle may also comprise anionic polymer compositions, cationic polymer compositions, and cationic polypeptide compositions. In some cases, the nanoparticle has a metal particle core, and the payload is associated with the core (in some cases conjugated to it, e.g., to its exterior). In some embodiments, the payload is part of the core of the nanoparticle. Thus, the core of the nanoparticles of the present invention may comprise nucleic acids, DNA, RNA, and / or proteins. Thus, in some cases, the nanoparticles of the present invention comprise nucleic acids (DNA and / or RNA) and proteins. In some cases, the core of the nanoparticles of the present invention comprises a ribonucleoprotein (RNA and protein) complex. In some cases, the core of the nanoparticles of the present invention comprises a deoxyribonucleoprotein (DNA and protein (e.g., donor DNA and ZFN, TALEN, or CRISPR / Cas effector protein)) complex. In some cases, the core of the nanoparticles of the invention comprises a ribo-deoxyribonucleoprotein (RNA, DNA, and protein (e.g., guide RNA, donor DNA, and CRISPR / Cas effector protein)) complex. In some cases, the core of the nanoparticles of the invention comprises a PNA. In some cases, the core of the nanoparticles of the invention comprises a PNA and DNA.
[0063] The nucleic acid payloads of the present invention may comprise a morpholino backbone structure. In some cases, the nucleic acid payloads of the present invention (e.g., donor DNA, nucleic acids encoding sequence-specific nucleases, and / or nucleic acids encoding recombinases) may comprise one or more locked nucleic acids (LNAs). Suitable sugar substituents include methoxy (-O-CH), aminopropoxy (-OCHCHCHNH), allyl (-CH-CH=CH), -O-allyl (-O-CH-CH=CH), and fluoro (F). The 2'-sugar substituent may be at the arabino position (up) or the ribo position (down). Suitable base modifications include 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine, 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (-C=C-CH3) uracil and cytosine, other alkynyl derivatives of pyrimidine bases, 6-azouracil, cytosine, and thymine, 5-uracil ( These include synthetic and natural nucleobases such as uracil, 2-isopropyl ...Further modified nucleobases include G-clamps such as phenoxazine cytidine (1H-pyrimido(5,4-b)(1,4)benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido(5,4-b)(1,4)benzothiazin-2(3H)-one), substituted phenoxazine cytidines (e.g., 9-(2-aminoethoxy)-H-pyrimido(5,4-(b)(1,4)benzoxazin-2(3H)-one), tricyclic pyrimidines such as carbazole cytidine (2H-pyrimido(4,5-b)indol-2-one), and pyridoindole cytidine (H-pyrido(3',2':4,5)pyrrolo(2,3-d)pyrimidin-2-one).
[0064] In some cases, the nucleic acid payload may contain a conjugate moiety (e.g., a moiety that enhances the activity, stability, intracellular distribution, or cellular uptake of the nucleic acid payload). These moieties or conjugates may include a conjugate group covalently attached to a functional group, such as a primary or secondary hydroxyl group. Conjugate groups include, but are not limited to, intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Suitable conjugate groups include, but are not limited to, cholesterol, lipids, phospholipids, biotin, phenazine, folic acid, phenanthridine, anthraquinone, acridine, fluorescein, rhodamine, coumarin, and dyes. Groups that enhance the pharmacodynamic properties include groups that improve uptake, enhance resistance to degradation, and / or strengthen sequence-specific hybridization with the target nucleic acid. Groups that enhance the pharmacokinetic properties include groups that improve the uptake, distribution, metabolism, or excretion of the nucleic acids of the invention.
[0065] Any convenient polynucleotide can be used as the nucleic acid payload of the present invention, other than donor DNA (e.g., for delivering site-specific nucleases and / or site-specific recombinases). Examples include, but are not limited to, RNA and DNA molecular species, including mRNA, m1A-modified mRNA (monomethylated at the 1-position of adenosine), morpholino RNA, peptoid and peptide nucleic acids, cDNA, DNA origami, DNA and RNA with synthetic nucleotides, DNA and RNA with defined secondary structures, and multimers and oligomers of the foregoing molecular species.
[0066] As noted above, more than one payload can be delivered as part of the same package (delivery vehicle) (e.g., nanoparticle); for example, in some cases, different payloads are part of different cores. One advantage of delivering multiple payloads as part of the same delivery vehicle (e.g., nanoparticle) is that the efficiency of each payload is not reduced. For example, if payload A and payload B are delivered in two separate packages / vehicles (package A and package B, respectively), the efficiency is multiplicative; for example, if package A and package B each have a transfection efficiency of 1%, the chance of delivering payload A and payload B to the same cell is 0.01% (1% x 1%). However, if payload A and payload B are both delivered as part of the same delivery vehicle, the chance of delivering payload A and payload B to the same cell is 1%, a 100-fold improvement over 0.01%.
[0067] Similarly, in a situation where package A and package B each have a transfection efficiency of 0.1%, the chance of delivering payload A and payload B to the same cell is 0.0001% (0.1% x 0.1%). However, in this situation, if payload A and payload B are both delivered as the same package (e.g., as part of the same nanoparticle (package A)), the chance of delivering payload A and payload B to the same cell is 0.1%, a 1000-fold improvement over 0.0001%.
[0068] Thus, in some embodiments, one or more gene editing tools (e.g., as described above) and donor DNA are delivered in combination (e.g., as part of the same nanoparticle) with a protein (and / or DNA or mRNA encoding the same) and / or a non-coding RNA that increases genome editing efficiency. In some cases, one or more gene editing tools (e.g., as described above) and donor DNA are delivered in combination (e.g., as part of the same nanoparticle) with a protein (and / or DNA or mRNA encoding the same) and / or a non-coding RNA that controls cell division and / or differentiation.
[0069] As non-limiting examples of the above, in some embodiments, the one or more gene editing tools and donor DNA may be delivered in combination with one or more of SCF (and / or DNA or mRNA encoding SCF), HoxB4 (and / or DNA or mRNA encoding HoxB4), BCL-XL (and / or DNA or mRNA encoding BCL-XL), SIRT6 (and / or DNA or mRNA encoding SIRT6), a nucleic acid molecule (e.g., siRNA and / or LNA) that inhibits miR-155, a nucleic acid molecule (e.g., siRNA, shRNA, microRNA) that reduces expression of ku70, and a nucleic acid molecule (e.g., siRNA, shRNA, microRNA) that reduces expression of ku80.
[0070] See Figure 9 for examples of microRNAs that can be delivered together (delivered as RNA or as DNA encoding the RNA). For example, the following microRNAs can be used: for blocking differentiation of pluripotent stem cells into the ectodermal lineage: miR-430 / 427 / 302 (e.g., MiRBase Accession Nos. MI0000738, MI0000772, MI0000773, MI0000774, MI0006417, MI0006418, MI0000402, MI0003716, MI0003717, and MI0003718); for blocking differentiation of pluripotent stem cells into the endodermal lineage: miR-109 and / or miR-24 ... MiR-Based Accession Numbers: MI0000080, MI0000081, MI0000231, and MI0000572; for driving the differentiation of pluripotent stem cells into the endodermal lineage: miR-122 (e.g., MiR-Based Accession Numbers: MI0000442 and MI0000256) and / or miR-192 (e.g., MiR-Based Accession Numbers: MI0000234 and MI0000551); for driving the differentiation of ectodermal progenitor cells into a keratinocyte fate: miR-203 (e.g., MiR-Based Accession Numbers: MI0000283, MI0017343, and MI0000572). 0000246); for driving differentiation of neural crest stem cells towards a smooth muscle fate: miR-145 (e.g., MiRBase Accession Numbers: MI0000461, MI0000169, and MI0021890); for driving differentiation of neural stem cells towards a glial and / or neuronal fate: miR-9 (e.g., MiRBase Accession Numbers: MI0000466, MI0000467, MI0000468, MI0000157, MI0000720, and MI0000721) and / or miR-124a (e.g., MiRBase Accession Numbers: MI0 000443, MI0000444, MI0000445, MI0000150, MI0000716 and MI0000717); for blocking the differentiation of mesodermal progenitor cells to a chondrocyte fate: miR-199a (e.g., MiRBase Accession Numbers: MI0000242, MI0000281, MI0000241 and MI0000713); for driving the differentiation of mesodermal progenitor cells to an osteoblast fate: miR-296 (e.g., MiRBase Accession Numbers: MI0000747 and MI0000394) and / or miR-2861 (e.g.,MiR-based accession numbers: MI0013006 and MI0013007; for driving the differentiation of mesodermal progenitor cells to a cardiac fate: miR-1 (e.g., MiR-based accession numbers: MI0000437, MI0000651, MI0000139, MI0000652, MI0006283); for blocking the differentiation of mesodermal progenitor cells to a cardiac fate: miR-133 (e.g., MiR-based accession numbers: MI0000450, MI0000451, MI0000822, MI0000159, MI00006283). 000820, MI0000821, and MI0021863); for the purpose of driving differentiation of mesodermal progenitor cells to a skeletal muscle fate: miR-214 (e.g., MiRBase Accession Nos. MI0000290 and MI0000698), miR-206 (e.g., MiRBase Accession Nos. MI0000490 and MI0000249), miR-1, and / or miR-26a (e.g., MiRBase Accession Nos. MI0000083, MI0000750, MI0000573, and MI0000706); for the purpose of driving differentiation of mesodermal progenitor cells to a skeletal muscle fate: miR-133 (e.g., MiRBase Accession Numbers: MI0000450, MI0000451, MI0000822, MI0000159, MI0000820, MI0000821, and MI0021863), miR-221 (e.g., MiRBase Accession Numbers: MI0000298 and MI0000709), and / or miR-222 (e.g., MiRBase Accession Numbers: MI0000299 and MI0000710) to block differentiation of progenitor cells to a skeletal muscle fate; miR-223 (e.g., MiRBase Accession Numbers: MI0000300 and MI0000703) for blocking differentiation of hematopoietic progenitor cells; miR-128a (e.g., MiRBase Accession Numbers: MI0000447 and MI0000155) and / or miR-181a (e.g., MiRBase Accession Numbers: MI0000269, MI0000289, MI0000223, and MI0000697) for driving differentiation of hematopoietic progenitor cells into lymphoid progenitor cells; miR-181 (e.g.,MiR-based accession numbers: MI0000269, MI0000270, MI0000271, MI0000289, MI0000683, MI0003139, MI0000223, MI0000723, MI0000697, MI0000724, MI0000823, and MI0005450; miR-146 (e.g., MiR-based accession numbers: MI0000477, MI0003129, MI0003782, MI0000170, and MI0004665) for blocking differentiation of hematopoietic progenitor cells into lymphoid progenitor cells; miR-155, miR-24a, and / or miR-17 (e.g., MiRBase Accession Numbers: MI0000071 and MI0000687) to block differentiation of lymphoid progenitors to a T cell fate; miR-150 (e.g., MiRBase Accession Numbers: MI0000479 and MI0000172) to drive differentiation of lymphoid progenitors to a T cell fate; miR-223 (e.g., MiRBase Accession Numbers: MI0000300 and MI0000703) to block differentiation of myeloid progenitors to a granulocytic fate; and miR-223 (e.g., MiRBase Accession Numbers: MI0000300 and MI0000703) to drive differentiation of myeloid progenitors to a monocytic fate. miR-17-5p (e.g., MiRBase accession numbers: MIMAT0000070 and MIMAT0000649), miR-20a (e.g., MiRBase accession numbers: MI0000076 and MI0000568), and / or miR-106a (e.g., MiRBase accession numbers: MI0000113 and MI0000406); miR-150 (e.g., MiRBase accession numbers: MI0000479 and MI0000172), miR-155, miR-221 (e.g., MiRBase accession numbers: MI0000479 and MI0000172), and / or miR-221 (e.g., MiRBase accession numbers: MI0000479 and MI0000172). MiRBase Accession Numbers: MI0000298 and MI0000709), and / or miR-222 (e.g., MiRBase Accession Numbers: MI0000299 and MI0000710); and for driving the differentiation of myeloid progenitor cells towards an erythroid fate: miR-451 (e.g., MiRBase Accession Numbers: MI0001729, MI0017360, MI0001730, and MI0021960) and / or miR-16 (e.g., MiRBase Accession Numbers: MI0000070, MI0000115, MI0000565, and MI0000566).
[0071] See Figure 10 for examples of signaling proteins (e.g., extracellular signaling proteins) that may be delivered (e.g., as proteins or DNA or RNA encoding the proteins) in combination with the gene editing tool, first and second donor DNA, and recombinase (or nucleic acid encoding same). The same proteins may also be used as part of the outer shell of the nanoparticles of the invention, as well as targeting ligands, for example, to bias differentiation in target cells that receive the nanoparticles. For example, the following signaling proteins (e.g., extracellular signaling proteins) may be used to drive the differentiation of hematopoietic stem cells down the common lymphoid progenitor lineage: IL-7 (e.g., NCBI Gene ID: 3574); to drive the differentiation of hematopoietic stem cells down the common myeloid progenitor lineage: IL-3 (e.g., NCBI Gene ID: 3562), GM-CSF (e.g., NCBI Gene ID: 1437), and / or M-CSF (e.g., NCBI Gene ID: 1435); to drive the differentiation of common lymphoid progenitors towards a B cell fate: IL-3, IL-4 (e.g., NCBI Gene ID: 3565), and / or IL-7; to drive the differentiation of common lymphoid progenitors towards a natural killer cell fate: IL-15 (e.g., NCBI Gene ID: 3600); to drive the differentiation of common lymphoid progenitors towards a T cell fate: IL-2 (e.g., NCBI Gene ID: 3601). ID: 3558), IL-7 and / or Notch (e.g., NCBI Gene IDs: 4851, 4853, 4854, 4855); for driving differentiation of common lymphoid progenitors towards a dendritic cell fate: Flt-3 ligand (e.g., NCBI Gene ID: 2323); for driving differentiation of common myeloid progenitors towards a dendritic cell fate: Flt-3 ligand, GM-CSF and / or TNFα (e.g., NCBI Gene ID: 7124); for driving differentiation of common myeloid progenitors towards a granulocyte-macrophage progenitor lineage: GM-CSF; for driving differentiation of common myeloid progenitors towards a megakaryocytic-erythroid progenitor lineage: IL-3, SCF (e.g., NCBI Gene ID: 4254) and / or Tpo (e.g.,NCBI Gene ID: 7173); for driving differentiation of megakaryocyte-erythroid progenitors towards a megakaryocyte fate: IL-3, IL-6 (e.g., NCBI Gene ID: 3569), SCF and / or Tpo; for driving differentiation of megakaryocyte-erythroid progenitors towards an erythroid fate: erythropoietin (e.g., NCBI Gene ID: 2056); for driving differentiation of megakaryocytes towards a platelet fate: IL-11 (e.g., NCBI Gene ID: 3589) and / or Tpo; for driving differentiation of granulocyte-macrophage progenitors towards a monocyte lineage: GM-CSF and / or M-CSF; for driving differentiation of granulocyte-macrophage progenitors towards an osteoblast lineage: GM-CSF; for driving differentiation of monocytes towards a monocyte-derived dendritic cell fate: Flt-3 ligand, GM-CSF, IFNα (e.g., NCBI Gene ID: 3439) and / or IL-4; for driving the differentiation of monocytes towards a macrophage fate: IFNγ, IL-6, IL-10 (e.g., NCBI Gene ID: 3586) and / or M-CSF; for driving the differentiation of osteoblasts towards a neutrophil fate: G-CSF (e.g., NCBI Gene ID: 1440), GM-CSF, IL-6 and / or SCF; for driving the differentiation of osteoblasts towards an eosinophil fate: GM-CSF, IL-3, and / or IL-5 (e.g., NCBI Gene ID: 3567); and for driving the differentiation of osteoblasts towards a basophil fate: G-CSF, GM-CSF and / or IL-3.
[0072] Examples of proteins that can be delivered in combination with other payloads described herein (e.g., as proteins and / or nucleic acids encoding proteins, e.g., DNA or RNA) include, but are not limited to, SOX17, HEX, OSKM (Oct4 / Sox2 / Klf4 / c-myc), and / or bFGF (e.g., to drive differentiation toward a hepatic stem cell lineage); HNF4a (e.g., to drive differentiation toward a hepatic cell fate); Poly(I:C), BMP-4, bFGF, and / or 8-Br-cAMP (e.g., to drive differentiation toward an endothelial stem / progenitor cell lineage); VEGF (e.g., to drive differentiation toward an arterial endothelial fate); Sox-2, Brn4, Myt11, Neurod2, Ascl1 (e.g., to drive differentiation toward a neural stem / progenitor cell lineage); and BDNF, FCS, forskolin, and / or SHH (e.g., to drive differentiation toward a neuron, astrocyte, and / or oligodendrocyte fate).
[0073] Examples of signaling proteins (e.g., extracellular signaling proteins) that can be delivered along with other payloads described herein (e.g., as proteins and / or nucleic acids encoding proteins, e.g., DNA or RNA) include, but are not limited to, cytokines (e.g., IL-1 and / or IL-15, for example, to activate CD8+ T cells); ligands and / or signaling proteins that modulate one or more of the Notch, Wnt, and / or Smad signaling pathways; SCF; stem cell differentiation factors (e.g., Sox2, Oct3 / 4, Nanog, Klf4, c-Myc, etc.); and transient surface marker "tags" and / or fluorescent reporters for subsequent isolation / purification / enrichment. For example, fibroblasts can be converted into neural stem cells via delivery of Sox2, but will become cardiomyocytes in the presence of Oct3 / 4 and a small molecule "epigenetic resetter." In patients with Huntington's disease or CXCR4 mutations, these fibroblasts can encode diseased phenotypic traits associated with neurons and cardiac cells, respectively. By delivering the gene editing correction and these factors in a single package, the risk of adverse effects due to one or more, if not all, of the introduced factors / payloads may be significantly reduced.
[0074] Because the timing and / or location of payload release can be controlled (as described in more detail elsewhere herein), packaging multiple payloads within the same package (e.g., the same nanoparticle) does not preclude achieving different release times / rates and / or locations for different payloads. For example, the release of the above-mentioned proteins (and / or DNA or mRNA encoding them) and / or non-coding RNAs can be controlled separately from the release of one or more gene editing tools that are part of the same package. For example, proteins and / or nucleic acids (e.g., DNA, mRNA, non-coding RNA, miRNA) that control cell proliferation and / or differentiation may be released earlier or later than one or more gene editing tools. This can be achieved, for example, by using more than one decidual layer and / or more than one core (e.g., where one core has a different release profile from the other cores, e.g., where a different D-isomer to L-isomer ratio is used, where a different ESP:ENP:EPP profile is used, etc.). In this way, the donor and nuclease can be released in a stepwise manner that allows for optimal editing and insertion efficiency. Similarly, in some cases, it may be desirable to release the first donor DNA and nuclease (or nucleic acid encoding same) before releasing the recombinase (or nucleic acid encoding same) and second donor DNA.
[0075] Nanoparticle Core The core of the nanoparticles of the present invention can comprise an anionic polymer composition (e.g., poly(glutamic acid)), a cationic polymer composition (e.g., poly(arginine)), a cationic polypeptide composition (e.g., histone tail peptide), and a payload (e.g., a nucleic acid and / or protein payload (e.g., one or more of first and second donor DNAs, a site-specific nuclease or a nucleic acid encoding a site-specific nuclease, and a site-specific recombinase or a nucleic acid encoding the same)). In some cases, the core is generated by condensation of the cationic amino acid polymer and the payload in the presence of the anionic amino acid polymer (and in some cases, in the presence of a cationic polypeptide of the cationic polypeptide composition). In some aspects, condensation of the components comprising the core can mediate increased transfection efficiency compared to conjugation of the cationic polymer with the payload. Incorporation of an anionic polymer into the core of the nanoparticle can extend the duration of nanoparticle retention in cells and payload release.
[0076] For the core cationic and anionic polymer compositions, the ratio of D- to L-isomer polymer can be controlled to control the sustained release of the payload, where increasing the ratio of D- to L-isomer polymer results in increased stability (decreased rate of payload release), which may enable, for example, long-lasting gene expression from the payload delivered by the nanoparticles of the present invention. In some cases, altering the ratio of D- to L-isomer polypeptides within the core of the nanoparticle can result in a gene expression profile (e.g., expression of a protein encoded by a payload molecule) on the order of 1 to 90 days (e.g., 1 to 80, 1 to 70, 1 to 60, 1 to 50, 1 to 40, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 3 to 90, 3 to 80, 3 to 70, 3 to 60, 3 to 50, 3 to 40, 3 to 30, 3 to 25, 3 to 20, 3 to 15, 3 to 10, 5 to 90, 5 to 80, 5 to 70, 5 to 60, 5 to 50, 5 to 40, 5 to 30, 5 to 25, 5 to 20, 5 to 15, or 5 to 10 days). Controlling payload release (e.g., when delivering gene editing tools) can be particularly effective for performing genome editing, for example, when homology-directed repair is desired.
[0077] In some aspects, the nanoparticles comprise a core and a shed layer encapsulating the core, wherein the core comprises: (a) an anionic polymer composition; (b) a cationic polymer composition; (c) a cationic polypeptide composition; and (d) a nucleic acid and / or protein payload, wherein one of (a) and (b) comprises a D-isomer polymer of an amino acid and the other of (a) and (b) comprises an L-isomer polymer of an amino acid, wherein the ratio of D-isomer polymer to L-isomer polymer is between 10:1 and 1.5:1 (e.g., 8:1 and 1.5:1, 6:1 and 1.5:1, 5:1 and 1.5:1, 4:1 and 1.5:1, 3:1 and 1.5:1, 2:1 and 1.5:1, 10:1 and 2 :1; 8:1 to 2:1, 6:1 to 2:1, 5:1 to 2:1, 10:1 to 3:1; 8:1 to 3:1, 6:1 to 3:1, 5:1 to 3:1, 10:1 to 4:1; 4:1 to 2:1, 6:1 to 4:1, or 10:1 to 5:1), or 1:1.5 to 1:10 (e.g., 1:1.5 to 1:8, 1:1.5 to 1:6, 1:1.5 to 1:5, 1:1.5 In some such cases, the ratio of D-isomer polymer to L-isomer polymer is not 1:1. In some such cases, the anionic polymer composition comprises an anionic polymer selected from poly(D-glutamic acid) (PDEA) and poly(D-aspartic acid) (PDDA), wherein (optionally), the cationic polymer composition may comprise a cationic polymer selected from poly(L-arginine), poly(L-lysine), poly(L-histidine), poly(L-ornithine), and poly(L-citrulline).In some cases, the cationic polymer composition comprises a cationic polymer selected from poly(D-arginine), poly(D-lysine), poly(D-histidine), poly(D-ornithine), and poly(D-citrulline), wherein (optionally), the anionic polymer composition may comprise an anionic polymer selected from poly(L-glutamic acid) (PLEA) and poly(L-aspartic acid) (PLDA).
[0078] In some embodiments, the nanoparticles comprise a core and a shedding layer encapsulating the core, wherein the core comprises (i) an anionic polymer composition; (ii) a cationic polymer composition; (iii) a cationic polypeptide composition; and (iv) a nucleic acid and / or protein payload, wherein (a) the anionic polymer composition comprises a polymer of a D-isomer of an anionic amino acid and a polymer of an L-isomer of an anionic amino acid; and / or (b) the cationic polymer composition comprises a polymer of a D-isomer of a cationic amino acid and a polymer of an L-isomer of a cationic amino acid. In some such cases, the anionic polymer composition comprises a first anionic polymer selected from poly(D-glutamic acid) (PDEA) and poly(D-aspartic acid) (PDDA); and a second anionic polymer selected from poly(L-glutamic acid) (PLEA) and poly(L-aspartic acid) (PLDA). In some cases, the cationic polymer composition comprises a first cationic polymer selected from poly(D-arginine), poly(D-lysine), poly(D-histidine), poly(D-ornithine), and poly(D-citrulline); and a second cationic polymer selected from poly(L-arginine), poly(L-lysine), poly(L-histidine), poly(L-ornithine), and poly(L-citrulline). In some cases, the polymer of the D-isomer of an anionic amino acid is present in a ratio ranging from 10:1 to 1:10 relative to the polymer of the L-isomer of the anionic amino acid. In some cases, the polymer of the D-isomer of a cationic amino acid is present in a ratio ranging from 10:1 to 1:10 relative to the polymer of the L-isomer of the cationic amino acid.
[0079] Nanoparticle components (timing) In some aspects, the timing of payload release can be controlled by, for example, selecting a particular type of protein as part of the core (e.g., part of the cationic polypeptide composition, part of the cationic polymer composition, and / or part of the anionic polymer composition). For example, it may be desirable to delay release of the payload for a particular time, or until the payload is present in a particular intracellular location (e.g., the cytosol, the nucleus, the lysosome, the endosome), or under particular conditions (e.g., low pH, high pH, etc.). Thus, in some cases, a protein is used (e.g., as part of the core) that is sensitive to a specific protein activity (e.g., an enzymatic activity), e.g., a substrate for a specific protein activity (e.g., an enzymatic activity), as opposed to being sensitive to a general, ubiquitous intracellular mechanism, e.g., a general degradation mechanism. Proteins that are sensitive to a specific protein activity are referred to herein as "enzyme-sensitive proteins" (ESPs). Examples of ESPs include, but are not limited to, (i) proteins that are substrates for matrix metalloproteinase (MMP) activity (an example of an extracellular activity), e.g., proteins containing a motif recognized by an MMP; (ii) proteins that are substrates for cathepsin activity (an example of an intracellular endosomal activity), e.g., proteins containing a motif recognized by a cathepsin; and (iii) proteins that are substrates for methyltransferase and / or acetyltransferase activity (an example of an intracellular activity), e.g., histone tail peptides (HTPs), e.g., proteins containing an enzymatically methylatable / demethylatable motif and / or an enzymatically acetylatable / deacetylatable motif. For example, in some cases, nucleic acid payloads are condensed with proteins (e.g., histone tail peptides) that are substrates for acetyltransferase activity, and acetylation of the protein causes the protein to release the payload (thus, payload release can be controlled by selecting proteins that are more or less sensitive to acetylation).
[0080] In some cases, the core of the nanoparticles of the present invention comprises an enzymatic neutral polypeptide (ENP), which is a polypeptide homopolymer (i.e., a protein with a repeat sequence), in which the polypeptide has no specific activity and is neutral. For example, unlike NLS sequences and HTPs, both of which have specific activity, ENPs have no specific activity.
[0081] In some cases, the core of the nanoparticles of the present invention comprises an enzyme protective polypeptide (EPP), which is a protein that is resistant to enzymatic activity. Examples of EPPs include, but are not limited to, (i) polypeptides containing D-isomer amino acids (e.g., D-isomer polymers) that can resist proteolysis; and (ii) self-sheltering domains, such as polyglutamine repeat domains (e.g., QQQQQQQQQQ) (SEQ ID NO: 170).
[0082] By controlling the relative amounts of sensitive proteins (ESPs), neutral proteins (ENPs), and protective proteins (EPPs) that are part of the nanoparticles of the present invention (e.g., part of the core of the nanoparticles), the release of the payload can be controlled. For example, the use of multiple ESPs can generally result in more rapid payload release than the use of multiple EPPs. In addition, the use of multiple ESPs generally results in payload release that is dependent on a particular set of conditions / circumstances, such as conditions / circumstances that result in the activity of a protein (e.g., an enzyme) to which the ESP is sensitive.
[0083] Nanoparticulate anionic polymer compositions Anionic polymer compositions can include one or more anionic amino acid polymers. For example, in some cases, the anionic polymer compositions of the present invention include a polymer selected from poly(glutamic acid) (PEA), poly(aspartic acid) (PDA), and combinations thereof. In some cases, a given anionic amino acid polymer can include a mixture of aspartic acid and glutamic acid residues. Each polymer can exist in the composition as either an L-isomer or a D-isomer, where the D-isomer takes longer to degrade and is therefore more stable within target cells. Thus, incorporating D-isomer poly(amino acids) into the core of nanoparticles slows core degradation and subsequent payload release. Thus, the payload release rate can be controlled and is proportional to the ratio of D-isomer polymer to L-isomer polymer, where the D-isomer to L-isomer ratio increases the duration of payload release (i.e., decreases the release rate). In other words, the relative amounts of D- and L-isomers can modulate the release kinetics of the nanoparticle core and its enzymatic susceptibility to degradation and payload release.
[0084] In some cases, the anionic polymer composition of the nanoparticles of the present invention comprises a polymer of the D-isomer and a polymer of the L-isomer of an anionic amino acid polymer (e.g., poly(glutamic acid) (PEA) and poly(aspartic acid) (PDA)). In some cases, the ratio of D- to L-isomers is between 10:1 and 1:10 (e.g., 8:1 and 1:10, 6:1 and 1:10, 4:1 and 1:10, 3:1 and 1:10, 2:1 and 1:10, 1:1 and 1:10, 10:1 and 1:8, 8:1 and 1:8, 6:1 and 1:8, 4:1 and 1:8, 3:1 and 1:8, 2:1 and 1:8, 1:1 and 1:8, 10:1 and 1:6, 8:1 and 1:6, 6:1 and 1:6, 4:1 and 1:6, 3:1 and 1:6, 2:1 and 1:6, 1:1 and 1:6, 10:1 and 1:4, 8: 1 to 1:4, 6:1 to 1:4, 4:1 to 1:4, 3:1 to 1:4, 2:1 to 1:4, 1:1 to 1:4, 10:1 to 1:3, 8:1 to 1:3, 6:1 to 1:3, 4:1 to 1:3, 3:1 to 1:3, 2:1 to 1:3, 1:1 to 1:3, 10:1 to 1:2, 8:1 to 1:2, 6:1 to 1:2, 4:1 to 1:2, 3:1 to 1:2, 2:1 to 1:2, 1:1 to 1:2, 10:1 to 1:1, 8:1 to 1:1, 6:1 to 1:1, 4:1 to 1:1, 3:1 to 1:1 or 2:1 to 1:1).
[0085] Thus, in some cases, the anionic polymer composition includes a first anionic polymer (e.g., an amino acid polymer) that is a polymer of a D-isomer (e.g., selected from poly(D-glutamic acid) (PDEA) and poly(D-aspartic acid) (PDDA)); and a second anionic polymer (e.g., an amino acid polymer) that is a polymer of an L-isomer (e.g., selected from poly(L-glutamic acid) (PLEA) and poly(L-aspartic acid) (PLDA)). In some cases, the ratio of the first anionic polymer (D-isomer) to the second anionic polymer (L-isomer) is 10:1 to 1:10 (e.g., 8:1 to 1:10, 6:1 to 1:10, 4:1 to 1:10, 3:1 to 1:10, 2:1 to 1:10, 1:1 to 1:10, 10:1 to 1:8, 8:1 to 1:8, 6:1 to 1:8, 4:1 to 1:8, 3:1 to 1:8, 2:1 to 1:8, 1:1 to 1:8, 10:1 to 1:6, 8:1 to 1:6, 6:1 to 1:6, 4:1 to 1:6, 3:1 to 1:6, 2:1 to 1:6, 1:1 to 1:1). :6, 10:1 to 1:4, 8:1 to 1:4, 6:1 to 1:4, 4:1 to 1:4, 3:1 to 1:4, 2:1 to 1:4, 1:1 to 1:4, 10:1 to 1:3, 8:1 to 1:3, 6:1 to 1:3, 4:1 to 1:3, 3:1 to 1:3, 2:1 to 1:3, 1:1 to 1:3, 10:1 to 1:2, 8:1 to 1:2, 6:1 to 1:2, 4:1 to 1:2, 3:1 to 1:2, 2:1 to 1:2, 1:1 to 1:2, 10:1 to 1:1, 8:1 to 1:1, 6:1 to 1:1, 4:1 to 1:1, 3:1 to 1:1, or 2:1 to 1:1).
[0086] In some aspects, the anionic polymer composition of the core of the nanoparticles of the invention comprises an anionic polymer comprising a glycosaminoglycan, a glycoprotein, a polysaccharide, poly(mannuronic acid), poly(glucuronic acid), heparin, heparin sulfate, chondroitin, chondroitin sulfate, keratan, keratan sulfate, aggrecan, poly(glucosamine), or any combination thereof (e.g., in addition to or instead of any of the foregoing examples of anionic polymers).
[0087] In some embodiments, the anionic polymer in the core can have a molecular weight of 1 to 200 kDa (e.g., 1 to 150, 1 to 100, 1 to 50, 5 to 200, 5 to 150, 5 to 100, 5 to 50, 10 to 200, 10 to 150, 10 to 100, 10 to 50, 15 to 200, 15 to 150, 15 to 100, or 15 to 50 kDa). By way of example, in some cases, the anionic polymer comprises poly(glutamic acid) having a molecular weight of about 15 kDa.
[0088] In some cases, the anionic amino acid polymer comprises a cysteine residue that facilitates conjugation with, for example, a linker, an NLS, and / or a cationic polypeptide (e.g., a histone or HTP). For example, the cysteine residue can be used for cross-linking (conjugation) via sulfhydryl chemistry (e.g., disulfide bond) and / or amine-reactive chemistry. Thus, in some embodiments, the anionic amino acid polymer of the anionic polymer composition (e.g., poly(glutamic acid) (PEA), poly(aspartic acid) (PDA), poly(D-glutamic acid) (PDEA), poly(D-aspartic acid) (PDDA), poly(L-glutamic acid) (PLEA), poly(L-aspartic acid) (PLDA)) comprises a cysteine residue. In some cases, the anionic amino acid polymer comprises a cysteine residue at the N- and / or C-terminus. In some cases, the anionic amino acid polymer comprises an internal cysteine residue.
[0089] In some cases, the anionic amino acid polymer comprises (and / or is conjugated to) a nuclear localization signal (NLS) (described in more detail below). Thus, in some embodiments, the anionic amino acid polymers of the anionic polymer composition (e.g., poly(glutamic acid) (PEA), poly(aspartic acid) (PDA), poly(D-glutamic acid) (PDEA), poly(D-aspartic acid) (PDDA), poly(L-glutamic acid) (PLEA), poly(L-aspartic acid) (PLDA)) comprise (and / or are conjugated to) one or more (e.g., two or more, three or more, or four or more) NLSs. In some cases, the anionic amino acid polymer comprises an NLS at the N- and / or C-terminus. In some cases, the anionic amino acid polymer comprises an internal NLS.
[0090] In some cases, the anionic polymer is added before the cationic polymer when producing the core of the nanoparticles of the present invention.
[0091] Nanoparticulate cationic polymer compositions The cationic polymer composition may contain one or more cationic amino acid polymers. For example, in some cases, the cationic polymer composition of the present invention contains a polymer selected from poly(arginine) (PR), poly(lysine) (PK), poly(histidine) (PH), poly(ornithine), poly(citrulline), and combinations thereof. In some cases, a given cationic amino acid polymer may contain a mixture of arginine, lysine, histidine, ornithine, and citrulline residues (in any convenient combination). Each polymer may exist in the composition as either an L-isomer or a D-isomer, where the D-isomer takes longer to degrade and is therefore more stable within target cells. Therefore, incorporating D-isomer poly(amino acids) into the core of nanoparticles delays core degradation and subsequent payload release. Thus, the rate of payload release can be controlled and is proportional to the ratio of D- to L-isomer polymer, where increasing the ratio of D- to L-isomer increases the duration of payload release (i.e., decreases the release rate). In other words, the relative amounts of D- and L-isomers can modulate the sustained release kinetics and enzymatic susceptibility of the nanoparticle core to degradation and payload release.
[0092] In some cases, the cationic polymer composition of the nanoparticles of the present invention includes a polymer of the D-isomer and a polymer of the L-isomer of a cationic amino acid polymer (e.g., poly(arginine) (PR), poly(lysine) (PK), poly(histidine) (PH), poly(ornithine), poly(citrulline)). In some cases, the ratio of D- to L-isomers is between 10:1 and 1:10 (e.g., 8:1 and 1:10, 6:1 and 1:10, 4:1 and 1:10, 3:1 and 1:10, 2:1 and 1:10, 1:1 and 1:10, 10:1 and 1:8, 8:1 and 1:8, 6:1 and 1:8, 4:1 and 1:8, 3:1 and 1:8, 2:1 and 1:8, 1:1 and 1:8, 10:1 and 1:6, 8:1 and 1:6, 6:1 and 1:6, 4:1 and 1:6, 3:1 and 1:6, 2:1 and 1:6, 1:1 and 1:6, 10:1 and 1:4, 8: 1-1:4, 6:1-1:4, 4:1-1:4, 3:1-1:4, 2:1-1:4, 1:1-1:4, 10:1-1:3, 8:1-1:3, 6:1-1:3, 4:1-1:3, 3:1-1:3, 2:1-1:3, 1:1-1:3, 10:1-1:2, 8:1-1:2, 6:1-1:2, 4:1-1:2, 3:1-1:2, 2:1-1:2, 1:1-1:2, 10:1-1:1, 8:1-1:1, 6:1-1:1, 4:1-1:1, 3:1-1:1, or 2:1-1:1).
[0093] Thus, in some cases, the cationic polymer composition includes a first cationic polymer (e.g., an amino acid polymer) that is a polymer of a D-isomer (e.g., selected from poly(D-arginine), poly(D-lysine), poly(D-histidine), poly(D-ornithine), and poly(D-citrulline)); and a second cationic polymer (e.g., an amino acid polymer) that is a polymer of an L-isomer (e.g., selected from poly(L-arginine), poly(L-lysine), poly(L-histidine), poly(L-ornithine), and poly(L-citrulline)). In some cases, the ratio of the first cationic polymer (D-isomer) to the second cationic polymer (L-isomer) is 10:1 to 1:10 (e.g., 8:1 to 1:10, 6:1 to 1:10, 4:1 to 1:10, 3:1 to 1:10, 2:1 to 1:10, 1:1 to 1:10, 10:1 to 1:8, 8:1 to 1:8, 6:1 to 1:8, 4:1 to 1:8, 3:1 to 1:8, 2:1 to 1:8, 1:1 to 1:8, 10:1 to 1:6, 8:1 to 1:6, 6:1 to 1:6, 4:1 to 1:6, 3:1 to 1:6, 2:1 to 1:6, 1:1 to 1:1). :6, 10:1 to 1:4, 8:1 to 1:4, 6:1 to 1:4, 4:1 to 1:4, 3:1 to 1:4, 2:1 to 1:4, 1:1 to 1:4, 10:1 to 1:3, 8:1 to 1:3, 6:1 to 1:3, 4:1 to 1:3, 3:1 to 1:3, 2:1 to 1:3, 1:1 to 1:3, 10:1 to 1:2, 8:1 to 1:2, 6:1 to 1:2, 4:1 to 1:2, 3:1 to 1:2, 2:1 to 1:2, 1:1 to 1:2, 10:1 to 1:1, 8:1 to 1:1, 6:1 to 1:1, 4:1 to 1:1, 3:1 to 1:1 or 2:1 to 1:1).
[0094] In some aspects, the cationic polymer composition of the core of the nanoparticles of the invention comprises (e.g., in addition to or instead of any of the foregoing examples of cationic polymers) a cationic polymer (e.g., in linear or branched form) comprising poly(ethyleneimine), poly(amidoamine) (PAMAM), poly(aspartamide), polypeptoid (e.g., to form "spiderweb"-like branching for core condensation), charge-functionalized polyester, cationic polysaccharide, acetylated amino sugar, chitosan, or any combination thereof.
[0095] In some embodiments, the cationic polymer in the core can have a molecular weight of 1 to 200 kDa (e.g., 1 to 150, 1 to 100, 1 to 50, 5 to 200, 5 to 150, 5 to 100, 5 to 50, 10 to 200, 10 to 150, 10 to 100, 10 to 50, 15 to 200, 15 to 150, 15 to 100, or 15 to 50 kDa). By way of example, in some cases, the cationic polymer comprises poly(L-arginine) having a molecular weight of about 29 kDa. As another example, in some cases, the cationic polymer comprises linear poly(ethyleneimine) having a molecular weight of about 25 kDa. As another example, in some cases, the cationic polymer comprises branched poly(ethyleneimine) having a molecular weight of about 10 kDa. As another example, in some cases, the cationic polymer comprises a branched poly(ethyleneimine) having a molecular weight of about 70 kDa. In some cases, the cationic polymer comprises PAMAM.
[0096] In some cases, the cationic amino acid polymers include cysteine residues that facilitate conjugation with, for example, a linker, an NLS, and / or a cationic polypeptide (e.g., a histone or HTP). For example, the cysteine residues can be used for cross-linking (conjugation) via sulfhydryl chemistry (e.g., disulfide bonding) and / or amine-reactive chemistry. Thus, in some embodiments, the cationic amino acid polymers of the cationic polymer composition (e.g., poly(arginine) (PR), poly(lysine) (PK), poly(histidine) (PH), poly(ornithine), and poly(citrulline), poly(D-arginine) (PDR), poly(D-lysine) (PDK), poly(D-histidine) (PDH), poly(D-ornithine), and poly(D-citrulline), poly(L-arginine) (PLR), poly(L-lysine) (PLK), poly(L-histidine) (PLH), poly(L-ornithine), and poly(L-citrulline)) comprise cysteine residues. In some cases, the cationic amino acid polymers comprise cysteine residues at the N- and / or C-terminus. In some cases, the cationic amino acid polymers comprise internal cysteine residues.
[0097] In some cases, the cationic amino acid polymer comprises (and / or is conjugated to) a nuclear localization signal (NLS) (described in more detail below). Thus, in some embodiments, the cationic amino acid polymers of the cationic polymer composition (e.g., poly(arginine) (PR), poly(lysine) (PK), poly(histidine) (PH), poly(ornithine), and poly(citrulline), poly(D-arginine) (PDR), poly(D-lysine) (PDK), poly(D-histidine) (PDH), poly(D-ornithine), and poly(D-citrulline), poly(L-arginine) (PLR), poly(L-lysine) (PLK), poly(L-histidine) (PLH), poly(L-ornithine), and poly(L-citrulline)) comprise (and / or are conjugated to) one or more (e.g., two or more, three or more, or four or more) NLSs. In some cases, the cationic amino acid polymers comprise an NLS at the N- and / or C-terminus. In some cases, the cationic amino acid polymer comprises an internal NLS.
[0098] Nanoparticulate cationic polypeptide compositions In some embodiments, the cationic polypeptide composition of the nanoparticles may mediate stability, intracellular compartmentalization, and / or payload release. As one example, N-terminal fragments of histone proteins, commonly referred to as histone tail peptides, within the core of the nanoparticles of the present invention may not only be deprotonated, in some cases, by various histone modifications, e.g., during histone acetyltransferase-mediated acetylation, but may also mediate efficient, nuclear-specific unpacking of nanoparticle core components (e.g., payloads). In some cases, the cationic polypeptide composition includes histones and / or histone tail peptides (e.g., the cationic polypeptide can be a histone and / or a histone tail peptide). In some cases, the cationic polypeptide composition includes an NLS-containing peptide (e.g., the cationic polypeptide can be an NLS-containing peptide). In some cases, the cationic polypeptide composition includes one or more NLS-containing peptides separated by cysteine residues to facilitate cross-linking. In some cases, the cationic polypeptide composition includes a peptide that includes a mitochondrial localization signal (eg, the cationic polypeptide can be a peptide that includes a mitochondrial localization signal).
[0099] Nanoparticle shedding layer (shedding coat) In some embodiments, the nanoparticles of the present invention comprise a decidual layer (also referred to herein as a "transient stabilizing layer") that surrounds (encapsulates) the core. In some cases, the decidual layer of the present invention can protect the payload prior to and during initial cellular uptake. For example, without the decidual layer, much of the payload would be lost during cellular internalization. Upon entering the intracellular environment, the decidual layer is "shed" (e.g., the layer can be pH (and / or glutathione) sensitive), exposing components of the core.
[0100] In some cases, the decidual layer of the present invention comprises silica. In some cases, when the nanoparticles of the present invention comprise a decidual layer (e.g., silica), a high cellular delivery efficiency can be observed despite a reduced probability of cellular uptake. Without wishing to be bound by a particular theory, coating the core of a nanoparticle with a decidual layer (e.g., silica coating) can seal the core and stabilize it until the layer is removed, resulting in the release of the payload (e.g., during processing within the intended intracellular compartment). After entering a cell via receptor-mediated endocytosis, the nanoparticle sheds its outermost layer, which decomposes in the acidic environment of the endosome or the reducing environment of the cytosol, exposing the core, in some cases, displaying a localization signal, such as a nuclear localization signal (NLS) and / or a mitochondrial localization signal. Furthermore, the core of a nanoparticle encapsulated by a decidual layer can be stable in serum and suitable for in vivo administration.
[0101] Any desired decidual layer may be used, and one skilled in the art can consider where (e.g., under what conditions, e.g., low pH) within the target cell one desires the payload to be released (e.g., endosome, cytosol, nucleus, lysosome, etc.). Depending on when, where, and / or under what conditions one desires the decidual coat to be shed (and thereby release the payload), different decidual layers may be more desirable. For example, the decidual layer may be acid-labile. In some cases, the decidual layer is an anionic decidual layer (anionic coat). In some cases, the decidual layer comprises silica, peptoid, polycysteine, and / or a ceramic (e.g., a bioceramic). In some cases, the decidual agent comprises one or more of calcium, manganese, magnesium, iron (e.g., the decidual layer may be a magnetic layer, e.g., Fe3MnO2), and lithium. Each of these may comprise a phosphate or sulfate. Thus, in some cases, the shedding agent comprises one or more of calcium phosphate, calcium sulfate, manganese phosphate, manganese sulfate, magnesium phosphate, magnesium sulfate, iron phosphate, iron sulfate, lithium phosphate, and lithium sulfate; each of these may have a particular effect on how and / or under what conditions the shedding layer "sheds." Thus, in some cases, the shedding layer comprises one or more of silica, peptoid, polycysteine, ceramic (e.g., bioceramic), calcium, calcium phosphate, calcium sulfate, calcium oxide, hydroxyapatite, manganese, manganese phosphate, manganese sulfate, manganese oxide, magnesium, magnesium phosphate, magnesium sulfate, magnesium oxide, iron, iron phosphate, iron sulfate, iron oxide, lithium, lithium phosphate, and lithium sulfate (in any combination thereof) (e.g., the shedding layer can be a coating with silica, peptoid, polycysteine, ceramic (e.g., bioceramic), calcium phosphate, calcium sulfate, manganese phosphate, manganese sulfate, magnesium phosphate, magnesium sulfate, iron phosphate, iron sulfate, lithium phosphate, lithium sulfate, or combinations thereof).In some cases, the shedding layer comprises silica (e.g., the shedding layer can be silica coated). In some cases, the shedding layer comprises an alginate gel.
[0102] In some cases, different release times for different payloads are desired. For example, in some cases, it may be desirable to release the payload early (e.g., within 0.5 to 7 days of contacting the target cells), and in some cases, it may be desirable to release the payload late (e.g., within 6 to 30 days of contacting the target cells). For example, in some cases, it may be desirable to release the payload (e.g., first donor DNA and gene editing tool, e.g., CRISPR / Cas guide RNA, a DNA molecule encoding the CRISPR / Cas guide RNA, a CRISPR / Cas RNA-guided polypeptide, and / or a nucleic acid molecule encoding the CRISPR / Cas RNA-guided polypeptide) within 0.5 to 7 days of contacting the target cells (e.g., within 0.5 to 5 days, 0.5 to 3 days, 1 to 7 days, 1 to 5 days, or 1 to 3 days of contacting the target cells). In some cases, it may be desirable to release the payload (e.g., the second donor DNA molecule and the recombinase or a nucleic acid encoding same) within 6 to 40 days of contacting the target cells (e.g., within 6 to 30, 6 to 20, 6 to 15, 7 to 40, 7 to 30, 7 to 20, 7 to 15, 9 to 40, 9 to 30, 9 to 20, or 9 to 15 days of contacting the target cells). In some cases, the release time may be controlled by delivering nanoparticles with different payloads at different times. In some cases, the release time may be controlled by delivering nanoparticles at the same time (either as part of different formulations or as part of the same formulation), where the components of the nanoparticle are designed to achieve the desired release time. For example, fast- or slow-degrading shed layers, core components that are more or less resistant to degradation, core components that are more or less susceptible to decondensation, etc. may be used (and any or all of the components may be selected in any convenient combination to achieve the desired timing).
[0103] In some cases, it is desirable for the payloads to be released at different times. This can be achieved in a number of different ways. For example, a nanoparticle may have more than one core, in which case one core contains a payload (e.g., a first donor DNA and / or a genome editing tool, such as a ZFP or a nucleic acid encoding a ZFP, a TALE or a nucleic acid encoding a TALE, a ZFN or a nucleic acid encoding a ZFN, a TALEN or a nucleic acid encoding a TALEN, a CRISPR / Cas guide RNA or a DNA molecule encoding a CRISPR / Cas guide RNA, a CRISPR / Cas RNA-guided polypeptide or a CRISPR / Cas One core is engineered with components capable of releasing a payload (e.g., a nucleic acid molecule encoding an RNA-guided polypeptide) quickly (e.g., within 0.5 to 7 days of contacting the target cell, e.g., within 0.5 to 5 days, 0.5 to 3 days, 1 to 7 days, 1 to 5 days, or 1 to 3 days of contacting the target cell), and the other core is engineered with components capable of releasing a payload (e.g., a second donor DNA molecule and / or a recombinase (or a nucleic acid encoding same)) slowly (e.g., within 6 to 40 days of contacting the target cell, e.g., within 6 to 30, 6 to 20, 6 to 15, 7 to 40, 7 to 30, 7 to 20, 7 to 15, 9 to 40, 9 to 30, 9 to 20, or 9 to 15 days of contacting the target cell).
[0104] As another example, a nanoparticle can include more than one decidual layer, in which case an outer decidual layer sheds (releasing a payload) before an inner decidual layer sheds (releasing another payload). In some cases, the inner payload is a first donor DNA molecule and one or more gene editing tools (e.g., ZFN or a nucleic acid encoding a ZFN, TALEN or a nucleic acid encoding a TALEN, CRISPR / Cas guide RNA or a DNA molecule encoding a CRISPR / Cas guide RNA, CRISPR / Cas RNA-guided polypeptide or a nucleic acid molecule encoding a CRISPR / Cas RNA-guided polypeptide, etc.), and the outer payload is a second donor DNA and a sequence-specific recombinase (or a nucleic acid encoding the same). The inner and outer payloads can be any desired payload, and one or both can include, for example, one or more siRNAs and / or one or more mRNAs. Thus, in some cases, a nanoparticle can have more than one decidual layer, and can contain more than one payload (e.g., donor DNA and / or genome editing tools, such as ZFPs or nucleic acids encoding ZFPs, TALEs or nucleic acids encoding TALEs, ZFNs or nucleic acids encoding ZFNs, TALENs or nucleic acids encoding TALENs, CRISPR / Cas guide RNAs or DNA molecules encoding CRISPR / Cas guide RNAs, CRISPR / Cas RNA-guided polypeptides or CRISPR / Cas RNA-guided polypeptides). The nucleic acid molecule may be designed to release a payload (e.g., a nucleic acid molecule encoding an RNA-guided polypeptide) quickly (e.g., within 0.5 to 7 days of contacting the target cells, e.g., within 0.5 to 5 days, 0.5 to 3 days, 1 to 7 days, 1 to 5 days, or 1 to 3 days of contacting the target cells) and release another payload (e.g., a second donor DNA molecule and / or a recombinase) later (e.g., within 6 to 40 days of contacting the target cells, e.g., within 6 to 30, 6 to 20, 6 to 15, 7 to 40, 7 to 30, 7 to 20, 7 to 15, 9 to 40, 9 to 30, 9 to 20, or 9 to 15 days of contacting the target cells).
[0105] In some embodiments (e.g., those described above), the time of altered gene expression can be used as a surrogate for the time of payload release. By way of example, if one desires to determine whether the payload has been released by day 12, one can assay for the desired outcome of nanoparticle delivery on day 12. For example, if the desired outcome is to express a protein of interest by inserting a DNA sequence encoding the protein of interest, one may assay / monitor expression of the protein of interest to determine whether the payload has been released. As yet another example, if the desired outcome is to alter the genome of a target cell via cleavage of genomic DNA and / or insertion of a sequence from a donor DNA molecule, one may assay / monitor expression from the targeted locus and / or the presence of genomic alteration to determine whether the payload has been released.
[0106] Thus, in some cases, the shedding layers provide for the staged release of nanoparticle components. For example, in some cases, a nanoparticle has more than one (e.g., two, three, or four) shedding layers. For example, in a nanoparticle with two shedding layers, such a nanoparticle may have, from innermost to outermost, a core carrying, for example, a first payload; a middle layer carrying, for example, a second payload; and a second shedding layer surrounding the middle layer (e.g., FIG. 3). Such a configuration (multiple shedding layers) facilitates the staged release of various desired payloads. As another example, a nanoparticle with two shedding layers (as described above) may include donor DNA and / or one or more desired gene editing tools (e.g., one or more of a donor DNA molecule, a CRISPR / Cas guide RNA, a DNA encoding a CRISPR / Cas guide RNA, etc.) in the core, and another desired gene editing tool (e.g., a second donor DNA and a recombinase or a nucleic acid encoding the same) (in any desired combination) in the middle layer.
[0107] Alternative packaging (e.g. lipid formulations) In some embodiments, the cores of the invention (e.g., comprising any combination of the components and / or configurations described above) are part of a lipid-based delivery system, e.g., a cationic lipid delivery system (see, e.g., Chesnoy and Huang, Annu Rev Biophys Biomol Struct. 2000, 29:27-47; Hirko et al., Curr Med Chem. 2003 Jul 10(14):1185-93; and Liu et al., Curr Med Chem. 2003 Jul 10(14):1307-15). In some cases, the cores of the invention (e.g., comprising any combination of the components and / or configurations described above) are not surrounded by a decidual layer. As described above, the core can comprise an anionic polymer composition (e.g., poly(glutamic acid)), a cationic polymer composition (e.g., poly(arginine)), a cationic polypeptide composition (e.g., histone tail peptide), and a payload (e.g., a nucleic acid and / or protein payload).
[0108] When the core is part of a lipid-based delivery system, the core is designed for sustained release and / or positional release (e.g., environment-specific release). For example, in some cases, the core includes an ESP, an ENP, and / or an EPP, and in such cases, these components may be present in a ratio such that release of the payload is delayed until the core encounters a desired condition (e.g., intracellular location, intracellular conditions, e.g., pH, the presence of a specific enzyme, etc.) (e.g., as described above). In some such embodiments, the core includes a polymer of a D-isomer of an anionic amino acid and a polymer of an L-isomer of an anionic amino acid, and in some cases, the polymers of the D-isomer and the L-isomer are present in a specific ratio range (e.g., as described above). In some cases, the core includes a polymer of a D-isomer of a cationic amino acid and a polymer of an L-isomer of a cationic amino acid, and in some cases, the polymers of the D-isomer and the L-isomer are present in a specific ratio range (e.g., as described above). In some cases, the core comprises a polymer of a D-isomer of an anionic amino acid and a polymer of an L-isomer of a cationic amino acid, and in some cases, the polymer of the D-isomer and the L-isomer are present in a specific range of ratios (e.g., as described above). In some cases, the core comprises a polymer of an L-isomer of an anionic amino acid and a polymer of a D-isomer of a cationic amino acid, and in some cases, the polymer of the D-isomer and the L-isomer are present in a specific range of ratios (e.g., as described elsewhere herein). In some cases, the core comprises a protein comprising an NLS (e.g., as described elsewhere herein). In some cases, the core comprises an HTP (e.g., as described elsewhere herein).
[0109] Cationic lipids are nonviral vectors that can be used for gene delivery and have the ability to condense plasmid DNA. Following the synthesis of N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride for lipofection, refinement of the molecular structure of cationic lipids, including modification of the head group, linker, and hydrophobic domain, has become an active area of research. Modifications have included the use of polyvalent polyamines, which can improve DNA binding and delivery through the use of sterol-based hydrophobic groups, such as 3B-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol, which can increase surface charge density and limit toxicity. Helper lipids, such as dioleoylphosphatidylethanolamine (DOPE), can be used to improve transgene expression and facilitate endosomal escape through increased liposome hydrophobicity and hexagonal inverse phase transition. In some cases, the lipid formulation includes one or more of DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, DLin-MC3-DMA, 98N12-5, C12-200, cholesterol, PEG-lipid, lipid polyamine; dexamethasone-spermine (DS); and disubstituted spermine (D2S) (e.g., obtained by conjugation of dexamethasone with the polyamine spermine). DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, 98N12-5, C12-200, and DLin-MC3-DMA can be synthesized by methods generally described in the art (see, e.g., Heyes et al., J. Control Release, 2005, 107, 276-287; Semple et al., Nature Biotechnology, 2010, 28, 172-176; Akinc et al., Nature Biotechnology, 2008, 26, 561-569; Love et al., PNAS, 2010, 107, 1864-1869; WO 2010 / 054401; all of which are incorporated herein by reference in their entireties).
[0110] Examples of various lipid-based delivery systems include, but are not limited to, the delivery systems described in the following publications: International Publication No. 2016 / 081029; U.S. Patent Application Publication Nos. 2016 / 0263047 and 2016 / 0237455; and U.S. Patent Nos. 9,533,047; 9,504,747; 9,504,651; 9,486,538; 9,393,200; 9,326,940; 9,315,828; and 9,308,267; all of which are incorporated herein by reference in their entirety.
[0111] Thus, in some cases, the cores of the present invention are surrounded by lipids (e.g., cationic lipids, e.g., LIPOFECTAMINE transfection reagent). In some cases, the cores of the present invention are present in a lipid formulation (e.g., a lipid nanoparticle formulation). The lipid formulation may include liposomes and / or lipoplexes. The lipid formulation may include Spontaneous Vesicle Formation by Ethanol Dilution (SNALP) liposomes (e.g., lipid formulations comprising cationic lipids in combination with neutral helper lipids, which may be coated with polyethylene glycol (PEG) and / or protamine).
[0112] Lipid formulations can be lipidoid-based formulations.The synthesis of lipidoids has been widely described, and the formulations containing these compounds are included in the lipid formulations of the present invention (see, for example, Mahon et al., Bioconjug Chem. 2010 21:1448-1454; Schroeder et al., J Intern Med. 2010 267:9-21; Akinc et al., Nat Biotechnol. 2008 26:561-569; Love et al., Proc Natl Acad Sci USA. 2010 107:1864-1869 and Siegwart et al., Proc Natl Acad Sci USA. 2011 108:12996-3001; all of which are incorporated herein by reference in their entirety). In some cases, the lipid formulations of the present invention may comprise 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC); 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE); N-[1-(2,3-dioleyloxy)propyl]N,N,N-trimethylammonium chloride (DOTMA); 1,2-dioleoyloxy-3-trimethylammonium-propane (DOTAP); dioctadecylamidoglycylspermine (DOGS); N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1 (GAP-DLRIE); propanaminium bromide; cetyltrimethylammonium bromide; romide (CTAB); 6-lauroxyhexylornithinate (LHON); 1-(2,3-dioleoyloxypropyl)-2,4,6-trimethylpyridinium (2Oc); 2,3-dioleyloxy-N-[2(sperminecarboxamido-ethyl]-N,N-dimethyl-1(DOSPA); propanaminium trifluoroacetate; 1,2-dioleyl-3-trimethylammonium-propane (DOPA); N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1(MDRIE); propanaminium bromide; dimyristoxypropyldimethylhydroxyethylammonium bromide (DMRI);3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol, DC-Chol; bis-guanidinium-tren-cholesterol (BGTC); 1,3-diodeoxy-2-(6-carboxy-spermyl)-propylamide (DOSPER); dimethyloctadecylammonium bromide (DDAB); dioctadecylamidoglycylspermidine (DSL); rac-[(2,3-dioctadecyloxypropyl)(2-hydroxyethyl)]-dimethylammonium (CLIP-1); chloride rac-[2(2,3-dihexadecyloxypropyloxymethyloxy)ethyl]trimethylammonium bromide (CLIP-6); ethyl dimyristoylphosphatidylcholine (EDMPC); 1,2-distearyloxy-N,N-dimethyl-3-aminopropane (DSDMA); 1,2-dimyristoyl-trimethylammoniumpropane (DMTAP); O,O'-dimyristyl-N-lysylaspartate (DMKE); 1,2-distearoyl-sn-glycero-3-ethylphosphocholine (DSEPC); N-pal Mitoyl D-erythro-sphingosylcarbamoyl-spermine (CCS);Nt-butyl-N0-tetradecyl-3-tetradecylaminopropionamidine;DiC14-amidine;Octadecenoyloxy[ethyl-2-heptadecenyl-3-hydroxyethyl]imidazolinium (DOTIM);Chloride N1-cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine (CDAN);2-[3-[bis(3-aminopropyl)amino]propylamino]-N-[2-[di(tetradecyl)amino]-2-oxo [isoethyl]acetamide (RPR209120); ditetradecylcarbamoylmethylacetamide; 1,2-Dilinoleyloxy-3-dimethylaminopropane (DLinDMA); 2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane; DLin-KC2-DMA; Dilinoleyl-methyl-4-dimethylaminobutyrate; DLin-MC3-DMA; DLin-K-DMA; 98N12-5; C12-200; Cholesterol; PEG-lipid; Lipidpolyamine; Dexamethasone-spermine (DS);and disubstituted spermine (D2S), in any desired combination;
[0113] Nanoparticle surface coating (outer shell) In some cases, the decidual layer (coat) is itself coated with an additional layer, referred to herein as an "outer shell," "outer coat," or "surface coat." The surface coat can serve several different functions. For example, the surface coat can increase delivery efficiency and / or target the nanoparticles of the present invention to specific cells. The surface coat can comprise a peptide, a polymer, or a ligand-polymer conjugate. The surface coat can comprise a targeting ligand. For example, an aqueous solution of one or more targeting ligands (with or without a linker domain) is added to a coated nanoparticle suspension (a suspension of nanoparticles coated with the decidual layer). For example, in some cases, the final concentration of protonated anchoring residues (of the anchor domain) is between 25 and 300 μM. In some cases, the step of adding the surface coat results in a monodisperse suspension of particles with an average particle size between 50 and 150 nm and a zeta potential between 0 and -10 mV.
[0114] In some cases, the surface coat interacts electrostatically with the outermost shed layer. For example, in some cases, the nanoparticle has two shed layers (e.g., from innermost to outermost, e.g., a core with a first payload; the first shed layer, e.g., a middle layer with a second payload; and a second shed layer surrounding the middle layer), and the outer shell (surface coat) can interact (e.g., electrostatically) with the second shed layer. In some cases, the nanoparticle has only one shed layer (e.g., an anionic silica layer), and in some cases, the outer shell can interact electrostatically with the shed layer.
[0115] Thus, when a shedding layer (e.g., the outermost shedding layer) is anionic (e.g., in some cases, the shedding layer is a silica coat), the surface coat may electrostatically interact with the shedding layer if the surface coat includes a cationic component. For example, in some cases, the surface coat includes a delivery molecule, in which case the targeting ligand is conjugated to a cationic anchor domain. The cationic anchor domain electrostatically interacts with the shedding layer, anchoring the delivery molecule to the nanoparticle. Similarly, when a shedding layer (e.g., the outermost shedding layer) is cationic, the surface coat may electrostatically interact with the shedding layer if the surface coat includes an anionic component.
[0116] In some embodiments, the surface coat comprises a cell membrane-penetrating peptide (CPP). In some cases, polymers of cationic amino acids can function as CPPs (also referred to as "protein transduction domains" (PTDs)), a term used to refer to polypeptides, polynucleotides, carbohydrates, or organic or inorganic compounds that facilitate crossing of lipid bilayers, micelles, cell membranes, organelle membranes, or vesicle membranes. A PTD conjugated to another molecule (e.g., embedded within and / or interacting with the decidual layer of a nanoparticle of the invention), which can range from small polar molecules to large macromolecules and / or nanoparticles, facilitates crossing of the molecule across a membrane, e.g., from the extracellular space to the intracellular space, or from the cytosol into an organelle (e.g., the nucleus).
[0117] Examples of CPPs include a minimal undecapeptide protein transduction domain (containing YGRKKRRQRRR (SEQ ID NO: 160), corresponding to residues 47-57 of HIV-1 TAT); a polyarginine sequence containing a sufficient number of arginines (e.g., 3, 4, 5, 6, 7, 8, 9, 10, or 10-50 arginines) for direct cell entry; a VP22 domain (Zender et al. (2002) Cancer Gene Ther. 9(6):489-96); a Drosophila Antennapedia protein transduction domain (Noguchi et al. (2003) Diabetes 52(7):1732-1737); a truncated human calcitonin peptide (Trehin et al. (2004) Pharm. Research 21:1248-1256); polylysine (Wender et al. (2000) Proc. Natl. Acad. Sci. USA 97:13003-13008; RRQRRTSKLMKR (SEQ ID NO: 161); transportan GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO: 162); KALAWEAKLAKALAKALAKHLAKALAKALKCEA (SEQ ID NO: 163); and RQIKIWFQNRRMKWKK (SEQ ID NO: 164). Representative CPPs include, but are not limited to, YGRKKRRQRRR (SEQ ID NO: 160), RKKRRQRRR (SEQ ID NO: 165), arginine homopolymers of 3 to 50 arginine residues, RKKRRQRR (SEQ ID NO: 166), YARAAARQARA (SEQ ID NO: 167), THRLPRRRRRR (SEQ ID NO: 168), and GGRRARRRRRR (SEQ ID NO: 169). In some embodiments, the CPP is an activated CPP (ACPP) (Aguilera et al. (2009) Integr Biol (Camb) June; 1(5-6): 371-381).ACPPs comprise a polycationic CPP (e.g., Arg9 or "R9") connected to a matching polyanion (e.g., Glu9 or "E9") via a cleavable linker, thereby reducing the net charge to near zero, thereby inhibiting cellular adhesion and uptake. Upon cleavage of the linker, the polyanion is released, locally unmasking the polyarginine and its inherent adhesive properties, thereby "activating" the ACPP and allowing it to cross membranes.
[0118] In some cases, CPPs may be added to nanoparticles by contacting the coated core (core surrounded by a shed layer) with a composition (e.g., a solution) containing the CPPs. The CPPs may then interact (e.g., electrostatically) with the shed layer.
[0119] In some cases, the surface coat comprises a polymer of a cationic amino acid (e.g., poly(arginine), e.g., poly(L-arginine) and / or poly(D-arginine), poly(lysine), e.g., poly(L-lysine) and / or poly(D-lysine), poly(histidine), e.g., poly(L-histidine) and / or poly(D-histidine), poly(ornithine), e.g., poly(L-ornithine) and / or poly(D-ornithine), poly(citrulline), e.g., poly(L-citrulline) and / or poly(D-citrulline), etc.). Thus, in some cases, the surface coat comprises poly(arginine), e.g., poly(L-arginine).
[0120] In some embodiments, the surface coat comprises a heptapeptide, such as selanc (TKPRPGP: SEQ ID NO: 147) (e.g., N-acetylselanc) and / or semax (MEHFPGP: SEQ ID NO: 148) (e.g., N-acetylsemax). Thus, in some cases, the surface coat comprises selanc (e.g., N-acetylselanc). In some cases, the surface coat comprises semax (e.g., N-acetylsemax).
[0121] In some aspects, the surface coat comprises a delivery molecule. The delivery molecule comprises a targeting ligand, and in some cases, the targeting ligand is conjugated to an anchor domain (e.g., a cationic anchor domain or an anionic anchor domain). In some cases, the targeting ligand is conjugated to an anchor domain (e.g., a cationic anchor domain or an anionic anchor domain) via an intervening linker.
[0122] Multivalent Surface Coating In some cases, the surface coat comprises (i) one or more of the polymers described above, and (ii) one or more targeting ligands, one or more CPPs, and one or more heptapeptides (in any desired combination). For example, in some cases, the surface coat may comprise one or more (e.g., two or more, three or more) targeting ligands, but may also comprise one or more of the cationic polymers described above. In some cases, the surface coat may comprise one or more (e.g., two or more, three or more) targeting ligands, but may also comprise one or more CPPs. Furthermore, the surface coat may comprise any combination of glycopeptides that promote stealth functionality, i.e., prevent serum protein adsorption and complement activation. This can be achieved via azide-alkyne click chemistry, in which a peptide containing a propargyl-modified residue is coupled to an azide-containing derivative, such as sialic acid or neuraminic acid.
[0123] In some cases, the surface coating comprises a combination of CD34 and a targeting ligand that binds to heparin sulfate proteoglycans. For example, poly(L-arginine) can be used as part of the surface coating to bind to heparin sulfate proteoglycans. Thus, in some cases, nanoparticles are surface-coated with a cationic polymer (e.g., poly(L-arginine)), and then the coated nanoparticles are incubated with hyaluronic acid, thereby forming a zwitterionic and multivalent surface.
[0124] In some embodiments, the surface coat is multivalent. A multivalent surface coat is a surface coat that includes two or more targeting ligands (e.g., two or more delivery molecules that include different ligands). An example of a multimeric (in this case, trimeric) surface coat (shell) is a surface coat that includes the targeting ligands stem cell factor (SCF) (which targets the c-Kit receptor, also known as CD117), CD70 (which targets CD27), and SH2 domain-containing protein 1A (SH2D1A) (which targets CD150). For example, in some cases, hematopoietic stem cells (HSCs) [c-Kit receptor (KLS)] are targeted to the surface coat. + Lin - Sca-1 + ) and CD27 + / IL-7Ra - / CD150 + / CD34 - To target HSPCs, the nanoparticles of the invention comprise a surface coating comprising a combination of targeting ligands SCF, CD70, and SH2 domain-containing protein 1A (SH2D1A), which target c-Kit, CD27, and CD150, respectively (see, e.g., Table 1). In some cases, such surface coatings may selectively target HSPCs and long-term HSCs (c-Kit / Lin / Sca-1 / CD27 / IL-7Ra / CD150 / CD34) over other lymphoid and myeloid progenitor cells.
[0125] In some exemplary embodiments, all three targeting ligands (SCF, CD70, and SH2D1A) are anchored to the nanoparticle via fusion to a cationic anchor domain (e.g., polyhistidine such as 6H, polyarginine such as 9R, etc.). For example, (1) the targeting polypeptide, SCF (targeting the c-Kit receptor), is:
[0126] [ka]
[0127] wherein X is a cationic anchor domain (e.g., polyhistidine such as 6H, polyarginine such as 9R, etc.), optionally at the N-terminus and / or C-terminus and embedded within the polypeptide sequence; (2) a targeting polypeptide, CD70 (targeting CD27),
[0128] [ka]
[0129] wherein X is a cationic anchor domain (e.g., polyhistidine such as 6H, polyarginine such as 9R, etc.), optionally at the N-terminus and / or C-terminus and embedded within the polypeptide sequence; (3) a targeting polypeptide, SH2D1A (targeting CD150),
[0130] [ka]
[0131] [wherein X is a cationic anchor domain (e.g., polyhistidine, e.g., 6H, polyarginine, e.g., 9R, etc.), which may, for example, in some cases, be at the N- and / or C-terminus or embedded within the polypeptide sequence] (e.g.,
[0132] [ka]
[0133] ).
[0134] As mentioned above, the nanoparticles of the present disclosure can include multiple targeting ligands (as part of the surface coat) to target a desired cell or combination of cells. Examples of cells of interest within the hematopoietic lineage in mice and humans are shown in Figures 7-8, along with markers that have been identified for these cells. For example, various combinations of cell surface markers of interest may be used, such as: [mouse] (i) CD150; (ii) Sca1, cKit, CD150; (iii) CD150 and CD49b; (iv) Sca1, cKit, CD150, and CD49b; (v) CD150 and Flt3; (vi) Sca1, cKit, CD150, and Flt3; (vii) Flt3 and CD34; (viii) Flt3, CD34, Sca1, and cKit; (ix) Flt3 and CD127; (x) Sca1, cKit, Flt3, and CD127; (xi) CD34; (xii) cKit and CD34; (xiv) cKit, CD16 / 32, and CD34; and (xv) cKit; and [human] (i) CD90 and CD49f; (ii) CD34, CD90, and CD49f; (iii) CD34; (iv) CD45RA and CD10; (v) CD34, CD45RA, and CD10; (vi) CD45RA and CD135; (vii) CD34, CD38, CD45RA, and CD135; (viii) CD135; (ix) CD34, CD38, and CD135; and (x) CD34 and CD38.Thus, in some cases, the surface coat may be composed of: [mouse] (i) CD150; (ii) Sca1, cKit, CD150; (iii) CD150 and CD49b; (iv) Sca1, cKit, CD150, and CD49b; (v) CD150 and Flt3; (vi) Sca1, cKit, CD150, and Flt3; (vii) Flt3 and CD34; (viii) Flt3, CD34, Sca1, and cKit; (ix) Flt3 and CD127; (x) Sca1, cKit, Flt3, and CD127; (xi) CD34; (xii) cKit and CD34; (xiii) CD16 / 32 and CD34; (xiv (viii) CD135; (ix) CD34, CD38, and CD135; and (x) CD34 and CD38. Because nanoparticles of the present invention can contain more than one targeting ligand, and some cells contain overlapping markers, multiple different cells may be targeted using a combination of surface coats; for example, in some cases, the surface coat may target one specific cell, while in other cases, the surface coat may target more than one specific cell (e.g., two or more, three or more, four or more cells). For example, any combination of cells within the hematopoietic lineage may be targeted. For example, targeting CD34 (using a targeting ligand that binds CD34) can result in delivery of the payload by the nanoparticle to several different cells within the hematopoietic lineage (e.g., Figures 7-8).
[0135] delivery molecule Delivery molecules are provided that include a targeting ligand (peptide) conjugated to (i) a protein or nucleic acid payload or (ii) a polypeptide domain that is a charged polymer. The targeting ligand provides (i) targeted binding to a cell surface protein and, in some cases, (ii) engagement in the long-term endosomal recycling pathway. In some cases, when the targeting ligand is conjugated to the polypeptide domain that is a charged polymer, the polypeptide domain that is a charged polymer interacts with (e.g., condenses with) the nucleic acid payload and / or protein payload. In some cases, the targeting ligand is conjugated via an intervening linker. For examples of different possible conjugation strategies (i.e., different possible arrangements of the components of the delivery molecules of the present invention), see Figures 5A-D. In some cases, the targeting ligand binds to a cell surface protein but does not necessarily engage in the long-term endosomal recycling pathway. Thus, also provided are delivery molecules comprising a targeting ligand (e.g., a peptide targeting ligand) conjugated to a protein or nucleic acid payload or to a polypeptide domain that is a charged polymer, where the targeting ligand binds to a cell surface protein (but does not necessarily result in engagement in the long-term endosomal recycling pathway).
[0136] In some cases, the delivery molecules disclosed herein are designed so that the nucleic acid or protein payload reaches its extracellular target (e.g., by binding to a cell surface protein) and preferentially avoids destruction within lysosomes or sequestering in "short" endosomal recycling endosomes. Instead, the delivery molecules of the present disclosure may result in engagement of the "long" (indirect / slow) endosomal recycling pathway, which may enable endosomal escape and / or fusion with endosomal organelles.
[0137] For example, in some cases, β-arrestins are involved in mediating the scission of seven-transmembrane GPCRs (McGovern et al., Handb Exp Pharmacol. 2014;219:341-59; Goodman et al., Nature. 1996 Oct 3;383(6599):447-50; Zhang et al., J Biol Chem. 1997 Oct 24;272(43):27005-14) and / or single-transmembrane receptor tyrosine kinases (RTKs) from the actin cytoskeleton (e.g., during endocytosis) to trigger the desired endosomal sorting pathway. Thus, in some embodiments, the targeting ligand of a delivery molecule of the present disclosure results in the engagement of β-arrestins upon binding to cell surface proteins (e.g., biasing signaling and promoting internalization via endocytosis following orthosteric binding).
[0138] Polypeptide domains that are charged polymers In some cases, a targeting ligand (e.g., of a delivery molecule of the present invention) is conjugated to a polypeptide domain (anchor domain, e.g., a cationic anchor domain or an anionic anchor domain) that is a charged polymer (see, e.g., Figures 4 and 5A-D). The polypeptide domain that is a charged polymer can include repeating residues (e.g., cationic residues, e.g., arginine, lysine, histidine). In some cases, the polypeptide domain that is a charged polymer (anchor domain) is 3 to 30 amino acids in length (e.g., 3 to 28, 3 to 25, 3 to 24, 3 to 20, 4 to 30, 4 to 28, 4 to 25, 4 to 24, or 4 to 20; or e.g., 4 to 15, 4 to 12, 5 to 30, 5 to 28, 5 to 25, 5 to 20, 5 to 15, 5 to 12). In some cases, the polypeptide domain that is a charged polymer (anchor domain) is 4 to 24 amino acids in length. In some cases, the polypeptide domain that is a charged polymer (anchor domain) has a length of 5 to 10 amino acids. Suitable examples of polypeptide domains that are charged polymers include, but are not limited to, RRRRRRRRR(9R) (SEQ ID NO: 15) and HHHHHH(6H) (SEQ ID NO: 16).
[0139] The polypeptide domain that is a charged polymer (cationic anchor domain, anionic anchor domain) can be any convenient charged domain (e.g., a cationic charged domain). For example, such a domain can be a histone tail peptide (HTP) (described in more detail elsewhere herein). In some cases, the polypeptide domain that is a charged polymer comprises a histone and / or a histone tail peptide (e.g., a cationic polypeptide can be a histone and / or a histone tail peptide). In some cases, the polypeptide domain that is a charged polymer comprises an NLS-containing peptide (e.g., a cationic polypeptide can be an NLS-containing peptide). In some cases, the polypeptide domain that is a charged polymer comprises a peptide that includes a mitochondrial localization signal (e.g., a cationic polypeptide can be a peptide that includes a mitochondrial localization signal).
[0140] In some cases, the polypeptide domain of the delivery molecules of the invention that is a charged polymer is used as a way for the delivery molecule to interact (e.g., for condensation, e.g., electrostatically interact) with a payload (e.g., a nucleic acid payload and / or a protein payload).
[0141] In some cases, the charged polymer polypeptide domain of the delivery molecule of the present invention is used as an anchor to coat the surface of the nanoparticle with a delivery molecule, for example, so that a targeting ligand is used to target the nanoparticle to a desired cell / cell surface protein (see, for example, Figure 4). Thus, in some cases, the charged polymer polypeptide domain electrostatically interacts with the charged stabilizing layer of the nanoparticle. For example, in some cases, the nanoparticle comprises a core (e.g., containing a payload that is a nucleic acid, protein, and / or ribonucleoprotein complex) surrounded by a stabilizing layer (e.g., silica, peptoid, polycysteine, or calcium phosphate coating). In some cases, the stabilizing layer has a negative charge, and therefore the positively charged polymer polypeptide domain can interact with the stabilizing layer, effectively anchoring the delivery molecule to the nanoparticle and coating the nanoparticle surface with the targeting ligand of the present invention (see, for example, Figure 4). In some cases, the stabilizing layer has a positive charge, and therefore the polypeptide domain, which is a negatively charged polymer, can interact with the stabilizing layer, effectively anchoring the delivery molecule to the nanoparticle and coating the nanoparticle surface with the targeting ligand of the present invention. Conjugation can be achieved by any convenient technique, and many different conjugation chemistries will be known to those skilled in the art. In some cases, conjugation is via sulfhydryl chemistry (e.g., disulfide bond). In some cases, conjugation is achieved using amine-reactive chemistry. In some cases, the targeting ligand and the polypeptide domain, which is a charged polymer, are conjugated by being part of the same polypeptide.
[0142] In some cases, the polypeptide domain (cationic), which is a charged polymer, may comprise a polymer selected from poly(arginine) (PR), poly(lysine) (PK), poly(histidine) (PH), poly(ornithine), poly(citrulline), and combinations thereof. In some cases, a given cationic amino acid polymer may comprise a mix of arginine, lysine, histidine, ornithine, and citrulline residues (in any convenient combination). The polymer may exist as an L-isomer polymer or a D-isomer polymer, where the D-isomer takes longer to degrade and is therefore more stable within target cells. Thus, the incorporation of D-isomer poly(amino acids) slows degradation (and subsequent payload release). Thus, the payload release rate may be controlled and is proportional to the ratio of D-isomer polymer to L-isomer polymer, where the ratio of D-isomer to L-isomer increases the duration of payload release (i.e., decreases the release rate). In other words, the relative amounts of D- and L-isomers can modulate the release kinetics of the nanoparticle core and its enzymatic susceptibility to degradation and payload release.
[0143] In some cases, the cationic polymer comprises D- and L-isomers of cationic amino acid polymers (e.g., poly(arginine) (PR), poly(lysine) (PK), poly(histidine) (PH), poly(ornithine), poly(citrulline)). In some cases, the ratio of D- to L-isomers is between 10:1 and 1:10 (e.g., 8:1 and 1:10, 6:1 and 1:10, 4:1 and 1:10, 3:1 and 1:10, 2:1 and 1:10, 1:1 and 1:10, 10:1 and 1:8, 8:1 and 1:8, 6:1 and 1:8, 4:1 and 1:8, 3:1 and 1:8, 2:1 and 1:8, 1:1 and 1:8, 10:1 and 1:6, 8:1 and 1:6, 6:1 and 1:6, 4:1 and 1:6, 3:1 and 1:6, 2:1 and 1:6, 1:1 and 1:6, 10:1 and 1:4, 8:1 and 1:4, 6:1 to 1:4, 4:1 to 1:4, 3:1 to 1:4, 2:1 to 1:4, 1:1 to 1:4, 10:1 to 1:3, 8:1 to 1:3, 6:1 to 1:3, 4:1 to 1:3, 3:1 to 1:3, 2:1 to 1:3, 1:1 to 1:3, 10:1 to 1:2, 8:1 to 1:2, 6:1 to 1:2, 4:1 to 1:2, 3:1 to 1:2, 2:1 to 1:2, 1:1 to 1:2, 10:1 to 1:1, 8:1 to 1:1, 6:1 to 1:1, 4:1 to 1:1, 3:1 to 1:1, or 2:1 to 1:1).
[0144] Thus, in some cases, the cationic polymer comprises a first cationic polymer (e.g., an amino acid polymer) that is a polymer of a D-isomer (e.g., selected from poly(D-arginine), poly(D-lysine), poly(D-histidine), poly(D-ornithine), and poly(D-citrulline)); and a second cationic polymer (e.g., an amino acid polymer) that is a polymer of an L-isomer (e.g., selected from poly(L-arginine), poly(L-lysine), poly(L-histidine), poly(L-ornithine), and poly(L-citrulline)). In some cases, the ratio of the first cationic polymer (D-isomer) to the second cationic polymer (L-isomer) is 10:1 to 1:10 (e.g., 8:1 to 1:10, 6:1 to 1:10, 4:1 to 1:10, 3:1 to 1:10, 2:1 to 1:10, 1:1 to 1:10, 10:1 to 1:8, 8:1 to 1:8, 6:1 to 1:10, 4:1 to 1:10, 3:1 to 1:10, 2:1 to 1:10, 1:1 to 1:10, 10:1 to 1:8, 8:1 to 1:8, 6:1 to 1:8, 4:1 to 1:8, 3:1 to 1:8, 2:1 to 1:8, 1:1 to 1:8, 10:1 to 1:6, 8:1 to 1:6, 6:1 to 1:6, 4:1~1:6, 3:1~1:6, 2:1~1:6, 1:1~1:6, 10:1~1:4, 8:1~1:4, 6:1~1:4, 4:1~1:4, 3:1~1:4, 2:1~1:4, 1:1~1:4, 10:1~1:3, 8:1~1:3, 6:1~1:3, 4:1~1:3, 3:1~1:3, 2:1 to 1:3, 1:1 to 1:3, 10:1 to 1:2, 8:1 to 1:2, 6:1 to 1:2, 4:1 to 1:2, 3:1 to 1:2, 2:1 to 1:2, 1:1 to 1:2, 10:1 to 1:1, 8:1 to 1:1, 6:1 to 1:1, 4:1 to 1:1, 3:1 to 1:1, or 2:1 to 1:1).
[0145] In some aspects, the cationic polymer comprises a cationic polymer (e.g., in linear or branched form) comprising poly(ethyleneimine), poly(amidoamine) (PAMAM), poly(aspartamide), polypeptoid (e.g., to form "spider web"-like branches for core condensation), charge-functionalized polyester, cationic polysaccharide, acetylated amino sugar, chitosan, or any combination thereof (e.g., in addition to or instead of any of the previous examples of cationic polymers).
[0146] In some embodiments, the cationic polymer can have a molecular weight of 1 to 200 kDa (e.g., 1 to 150, 1 to 100, 1 to 50, 5 to 200, 5 to 150, 5 to 100, 5 to 50, 10 to 200, 10 to 150, 10 to 100, 10 to 50, 15 to 200, 15 to 150, 15 to 100, or 15 to 50 kDa). For example, in some cases, the cationic polymer comprises poly(L-arginine) having a molecular weight of about 29 kDa. For another example, in some cases, the cationic polymer comprises linear poly(ethyleneimine) having a molecular weight of about 25 kDa (PEI). For another example, in some cases, the cationic polymer comprises branched poly(ethyleneimine) having a molecular weight of about 10 kDa. As another example, in some cases, the cationic polymer comprises a branched poly(ethyleneimine) having a molecular weight of about 70 kDa. In some cases, the cationic polymer comprises PAMAM.
[0147] In some cases, the cationic amino acid polymers contain cysteine residues that facilitate conjugation with, for example, a linker, an NLS, and / or a cationic polypeptide (e.g., a histone or HTP). For example, the cysteine residues can be used for cross-linking (conjugation) via sulfhydryl chemistry (e.g., disulfide bonding) and / or amine-reactive chemistry. Thus, in some embodiments, the cationic amino acid polymers of the cationic polymer composition (e.g., poly(arginine) (PR), poly(lysine) (PK), poly(histidine) (PH), poly(ornithine), and poly(citrulline), poly(D-arginine) (PDR), poly(D-lysine) (PDK), poly(D-histidine) (PDH), poly(D-ornithine), and poly(D-citrulline), poly(L-arginine) (PLR), poly(L-lysine) (PLK), poly(L-histidine) (PLH), poly(L-ornithine), and poly(L-citrulline)) comprise cysteine residues. In some cases, the cationic amino acid polymers comprise cysteine residues at the N- and / or C-terminus. In some cases, the cationic amino acid polymers comprise internal cysteine residues.
[0148] In some cases, the cationic amino acid polymer comprises (and / or is conjugated to) a nuclear localization signal (NLS) (described in more detail below). Thus, in some embodiments, the cationic amino acid polymer (e.g., poly(arginine) (PR), poly(lysine) (PK), poly(histidine) (PH), poly(ornithine) and poly(citrulline), poly(D-arginine) (PDR), poly(D-lysine) (PDK), poly(D-histidine) (PDH), poly(D-ornithine) and poly(D-citrulline), poly(L-arginine) (PLR), poly(L-lysine) (PLK), poly(L-histidine) (PLH), poly(L-ornithine) and poly(L-citrulline)) comprises one or more (e.g., two or more, three or more, or four or more) NLSs. In some cases, the cationic amino acid polymer comprises an NLS at the N- and / or C-terminus. In some cases, the cationic amino acid polymer comprises an internal NLS.
[0149] In some cases, the charged polymer polypeptide domain is condensed with a nucleic acid payload and / or a protein payload (see, e.g., Figures 5A-D). In some cases, the charged polymer polypeptide domain electrostatically interacts with the protein payload. In some cases, the charged polymer polypeptide domain is cocondensed with silica, salt, and / or anionic polymers to add endosomal buffering capacity, stability, and, optionally, for example, sustained release. In some cases, the charged polymer polypeptide domain of the delivery molecule of the invention is a stretch of repeating cationic residues (e.g., arginine, lysine, and / or histidine), e.g., about 4-25 amino acids in length or 4-15 amino acids in length. Such domains can enable the delivery molecule to interact electrostatically with an anionic decidual matrix (e.g., a cocondensed anionic polymer). Thus, in some cases, the charged polymer polypeptide domain of the delivery molecule of the invention is a stretch of repeating cationic residues that interacts (e.g., electrostatically) with the anionic decidual matrix and the nucleic acid and / or protein payload. Thus, in some cases, the delivery molecules of the present invention interact with a payload (e.g., a nucleic acid and / or a protein) and are present as part of a composition with an anionic polymer (e.g., co-condensed with the payload and the anionic polymer).
[0150] The anionic polymer of the anionic shedding matrix (i.e., the anionic polymer that interacts with the charged polymer polypeptide domain of the delivery molecule of the present invention) can be any convenient anionic polymer / polymer composition. Examples include, but are not limited to, poly(glutamic acid) (e.g., poly(D-glutamic acid) (PDE), poly(L-glutamic acid) (PLE), various desired ratios of both PDE and PLE, etc.). In some cases, a PDE is used as the anionic shedding matrix. In some cases, a PLE is used as the anionic shedding matrix (anionic polymer). In some cases, a PDE is used as the anionic shedding matrix (anionic polymer). In some cases, both a PDE and a PLE are used as the anionic shedding matrix (anionic polymer), for example, in a 1:1 ratio (50% PDE, 50% PLE).
[0151] Anionic Polymers The anionic polymer may comprise one or more anionic amino acid polymers. For example, in some cases, the anionic polymer composition of the present invention comprises a polymer selected from poly(glutamic acid) (PEA), poly(aspartic acid) (PDA), and combinations thereof. In some cases, a given anionic amino acid polymer may comprise a mixture of aspartic acid and glutamic acid residues. Each polymer may exist in the composition as either an L-isomer polymer or a D-isomer polymer, where the D-isomer takes longer to degrade and is therefore more stable in target cells. Thus, the incorporation of D-isomer poly(amino acids) may slow degradation (and subsequent payload release). Thus, the payload release rate may be controlled and is proportional to the ratio of D-isomer polymer to L-isomer polymer, where the D-isomer to L-isomer ratio increases the duration of payload release (i.e., decreases the release rate). In other words, the relative amounts of D- and L-isomers can modulate the release kinetics of the nanoparticle core and its enzymatic susceptibility to degradation and payload release.
[0152] In some cases, the anionic polymer composition includes a polymer of the D-isomer and a polymer of the L-isomer of an anionic amino acid polymer (eg, poly(glutamic acid) (PEA) and poly(aspartic acid) (PDA)). In some cases, the ratio of D- to L-isomers is between 10:1 and 1:10 (e.g., 8:1 and 1:10, 6:1 and 1:10, 4:1 and 1:10, 3:1 and 1:10, 2:1 and 1:10, 1:1 and 1:10, 10:1 and 1:8, 8:1 and 1:8, 6:1 and 1:8, 4:1 and 1:8, 3:1 and 1:8, 2:1 and 1:8, 1:1 and 1:8, 10:1 and 1:6, 8:1 and 1:6, 6:1 and 1:6, 4:1 and 1:6, 3:1 and 1:6, 2:1 and 1:6, 1:1 and 1:6, 10:1 and 1:4, 8:1 and 1:4, 6:1 to 1:4, 4:1 to 1:4, 3:1 to 1:4, 2:1 to 1:4, 1:1 to 1:4, 10:1 to 1:3, 8:1 to 1:3, 6:1 to 1:3, 4:1 to 1:3, 3:1 to 1:3, 2:1 to 1:3, 1:1 to 1:3, 10:1 to 1:2, 8:1 to 1:2, 6:1 to 1:2, 4:1 to 1:2, 3:1 to 1:2, 2:1 to 1:2, 1:1 to 1:2, 10:1 to 1:1, 8:1 to 1:1, 6:1 to 1:1, 4:1 to 1:1, 3:1 to 1:1, or 2:1 to 1:1).
[0153] Thus, in some cases, the anionic polymer composition includes a first anionic polymer (e.g., an amino acid polymer) that is a polymer of a D-isomer (e.g., selected from poly(D-glutamic acid) (PDEA) and poly(D-aspartic acid) (PDDA)); and a second anionic polymer (e.g., an amino acid polymer) that is a polymer of an L-isomer (e.g., selected from poly(L-glutamic acid) (PLEA) and poly(L-aspartic acid) (PLDA)). In some cases, the ratio of the first anionic polymer (D-isomer) to the second anionic polymer (L-isomer) is 10:1 to 1:10 (e.g., 8:1 to 1:10, 6:1 to 1:10, 4:1 to 1:10, 3:1 to 1:10, 2:1 to 1:10, 1:1 to 1:10, 10:1 to 1:8, 8:1 to 1:8, 6:1 to 1:8, 4:1 to 1:8, 3:1 to 1:8, 2:1 to 1:8, 1:1 to 1:8, 10:1 to 1:6, 8:1 to 1:6, 6:1 to 1:6, 4:1 to 1:6, 3:1 to 1:6, 2:1 to 1:6, 1: The ratio is in the range of 1 to 1:6, 10:1 to 1:4, 8:1 to 1:4, 6:1 to 1:4, 4:1 to 1:4, 3:1 to 1:4, 2:1 to 1:4, 1:1 to 1:4, 10:1 to 1:3, 8:1 to 1:3, 6:1 to 1:3, 4:1 to 1:3, 3:1 to 1:3, 2:1 to 1:3, 1:1 to 1:3, 10:1 to 1:2, 8:1 to 1:2, 6:1 to 1:2, 4:1 to 1:2, 3:1 to 1:2, 2:1 to 1:2, 1:1 to 1:2, 10:1 to 1:1, 8:1 to 1:1, 6:1 to 1:1, 4:1 to 1:1, or 2:1 to 1:1).
[0154] In some aspects, the anionic polymer composition comprises an anionic polymer comprising a glycosaminoglycan, a glycoprotein, a polysaccharide, poly(mannuronic acid), poly(glucuronic acid), heparin, heparin sulfate, chondroitin, chondroitin sulfate, keratan, keratan sulfate, aggrecan, poly(glucosamine), or any combination thereof (e.g., in addition to or instead of any of the previous examples of anionic polymers).
[0155] In some embodiments, the anionic polymer can have a molecular weight in the range of 1 to 200 kDa (e.g., 1 to 150, 1 to 100, 1 to 50, 5 to 200, 5 to 150, 5 to 100, 5 to 50, 10 to 200, 10 to 150, 10 to 100, 10 to 50, 15 to 200, 15 to 150, 15 to 100, or 15 to 50 kDa). By way of example, in some cases, the anionic polymer comprises poly(glutamic acid) having a molecular weight of about 15 kDa.
[0156] In some cases, the anionic amino acid polymer comprises a cysteine residue, which facilitates conjugation with, for example, a linker, an NLS, and / or a cationic polypeptide (e.g., a histone or HTP). For example, the cysteine residue can be used for cross-linking (conjugation) via sulfhydryl chemistry (e.g., disulfide bond) and / or amine-reactive chemistry. Thus, in some embodiments, the anionic amino acid polymer of the anionic polymer composition (e.g., poly(glutamic acid) (PEA), poly(aspartic acid) (PDA), poly(D-glutamic acid) (PDEA), poly(D-aspartic acid) (PDDA), poly(L-glutamic acid) (PLEA), poly(L-aspartic acid) (PLDA)) comprises a cysteine residue. In some cases, the anionic amino acid polymer comprises a cysteine residue at the N- and / or C-terminus. In some cases, the anionic amino acid polymer comprises an internal cysteine residue.
[0157] In some cases, the anionic amino acid polymer comprises (and / or is conjugated to) a nuclear localization signal (NLS) (described in more detail below). Thus, in some embodiments, the anionic amino acid polymers of the anionic polymer composition (e.g., poly(glutamic acid) (PEA), poly(aspartic acid) (PDA), poly(D-glutamic acid) (PDEA), poly(D-aspartic acid) (PDDA), poly(L-glutamic acid) (PLEA), poly(L-aspartic acid) (PLDA)) comprise (and / or are conjugated to) one or more (e.g., two or more, three or more, or four or more) NLSs. In some cases, the anionic amino acid polymer comprises an NLS at the N- and / or C-terminus. In some cases, the anionic amino acid polymer comprises an internal NLS.
[0158] In some cases, the anionic polymer is conjugated to a targeting ligand.
[0159] Linker In some aspects, the targeting ligand is conjugated to the anchor domain (e.g., cationic anchor domain, anionic anchor domain) or the payload via an intervening linker. The linker may be a protein linker or a non-protein linker. In some cases, the linker may aid in stability, prevent complement activation, and / or provide flexibility to the ligand relative to the anchor domain.
[0160] Conjugation of the targeting ligand to the linker or the linker to the anchor domain can be achieved in a number of different ways. In some cases, conjugation is via sulfhydryl chemistry (e.g., a disulfide bond between two cysteine residues). In some cases, conjugation is achieved using amine-reactive chemistry. In some cases, the targeting ligand includes a cysteine residue and is conjugated to the linker via the cysteine residue; and / or the anchor domain includes a cysteine residue and is conjugated to the linker via the cysteine residue. In some cases, the linker is a peptide linker and includes a cysteine residue. In some cases, the targeting ligand and the peptide linker are conjugated by being part of the same polypeptide; and / or the anchor domain and the peptide linker are conjugated by being part of the same polypeptide.
[0161] In some cases, the linker of the present invention is a polypeptide and can be referred to as a polypeptide linker. While a polypeptide linker is contemplated, it is understood that in some cases, non-polypeptide linkers (chemical linkers) are also used. For example, in some embodiments, the linker is a polyethylene glycol (PEG) linker. Suitable protein linkers include polypeptides between 4 and 60 amino acids in length (e.g., 4-50, 4-40, 4-30, 4-25, 4-20, 4-15, 4-10, 6-60, 6-50, 6-40, 6-30, 6-25, 6-20, 6-15, 6-10, 8-60, 8-50, 8-40, 8-30, 8-25, 8-20, or 8-15 amino acids in length).
[0162] In some embodiments, the linkers of the invention are rigid (e.g., linkers comprising one or more proline residues). One non-limiting example of an rigid linker is GAPGAPGAP (SEQ ID NO: 17). In some cases, the polypeptide linker comprises a C residue at the N- or C-terminus. Thus, in some cases, the rigid linker is selected from GAPGAPGAPC (SEQ ID NO: 18) and CGAPGAPGAP (SEQ ID NO: 19).
[0163] Peptide linkers with a degree of flexibility may be used. Thus, in some cases, the linkers of the present invention are flexible. The linking peptide may have virtually any amino acid sequence, keeping in mind that flexible linkers generally have sequences that result in flexible peptides. The use of small amino acids, such as glycine and alanine, is useful in creating flexible peptides. Creating such sequences is within the skill of the art. A variety of different linkers are commercially available and may be suitable for use. An exemplary linker polypeptide is a glycine polymer (G) n , glycine-serine polymers (e.g., (GS), GSGGS n (including SEQ ID NO: 20), GGSGGS n (SEQ ID NO: 21), and GGGS n(SEQ ID NO:22) [where n is an integer equal to or greater than 1], glycine-alanine polymers, and alanine-serine polymers. Representative linkers may include amino acid sequences including, but not limited to, GGSG (SEQ ID NO:23), GGSGG (SEQ ID NO:24), GSGSG (SEQ ID NO:25), GSGGG (SEQ ID NO:26), GGGSG (SEQ ID NO:27), and GSSSG (SEQ ID NO:28). Those skilled in the art will recognize that the design of peptides conjugated to any of the above elements may include fully or partially flexible linkers, such that flexible linkers may include one or more moieties that impart small, flexible structures. Further examples of flexible linkers include, but are not limited to, GGGGSGGGGGG (SEQ ID NO:29) and GGGGSGGGGS (SEQ ID NO:30). As noted above, in some cases, polypeptide linkers include a C residue at the N- or C-terminus. Thus, in some cases, the flexible linker comprises an amino acid sequence selected from GGGGGSGGGGGC (SEQ ID NO: 31), CGGGGGSGGGGG (SEQ ID NO: 32), GGGGGSGGGGSC (SEQ ID NO: 33), and CGGGGGSGGGGS (SEQ ID NO: 34).
[0164] In some cases, the polypeptide linker of the present invention is endosomolytic. Endosomolytic polypeptide linkers include, but are not limited to, KALA (SEQ ID NO: 35) and GALA (SEQ ID NO: 36). As mentioned above, in some cases, the polypeptide linker includes a C residue at the N- or C-terminus. Thus, in some cases, the linker of the present invention includes an amino acid sequence selected from CKALA (SEQ ID NO: 37), KALAC (SEQ ID NO: 38), CGALA (SEQ ID NO: 39), and GALAC (SEQ ID NO: 40).
[0165] Sulfhydryl Coupling Reaction Example (e.g., reactions using cysteine residues, e.g., for conjugation via sulfhydryl chemistry) (e.g., reactions to conjugate a targeting ligand or glycopeptide to a linker, to conjugate a targeting ligand or glycopeptide to an anchor domain (e.g., a cationic anchor domain), to conjugate a linker to an anchor domain (e.g., a cationic anchor domain), etc.)
[0166] Disulfide bonds Cysteine residues under reducing conditions, which contain free sulfhydryl groups, readily form disulfide bonds with protected thiols in a typical disulfide exchange reaction.
[0167] [ka]
[0168] Thioether / thioester bonds The sulfhydryl group of cysteine reacts with maleimide and acyl halide groups to form stable thioether and thioester bonds, respectively.
[0169] [ka]
[0170] [ka]
[0171] Azide-Alkyne Cycloaddition This conjugation is facilitated by chemical modification of cysteine residues to contain an alkyne bond or by the use of L-propargyl amino acid derivatives (e.g., L-propargylcysteine (illustrated below)) in synthetic peptide preparations (e.g., solid-phase synthesis). Coupling is then achieved by Cu-promoted click chemistry.
[0172] [ka]
[0173] Examples of targeting ligands Examples of targeting ligands include those having the following amino acid sequences: SCF (Target: c-Kit receptor) EGICRNRVTNNVKDVTKLVANLPKDYMITLKYVPGMDVLPSHCWISEMVVQLSDSLTDLLDKFSNISEGLSNYSIIDKLVNIVDDLVECVKENSSKDLKKSFKSPEPRLFTPEEFFRIFNRSIDAFKDFVVASETSDCVVSSTLSPEKDSRVSVTKPFMLPPVA (SEQ ID NO: 184); CD70 (Target: CD27) PEEGSGCSVRRRPYGCVLRAALVPLVAGLVICLVVCIQRFAQAQQQLPLESLGWDVAELQLNHTGPQQDPRLYWQGGPALGRSFLHGPELDKGQLRIHRDGIYMVHIQVTLAICSSTTASRHHPTTLAVGICSPASRSISLLRLSFHQGCTIASQRLTPLARGDTLCTNLTGTLLPSRNTDETFFGVQWVRP (SEQ ID NO: 185); and SH2 domain-containing protein 1A (SH2D1A) (Target: CD150) SSGLVPRGSHMDAVAVYHGKISRETGEKLLLATGLDGSYLLRDSESVPGVYCLCVLYHGYIYTYRVSQTETGSWSAETAPGVHKRYFRKIKNLISAFQKPDQGIVIPLQYPVEKKSSARSTQGTTGIREDPDVCLKAP (SEQ ID NO: 186) Examples of polypeptides include, but are not limited to, polypeptides comprising:
[0174] Thus, non-limiting examples of targeting ligands (which may be used alone or in combination with other targeting ligands) include:
[0175] [ka]
[0176] Includes:
[0177] Illustrative Delivery Molecules and Components (0a) Cysteine conjugation anchor 1 (CCA1) [anchor domain (e.g., cationic anchor domain)-linker (GAPGAPGAP)-cysteine] RRRRRRRRR GAPGAPGAP C (SEQ ID NO: 41) (0b) Cysteine conjugation anchor 2 (CCA2) [Cysteine-linker (GAPGAPGAP)-anchor domain (e.g., cationic anchor domain)] C GAPGAPGAP RRRRRRRRR (SEQ ID NO: 42)
[0178] (1a) α5β1 ligand [anchor domain (e.g., cationic anchor domain) - linker (GAPGAPGAP) - targeting ligand] RRRRRRRRR GAPGAPGAP RRETAWA (SEQ ID NO: 45) (1b) α5β1 ligand [targeting ligand-linker (GAPGAPGAP)-anchor domain (e.g., cationic anchor domain)] RRETAWA GAPGAPGAP RRRRRRRRR (SEQ ID NO: 46) (1c) α5β1 ligand (left Cys) CGAPGAPGAP (SEQ ID NO: 19) NOTE: This can be conjugated to CCA1 (see above) via sulfhydryl chemistry (e.g., disulfide bond) or amine-reactive chemistry. (1d) α5β1 ligand (right Cys) GAPGAPGAPC (SEQ ID NO: 18) NOTE: This can be conjugated to CCA2 (see above) via sulfhydryl chemistry (e.g., disulfide bond) or amine-reactive chemistry.
[0179] (2a) RGD α5β1 ligand [anchor domain (e.g., cationic anchor domain) - linker (GAPGAPGAP) - targeting ligand] RRRRRRRRR GAPGAPGAP RGD (SEQ ID NO: 47) (2b) RGD a5b1 ligand [targeting ligand-linker (GAPGAPGAP)-anchor domain (e.g., cationic anchor domain)] RGD GAPGAPGAP RRRRRRRRR (SEQ ID NO: 48) (2c) RGD ligand (left Cys) CRGD (SEQ ID NO: 49) NOTE: This can be conjugated to CCA1 (see above) via sulfhydryl chemistry (e.g., disulfide bond) or amine-reactive chemistry. (2d) RGD ligand (right Cys) RGDC (SEQ ID NO: 50) NOTE: This can be conjugated to CCA2 (see above) via sulfhydryl chemistry (e.g., disulfide bond) or amine-reactive chemistry.
[0180] (3a) Transferrin Ligand [anchor domain (e.g., cationic anchor domain) - linker (GAPGAPGAP) - targeting ligand] RRRRRRRRR GAPGAPGAP THRPPMWSPVWP (SEQ ID NO: 51) (3b) Transferrin Ligand [targeting ligand-linker (GAPGAPGAP)-anchor domain (e.g., cationic anchor domain)] THRPPMWSPVWP GAPGAPGAP RRRRRRRRR (SEQ ID NO: 52) (3c) Transferrin ligand (left Cys) CTHRPPMWSPVWP (SEQ ID NO: 53) CPTHRPPMWSPVWP (SEQ ID NO: 54) NOTE: This can be conjugated to CCA1 (see above) via sulfhydryl chemistry (e.g., disulfide bond) or amine-reactive chemistry. (3d) Transferrin ligand (right Cys) THRPPMWSPVWPC (SEQ ID NO: 55) NOTE: This can be conjugated to CCA2 (see above) via sulfhydryl chemistry (e.g., disulfide bond) or amine-reactive chemistry.
[0181] (4a) E-selectin ligand [1-21] [anchor domain (e.g., cationic anchor domain) - linker (GAPGAPGAP) - targeting ligand] RRRRRRRRR GAPGAPGAP MIASQFLSALTLVLLIKESGA (SEQ ID NO: 56) (4b) E-selectin ligand [1-21] [targeting ligand-linker (GAPGAPGAP)-anchor domain (e.g., cationic anchor domain)] MIASQFLSALTLVLLIKESGA GAPGAPGAP RRRRRRRRR (SEQ ID NO: 57) (4c) E-selectin ligand [1-21] (left Cys) CMIASQFLSALTLVLLIKESGA (SEQ ID NO: 58) NOTE: This can be conjugated to CCA1 (see above) via sulfhydryl chemistry (e.g., disulfide bond) or amine-reactive chemistry. (4d) E-selectin ligand [1-21] (right Cys) MIASQFLSALTLVLLIKESGAC (SEQ ID NO: 59) NOTE: This can be conjugated to CCA2 (see above) via sulfhydryl chemistry (e.g., disulfide bond) or amine-reactive chemistry.
[0182] (5a)FGF fragment [26~47] [anchor domain (e.g., cationic anchor domain) - linker (GAPGAPGAP) - targeting ligand] RRRRRRRRR GAPGAPGAP KNGGFFLRIHPDGRVDGVREKS (SEQ ID NO: 60) NOTE: This can be conjugated to CCA1 (see above) via sulfhydryl chemistry (e.g., disulfide bond) or amine-reactive chemistry. (5b) FGF fragment [26–47] [targeting ligand-linker (GAPGAPGAP)-anchor domain (e.g., cationic anchor domain)] KNGGFFLRIHPDGRVDGVREKS GAPGAPGAP RRRRRRRRR (SEQ ID NO: 61) NOTE: This can be conjugated to CCA1 (see above) via sulfhydryl chemistry (e.g., disulfide bond) or amine-reactive chemistry. (5c) FGF fragment [25–47] (left Cys is natural) CKNGGFFLRIHPDGRVDGVREKS (SEQ ID NO: 43) NOTE: This can be conjugated to CCA1 (see above) via sulfhydryl chemistry (e.g., disulfide bond) or amine-reactive chemistry. (5d) FGF fragment [26–47] (right Cys) KNGGFFLRIHPDGRVDGVREKSC (SEQ ID NO: 44) NOTE: This can be conjugated to CCA2 (see above) via sulfhydryl chemistry (e.g., disulfide bond) or amine-reactive chemistry.
[0183] (6a) Exendin (S11C) [1–39] HGEGTFTSDL C KQMEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO: 2) NOTE: This can be conjugated to CCA1 (see above) via sulfhydryl chemistry (e.g., disulfide bond) or amine-reactive chemistry.
[0184] Targeting Ligands A variety of targeting ligands (e.g., as part of a delivery molecule of the invention, e.g., as part of a nanoparticle) can be used, and many different targeting ligands are contemplated. In some embodiments, the targeting ligand is a fragment (e.g., a binding domain) of a wild-type protein. For example, in some cases, a targeting ligand of a delivery molecule of the invention that is a peptide can have a length of 4 to 50 amino acids (e.g., 4 to 40, 4 to 35, 4 to 30, 4 to 25, 4 to 20, 4 to 15, 5 to 50, 5 to 40, 5 to 35, 5 to 30, 5 to 25, 5 to 20, 5 to 15, 7 to 50, 7 to 40, 7 to 35, 7 to 30, 7 to 25, 7 to 20, 7 to 15, 8 to 50, 8 to 40, 8 to 35, 8 to 30, 8 to 25, 8 to 20, or 8 to 15 amino acids). A targeting ligand can be a fragment of a wild-type protein, but in some cases has mutations (e.g., insertions, deletions, substitutions) compared to the wild-type amino acid sequence (i.e., mutations compared to the corresponding wild-type protein sequence). For example, a targeting ligand can contain mutations that increase or decrease binding affinity for a surface protein of a target cell.
[0185] In some cases, the targeting ligand is the antigen-binding region of an antibody (F(ab)). In some cases, the targeting ligand is an ScFv. An "Fv" is the smallest antibody fragment containing a complete antigen recognition / binding site. In two-chain Fv species, this region consists of a dimer of one heavy chain / one light chain variable domain in tight, non-covalent association. In single-chain Fv species (scFv), the one heavy chain / one light chain variable domain can be covalently linked by a flexible peptide linker such that the light and heavy chains can associate in a "dimeric" structure similar to that in two-chain Fv species. For a review of scFvs, see Pluckthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).
[0186] In some cases, targeting ligands include viral glycoproteins that can bind to ubiquitous surface markers, such as heparin sulfate proteoglycans, and induce micropinocytosis (and / or macropinocytosis) in some cell populations via a membrane ruffling-related process. Poly(L-arginine) is another exemplary targeting ligand that can also be used to bind to surface markers, such as heparin sulfate proteoglycans.
[0187] In some cases, the particle surface (e.g., nanoparticle surface) is coated with a targeting ligand, either electrostatically or by covalently modifying the particle surface or by using one or more polymers on the particle surface. In some cases, the targeting ligand may include a mutation that adds a cysteine residue that facilitates conjugation with a linker and / or anchor domain (e.g., a cationic anchor domain). For example, the cysteine may be used for cross-linking (conjugation) via sulfhydryl chemistry (e.g., disulfide bond) and / or amine-reactive chemistry.
[0188] In some cases, the targeting ligand contains an internal cysteine residue. In some cases, the targeting ligand contains a cysteine residue at the N- and / or C-terminus. In some cases, to contain the cysteine residue, the targeting ligand is mutated (e.g., inserted or substituted), for example, compared to the corresponding wild-type sequence. Thus, any of the targeting ligands described herein can be modified by inserting and / or substituting a cysteine residue (e.g., inserting or substituting an internal, N- or C-terminal cysteine residue).
[0189] A "corresponding" wild-type sequence refers to a wild-type sequence from which a subject sequence is derived or may be derived (e.g., a wild-type protein sequence having a high degree of sequence identity to a sequence of interest). In some cases, a "corresponding" wild-type sequence is a wild-type sequence having 85% or more sequence identity (e.g., 90% or more, 92% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) with the amino acid sequence of interest. For example, for a targeting ligand that has one or more mutations (e.g., substitutions, insertions) but is otherwise highly similar to the wild-type sequence, the most similar amino acid sequence may be considered to be the corresponding wild-type amino acid sequence.
[0190] The corresponding wild-type protein / sequence need not be 100% identical (e.g., may be 85% or more identical, 90% or more identical, 95% or more identical, 98% or more identical, 99% or more identical, etc.) (outside of the positions that are modified), but the targeting ligand and the corresponding wild-type protein (e.g., a fragment of the wild-type protein) may be capable of binding to the intended cell surface protein and retain sufficient sequence identity (outside the regions that are modified) to be considered homologous. The amino acid sequence of the "corresponding" wild-type protein sequence may be identified / assessed using any convenient method (e.g., using any convenient sequence comparison / alignment software, e.g., BLAST, MUSCLE, T-COFFEE, etc.).
[0191] Examples of targeting ligands that can be used as part of a surface coat (e.g., as part of a surface-coated delivery molecule) include, but are not limited to, the targeting ligands listed in Table 1. Examples of targeting ligands that can be used as part of a delivery molecule of the invention include, but are not limited to, the targeting ligands listed in Table 3 (many of the sequences listed in Table 3 include, for example, a targeting ligand (e.g., SNRWLDVK in the second row) linked to a cationic polypeptide domain, e.g., 9R, 6R, via a linker (e.g., GGGGSGGGGS)). Examples of amino acid sequences that can be included within the targeting ligand include, but are not limited to, NPKLTRMLTFKFY (SEQ ID NO: xx) (IL2), TSVGKYPNTGYYGD (SEQ ID NO: xx) (CD3), SNRWLDVK (Siglec), EKFILKVRPAFKAV (SEQ ID NO: xx) (SCF); EKFILKVRPAFKAV (SEQ ID NO: xx) (SCF), EKFILKVRPAFKAV (SEQ ID NO: xx) (SCF), SNYSIIDKLVNIVDDLVECVKENS (SEQ ID NO: xx) (cKit), and Ac-SNYSAibADKAibANAibADDAibAEAibAKENS (SEQ ID NO: xx) (cKit). Thus, in some cases, the targeting ligand comprises an amino acid sequence having 85% or more (e.g., 90% or more, 95% or more, 98% or more, 99% or more, or 100%) sequence identity to NPKLTRMLTFKFY (SEQ ID NO: xx) (IL2), TSVGKYPNTGYYGD (SEQ ID NO: xx) (CD3), SNRWLDVK (Siglec), EKFILKVRPAFKAV (SEQ ID NO: xx) (SCF); EKFILKVRPAFKAV (SEQ ID NO: xx) (SCF), EKFILKVRPAFKAV (SEQ ID NO: xx) (SCF), or SNYSIIDKLVNIVDDLVECVKENS (SEQ ID NO: xx) (cKit).
[0192] [Table 1-1]
[0193] [Table 1-2]
[0194] [Table 1-3]
[0195] [Table 1-4]
[0196] [Table 1-5]
[0197] A targeting ligand (e.g., of a delivery molecule) can comprise an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) with the amino acid sequence RGD and / or the amino acid sequence set forth in any one of SEQ ID NOs: 1-12. In some cases, the targeting ligand comprises the amino acid sequence RGD and / or the amino acid sequence set forth in any one of SEQ ID NOs: 1-12. In some aspects, the targeting ligand can include a cysteine (internal, C-terminal, or N-terminal) and can also comprise an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) with the amino acid sequence RGD and / or the amino acid sequence set forth in any one of SEQ ID NOs: 1-12.
[0198] A targeting ligand (e.g., of a delivery molecule) can include the amino acid sequence RGD and / or an amino acid sequence having 85% or greater sequence identity (e.g., 90% or greater, 95% or greater, 97% or greater, 98% or greater, 99% or greater, 99.5% or greater, or 100% sequence identity) with the amino acid sequence set forth in any one of SEQ ID NOs: 1-12 and 181-187. In some cases, the targeting ligand includes the amino acid sequence RGD and / or an amino acid sequence set forth in any one of SEQ ID NOs: 1-12 and 181-187. In some embodiments, the targeting ligand can include a cysteine (internal, C-terminal, or N-terminal) and can also include an amino acid sequence having 85% or greater sequence identity (e.g., 90% or greater, 95% or greater, 97% or greater, 98% or greater, 99% or greater, 99.5% or greater, or 100% sequence identity) with the amino acid sequence RGD and / or the amino acid sequence set forth in any one of SEQ ID NOs: 1-12 and 181-187.
[0199] A targeting ligand (e.g., of a delivery molecule) can include the amino acid sequence RGD and / or an amino acid sequence having 85% or greater sequence identity (e.g., 90% or greater, 95% or greater, 97% or greater, 98% or greater, 99% or greater, 99.5% or greater, or 100% sequence identity) with the amino acid sequence set forth in any one of SEQ ID NOs: 1-12, 181-187, and 271-277. In some cases, the targeting ligand includes the amino acid sequence RGD and / or an amino acid sequence set forth in any one of SEQ ID NOs: 1-12, 181-187, and 271-277. In some embodiments, the targeting ligand can include a cysteine (internal, C-terminal, or N-terminal) and can also include an amino acid sequence having 85% or greater sequence identity (e.g., 90% or greater, 95% or greater, 97% or greater, 98% or greater, 99% or greater, 99.5% or greater, or 100% sequence identity) with the amino acid sequence RGD and / or the amino acid sequence set forth in any one of SEQ ID NOs: 1-12, 181-187, and 271-277.
[0200] In some cases, a targeting ligand (e.g., of a delivery molecule) can comprise an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) with an amino acid sequence set forth in any one of SEQ ID NOs: 181-187 and 271-277. In some cases, a targeting ligand comprises an amino acid sequence set forth in any one of SEQ ID NOs: 181-187 and 271-277. In some embodiments, the targeting ligand can include a cysteine (internal, C-terminal, or N-terminal) and can also include an amino acid sequence having 85% or greater sequence identity (e.g., 90% or greater, 95% or greater, 97% or greater, 98% or greater, 99% or greater, 99.5% or greater, or 100% sequence identity) with the amino acid sequence set forth in any one of SEQ ID NOs: 181-187 and 271-277.
[0201] In some cases, a targeting ligand (e.g., of a delivery molecule) can comprise an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) to the amino acid sequence set forth in any one of SEQ ID NOs: 181-187. In some cases, a targeting ligand can comprise an amino acid sequence set forth in any one of SEQ ID NOs: 181-187. In some aspects, a targeting ligand can include a cysteine (internal, C-terminal, or N-terminal) and can also comprise an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) to the amino acid sequence set forth in any one of SEQ ID NOs: 181-187.
[0202] In some cases, a targeting ligand (e.g., of a delivery molecule) can comprise an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) to the amino acid sequence set forth in any one of SEQ ID NOs: 271-277. In some cases, a targeting ligand can comprise an amino acid sequence set forth in any one of SEQ ID NOs: 271-277. In some aspects, a targeting ligand can include a cysteine (internal, C-terminal, or N-terminal) and can also comprise an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) to the amino acid sequence set forth in any one of SEQ ID NOs: 271-277.
[0203] As used herein, "targeting" and "targeted binding" are used to refer to specific binding. Terms such as "specifically binding," "specifically binds to," and the like refer to preferential binding, non-covalently or covalently, to a molecule relative to other molecules or moieties in a solution or reaction mixture (e.g., an antibody specifically binds to a particular polypeptide or epitope relative to other polypeptides it can bind to, and a ligand specifically binds to a particular receptor relative to other receptors it can bind to). In some embodiments, the affinity of one molecule for another molecule to which it specifically binds is greater than or equal to 10. -5 M or less (e.g., 10 -6 M or less, 10 -7 M or less, 10 -8 M or less, 10 -9 M or less, 10 -10 M or less, 10 -11 M or less, 10 -12 M or less, 10 -13 M or less, 10 -14 M or less, 10 -15 M or less, or 10 -16 M or less) K d "Affinity" refers to the strength of binding, and increased binding affinity is characterized by a low Kd correlates with.
[0204] In some cases, the targeting ligand binds to a cell surface protein selected from G protein-coupled receptor (GPCR) family B, receptor tyrosine kinase (RTK), cell surface glycoprotein, and intercellular adhesion molecule. Consideration of the spatial arrangement of the ligand upon docking to the receptor can be used to achieve the desired functional selectivity and endosomal sorting bias, for example, to ensure that the structure-function relationship between the ligand and the target is not disrupted due to conjugation of the targeting ligand to a payload or anchor domain (e.g., a cationic anchor domain). For example, conjugation to a nucleic acid, protein, ribonucleoprotein, or anchor domain (e.g., a cationic anchor domain) could potentially interfere with binding to the cleft.
[0205] Thus, in some cases, when a crystal structure of a desired target (cell surface protein) bound to its ligand is available (or when such a structure is available for a related protein), 3D structural modeling and sequence threading can be used to visualize the site of interaction between the ligand and target, which can, for example, facilitate the selection of internal sites for substitution and / or insertion (e.g., of cysteine residues).
[0206] By way of example, in some cases, the targeting ligand results in binding to a family B G protein-coupled receptor (GPCR) (also known as the "secretin family"), and in some cases, the targeting ligand results in binding to both the allosteric affinity domain and the orthosteric domain of the family B GPCR, resulting in targeted binding and engagement of the long-term endosomal recycling pathway, respectively.
[0207] G protein-coupled receptors (GPCRs) share a common molecular architecture (seven putative transmembrane segments) and a common signaling mechanism in that they interact with G proteins (heterotrimeric GTPases) to regulate the synthesis of intracellular second messengers, such as cyclic AMP, inositol phosphates, diacylglycerol, and calcium ions. Family B of GPCRs (the secretin receptor family or "family 2") is a small but structurally and functionally diverse group of proteins that includes receptors for polypeptide hormones and molecules thought to mediate cell-cell interactions at the cell membrane (see, e.g., Harmar et al., Genome Biol. 2001;2(12):REVIEWS3013). Significant advances have been made in the structural biology of members of the secretin receptor family, including the publication of several crystal structures of their N-termini, with and without ligand binding. These works have expanded our understanding of ligand binding and provide a useful platform for structure-based ligand design (see, e.g., Poyner et al., Br J Pharmacol. 2012 May;166(1):1-3).
[0208] For example, one may desire to use the delivery molecules of the present invention to target the pancreatic cell surface protein GLP1R (e.g., to target pancreatic islet beta cells) using an exendin 4 ligand or a derivative thereof (e.g., a cysteine-substituted exendin 4 targeting ligand, e.g., the targeting ligand presented as SEQ ID NO: 2). Because GLP1R is abundant in the brain and pancreas, targeting ligands that result in targeted binding to GLP1R can be used to target the brain and pancreas. Targeting GLP1R thus facilitates focused approaches (e.g., therapies) for the treatment of diseases (e.g., via delivery of one or more gene editing tools), such as Huntington's disease (CAG repeat expansion mutations), Parkinson's disease (LRRK2 mutations), ALS (SOD1 mutations), and other CNS diseases. Targeting GLP1R also facilitates focused methods (e.g., therapeutics) for delivering payloads to pancreatic islet beta cells for the treatment of diseases such as type 1 diabetes, type 2 diabetes, and pancreatic cancer (e.g., via delivery of one or more gene editing tools).
[0209] When modified forms of exendin-4 are used to target GLP1R, amino acids for cysteine substitution and / or insertion (e.g., for conjugation to a nucleic acid payload) can be identified by aligning the amino acid sequence of exendin-4, shown as HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO: 1), against the crystal structures of glucagon-GCGR (4ERS) and the GLP1-GLP1R-ECD complex (PDB: 3IOL), which may be rotated in 3D space to predict the direction the cross-linked complex must face to avoid disrupting the two binding clefts, using three-dimensional renderings from the PDB. If the desired crosslinking site (e.g., site for cysteine residue substitution / insertion) of a targeting ligand (targeting a family B GPCR) is sufficiently orthogonal to the two binding clefts of the corresponding receptor, high-affinity binding and synchronic sequestration into the long-term endosomal recycling pathway (e.g., for optimal payload release) can occur. Cysteine substitutions at amino acid positions 10, 11, and / or 12 of SEQ ID NO: 1 confer biphasic binding and specific induction of a Gs-biased signaling cascade, engagement of β-arrestins, and dissociation of the receptor from the actin cytoskeleton. In some cases, the targeting ligand induces nanoparticle internalization via receptor-mediated endocytosis, a mechanism that does not involve binding solely to the N-terminal domain of the GPCR without synchronic orthosteric site engagement (as in the case of binding solely to the affinity chain exendin-4 [31-39]).
[0210] In some cases, the targeting ligand of the present invention comprises an amino acid sequence having 85% or more (e.g., 90% or more, 95% or more, 98% or more, 99% or more, or 100%) identity to the amino acid sequence of exendin-4 (SEQ ID NO: 1). In some such cases, the targeting ligand comprises a cysteine substitution or insertion at one or more of positions corresponding to L10, S11, and K12 of the amino acid sequence set forth in SEQ ID NO: 1. In some cases, the targeting ligand comprises a cysteine substitution or insertion at a position corresponding to S11 of the amino acid sequence set forth in SEQ ID NO: 1. In some cases, the targeting ligand of the present invention comprises an amino acid sequence having the amino acid sequence of exendin-4 (SEQ ID NO: 1). In some cases, the targeting ligand is conjugated (with or without a linker) to an anchor domain (e.g., a cationic anchor domain).
[0211] As another example, in some cases, the targeting ligand of the present invention confers binding to a receptor tyrosine kinase (RTK), such as a fibroblast growth factor (FGF) receptor (FGFR). Thus, in some cases, the targeting ligand is a fragment of FGF (i.e., comprises the amino acid sequence of FGF). In some cases, the targeting ligand binds to a segment of the RTK that is occupied upon orthosteric binding (see, e.g., the Examples below). In some cases, the targeting ligand binds to the heparin affinity domain of the RTK. In some cases, the targeting ligand confers binding to an FGF receptor and comprises an amino acid sequence having 85% or greater sequence identity (e.g., 90% or greater, 95% or greater, 97% or greater, 98% or greater, 99% or greater, 99.5% or greater, or 100% sequence identity) with the amino acid sequence KNGGFFLRIHPDGRVDGVREKS (SEQ ID NO: 4). In some cases, the targeting ligand provides binding to an FGF receptor and comprises the amino acid sequence set forth as SEQ ID NO:4.
[0212] In some cases, small domains (e.g., 5-40 amino acids in length) occupying the orthosteric site of an RTK can be used to participate in the endocytic pathway for nuclear sorting of the RTK (e.g., FGFR) without engaging in the proliferative and oncogenic signaling cascades that may be characteristic of natural growth factor ligands. For example, a truncated bFGF (tbFGF) peptide (30-115 amino acids) contains the bFGF receptor-binding site and part of the heparin-binding site, and this peptide can effectively bind to FGFR on the cell surface without stimulating cell proliferation. The sequence of tbFGF is KRLYCKNGGFFLRIHPDGRVDGVREKSDPHIKLQLQAEERGVVSIKGVCANRYLAMKEDGRLLASKCVTDECFFFERLESNNYNTY (SEQ ID NO: 13) (see, e.g., Cai et al., Int J Pharm. 2011 Apr 15;408(1-2):173-82).
[0213] In some cases, the targeting ligand confers binding to an FGF receptor and comprises the amino acid sequence HFKDPK (SEQ ID NO: 5) (see, e.g., the Examples section below). In some cases, the targeting ligand confers binding to an FGF receptor and comprises the amino acid sequence LESNNYNT (SEQ ID NO: 6) (see, e.g., the Examples section below).
[0214] In some cases, the targeting ligand of the present invention binds to a cell surface glycoprotein. In some cases, the targeting ligand binds to an intercellular adhesion molecule. For example, in some cases, the targeting ligand binds to CD34, a cell surface glycoprotein that functions as an intercellular adhesion molecule and is found on hematopoietic stem cells (e.g., bone marrow). In some cases, the targeting ligand is a fragment of a selectin, such as E-selectin, L-selectin, or P-selectin (e.g., a signal peptide found within the first 40 amino acids of a selectin). In some cases, the targeting ligand of the present invention includes the sushi domain of a selectin (e.g., E-selectin, L-selectin, P-selectin).
[0215] In some cases, the targeting ligand comprises an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) with the amino acid sequence MIASQFLSALTLVLLIKESGA (SEQ ID NO: 7). In some cases, the targeting ligand comprises the amino acid sequence set forth as SEQ ID NO: 7. In some cases, the targeting ligand comprises an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) with the amino acid sequence MVFPWRCEGTYWGSRNILKLWVWTLLCCDFLIHHGTHC (SEQ ID NO: 8). In some cases, the targeting ligand comprises the amino acid sequence set forth as SEQ ID NO: 8. In some cases, the targeting ligand comprises an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) with the amino acid sequence MIFPWKCQSTQRDLWNIFKLWGWTMLCCDFLAHHGTDC (SEQ ID NO: 9). In some cases, the targeting ligand comprises the amino acid sequence set forth as SEQ ID NO: 9. In some cases, the targeting ligand comprises an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) with the amino acid sequence MIFPWKCQSTQRDLWNIFKLWGWTMLCC (SEQ ID NO: 10). In some cases, the targeting ligand comprises the amino acid sequence set forth as SEQ ID NO: 10.
[0216] In some cases, fragments of selectins (e.g., signal peptides found within the first 40 amino acids of selectins) that can be used as targeting ligands in the present invention are capable of achieving strong binding to specifically modified sialomucins, such as the various sialyl Lewis residues of extracellular CD34. xModification / O-sialylation can result in differential affinity for P-selectin, L-selectin, and E-selectin for the bone marrow, lymphoid, splenic, and tonsillar compartments. Conversely, in some cases, the targeting ligand can be the extracellular portion of CD34. In some such cases, modification of the sialylation of the ligand can be used to differentially target the targeting ligand to various selectins.
[0217] In some cases, the targeting ligand of the present invention binds to E-selectin. E-selectin can mediate adhesion of tumor cells to endothelial cells, and ligands for E-selectin may play a role in cancer metastasis. For example, P-selectin glycoprotein 1 (PSGL-1) (e.g., derived from human neutrophils) can function as a highly efficient ligand for E-selectin (e.g., expressed by endothelium). Therefore, the targeting ligand of the present invention may, in some cases, comprise the amino acid sequence of PSGL-1 (or a fragment thereof that binds to E-selectin). For another example, E-selectin ligand 1 (ESL-1) can bind to E-selectin. Therefore, the targeting ligand of the present invention may, in some cases, comprise the amino acid sequence of ESL-1 (or a fragment thereof that binds to E-selectin). In some cases, a targeting ligand comprising the amino acid sequence of PSGL-1 and / or ESL-1 (or a fragment thereof that binds to E-selectin) possesses one or more sialyl Lewis modifications for binding to E-selectin. As another example, in some cases, CD44, death receptor 3 (DR3), LAMP1, LAMP2, and Mac2-BP can bind to E-selectin, and therefore, in some cases, a targeting ligand of the present invention may comprise the amino acid sequence of any one of CD44, death receptor 3 (DR3), LAMP1, LAMP2, and Mac2-BP (or a fragment thereof that binds to E-selectin).
[0218] In some cases, the targeting ligands of the present invention bind to P-selectin. In some cases, PSGL-1 can mediate such targeted binding. Thus, in some cases, the targeting ligands of the present invention can include the amino acid sequence of PSGL-1 (or a fragment thereof that binds to P-selectin). In some cases, targeting ligands with the amino acid sequence of PSGL-1 (or a fragment thereof that binds to P-selectin) possess one or more sialyl Lewis modifications to bind to P-selectin.
[0219] In some cases, the targeting ligand of the invention is selected from the group consisting of CD3, CD28, CD90, CD45f, CD34, CD80, CD86, CD19, CD20, CD22, CD47, CD3ε, CD3γ, CD3δ; the constant regions of TCRα, TCRβ, TCRγ, and / or TCRδ; 4-1BB, OX40, OX40L, CD62L, ARP5, CCR5, CCR7, CCR10, CXCR3, CXCR4, CXCR5, CXCR6, CXCR7, CXCR8, CXCR9, CXCR10, CXCR11, CXCR12, CXCR13, CXCR14, CXCR15, CXCR16, CXCR17, CXCR18, CXCR19, CXCR19, CXCR20, CXCR21, CXCR22, CXCR23, CXCR24, CXCR25, CXCR26, CXCR27, CXCR28, CXCR29, CXCR30, CXCR31, CXCR32, CXCR33, CXCR34, CXCR35, CXCR36, CXCR37, CXCR38, CXCR39, CXCR40, CXCR41, CXCR42, CXCR43, CXCR44, CXCR45, CXCR46, CXCR47, CXCR48, CXCR49, CXCR49, CXCR49, CXCR49, CXCR41, CXCR42, CXCR43, CXCR44, CXCR45, CXCR46, CXCR48, CXCR49, CXCR49, CXCR49, CXCR49, CXCR49, CXCR4 and α5β1.
[0220] In some cases, the targeting ligand of the present invention binds to the transferrin receptor. In some such cases, the targeting ligand comprises an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) with the amino acid sequence THRPPMWSPVWP (SEQ ID NO: 11). In some cases, the targeting ligand comprises the amino acid sequence set forth as SEQ ID NO: 11.
[0221] In some cases, the targeting ligand of the present invention binds to an integrin (e.g., α5β1 integrin). In some such cases, the targeting ligand comprises an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) with the amino acid sequence RRETAWA (SEQ ID NO: 12). In some cases, the targeting ligand comprises the amino acid sequence set forth as SEQ ID NO: 12. In some cases, the targeting ligand comprises an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) with the amino acid sequence RGDGW (SEQ ID NO: 181). In some cases, the targeting ligand comprises the amino acid sequence RGD.
[0222] In some cases, the targeting ligand of the present invention binds to an integrin. In some such cases, the targeting ligand comprises an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) with the amino acid sequence GCGYGRGDSPG (SEQ ID NO: 182). In some cases, the targeting ligand comprises the amino acid sequence set forth as SEQ ID NO: 182. In some cases, such targeting ligands are acetylated at the N-terminus and / or amidated (NH2) at the C-terminus.
[0223] In some cases, the targeting ligand of the present invention binds to an integrin (e.g., α5β3 integrin). In some such cases, the targeting ligand comprises an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) to the amino acid sequence DGARYCRGDCFDG (SEQ ID NO: 187). In some cases, the targeting ligand comprises the amino acid sequence set forth as SEQ ID NO: 187.
[0224] In some embodiments, a targeting ligand used to target the brain comprises an amino acid sequence derived from rabies virus glycoprotein (RVG) (e.g., YTIWMPENPRPGTPCDIFTNSRGKRASNGGGG (SEQ ID NO: 183)). In some such cases, the targeting ligand comprises an amino acid sequence specified as an amino acid sequence having 85% or greater sequence identity (e.g., 90% or greater, 95% or greater, 97% or greater, 98% or greater, 99% or greater, 99.5% or greater, or 100% sequence identity) to SEQ ID NO: 183. As with any of the targeting ligands (described elsewhere herein), the RVG can be conjugated and / or fused to an anchor domain (e.g., a 9R peptide sequence). For example, a delivery molecule of the invention used as part of the surface coating of a nanoparticle of the invention can comprise the sequence YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRR (SEQ ID NO: 180).
[0225] In some cases, the targeting ligand of the present invention binds to the c-Kit receptor. In some such cases, the targeting ligand comprises an amino acid sequence set forth as an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) to SEQ ID NO: 184. In some cases, the targeting ligand comprises the amino acid sequence set forth as SEQ ID NO: 184.
[0226] In some cases, the targeting ligand of the present invention binds to CD27. In some such cases, the targeting ligand comprises an amino acid sequence set forth as an amino acid sequence having 85% or more sequence identity (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence identity) to SEQ ID NO: 185. In some cases, the targeting ligand comprises the amino acid sequence set forth as SEQ ID NO: 185.
[0227] In some cases, the targeting ligand of the present invention binds to CD150. In some such cases, the targeting ligand comprises an amino acid sequence set forth as an amino acid sequence having 85% or greater sequence identity (e.g., 90% or greater, 95% or greater, 97% or greater, 98% or greater, 99% or greater, 99.5% or greater, or 100% sequence identity) to SEQ ID NO: 186. In some cases, the targeting ligand comprises the amino acid sequence set forth as SEQ ID NO: 186.
[0228] In some embodiments, the targeting ligand binds to KLS CD27+ / IL-7Ra- / CD150+ / CD34- hematopoietic stem / progenitor cells (HSPCs). For example, gene editing tools (described elsewhere herein) can be introduced to disrupt expression of the BCL11a transcription factor, resulting in the development of fetal hemoglobin. As another example, the β-globin (HBB) gene can be directly targeted to correct the altered E7V substitution with a corresponding donor DNA molecule for homology-directed repair. By way of example, a CRISPR / Cas RNA-guided polypeptide (e.g., Cas9, CasX, CasY, Cpf1) can be delivered with an appropriate guide RNA so that it binds to a locus within the HBB gene, creates a double- or single-strand break in the genome, and triggers genome repair. In some cases, a donor DNA molecule (single- or double-stranded) may be introduced (as part of the payload) and this may be released for 14-30 days, while the guide RNA / CRISPR / Cas protein complex (ribonucleoprotein complex) may be released for 1-7 days.
[0229] In some embodiments, the targeting ligand binds to CD4+ or CD8+ T cells, hematopoietic stem / progenitor cells (HSPCs), or peripheral blood mononuclear cells (PBMCs) to modify the T cell receptor. For example, gene editing tools (described elsewhere herein) can be introduced to modify the T cell receptor. The T cell receptor can be directly targeted and replaced with a corresponding donor DNA molecule for a novel T cell receptor. As one example, a CRISPR / Cas RNA-guided polypeptide (e.g., Cas9, CasX, CasY, Cpf1) can be delivered with an appropriate guide RNA such that it binds to a locus within the TCR gene, creates a double- or single-stranded break in the genome, and triggers the insertion of a first donor DNA (bearing one or more target sequences for a sequence-specific recombinase), whereupon a nucleotide sequence of interest is inserted from a second donor DNA by a recombinase that recognizes the target sequence inserted by the first donor DNA. In some cases, a donor DNA molecule (single-stranded or double-stranded) is introduced (as part of the payload). It will be apparent to one of skill in the art that other CRISPR guide RNAs and donor sequences, and / or other expression vectors targeting β-globin, CCR5, T cell receptors, or other genes of interest may be used in accordance with the present disclosure.
[0230] In some aspects, the targeting ligand is a nucleic acid aptamer. In some aspects, the targeting ligand is a peptoid.
[0231] Also provided are delivery molecules with two different peptide sequences that constitute the targeting ligand. For example, in some cases, the targeting ligand is bivalent (e.g., heterobivalent). In some cases, a cell membrane-penetrating peptide and / or a heparin sulfate proteoglycan-binding ligand is used as a heterobivalent endocytosis trigger together with any of the targeting ligands disclosed herein. The heterobivalent targeting ligand may include an affinity sequence derived from one of the targeting ligands and an orthosteric binding sequence (e.g., an orthosteric binding sequence known to be involved in a desired endocytic trafficking pathway) derived from a different targeting ligand.
[0232] Anchor Domain In some embodiments, the delivery molecule comprises a targeting ligand bound to an anchor domain (e.g., a cationic anchor domain, an anionic anchor domain). In some cases, the delivery vehicle of the present invention comprises a payload that is condensed with and / or electrostatically interacts with the anchor domain (e.g., the delivery molecule can be the delivery vehicle used to deliver the payload). In some cases, the surface coat of a nanoparticle comprises such a delivery molecule with an anchor domain, and in some such cases, the payload is within (interacts with) the core of such a nanoparticle. For further details regarding anchor domains, see the section above describing polypeptide domains that are charged polymers.
[0233] Histone tail peptides (HTPs) In some embodiments, the cationic polypeptide composition of the nanoparticles of the present invention comprises a histone peptide or a fragment of a histone peptide, e.g., an N-terminal histone tail (e.g., the histone tail of an H1, H2 (e.g., H2A, H2AX, H2B), H3, or H4 histone protein). Herein, a tail fragment of a histone protein is referred to as a histone tail peptide (HTP). Because such proteins (histones and / or HTPs) can condense with a nucleic acid payload as part of the core of the nanoparticles of the present invention, a core comprising one or more histones or HTPs (e.g., as part of the cationic polypeptide composition) is also referred to herein as a nucleosome-mimetic core. The histones and / or HTPs can be incorporated as monomers, but in some cases can form dimers, trimers, tetramers, and / or octamers when condensing a nucleic acid payload into the core of the nanoparticle. In some cases, HTPs can not only be deprotonated by various histone modifications, for example, in the case of histone acetyltransferase-mediated acetylation, but can also mediate efficient nuclear-specific unpacking of core components (e.g., release of the payload). Trafficking of cores containing histones and / or HTPs may rely on alternative endocytic pathways that utilize retrograde transport through the Golgi apparatus and endoplasmic reticulum. Furthermore, some histones contain endogenous nuclear localization sequences, and incorporation of an NLS into the core can direct the core (including the payload) to the nucleus of target cells.
[0234] In some embodiments, cationic polypeptide compositions of the present invention comprise proteins having the amino acid sequence of H2A, H2AX, H2B, H3, or H4 proteins. In some cases, cationic polypeptide compositions of the present invention comprise proteins having an amino acid sequence corresponding to the N-terminal region of a histone protein. For example, a fragment (HTP) can comprise the first 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 N-terminal amino acids of a histone protein. In some cases, an HTP of the present invention comprises 5 to 50 amino acids (e.g., 5 to 45, 5 to 40, 5 to 35, 5 to 30, 5 to 25, 5 to 20, 8 to 50, 8 to 45, 8 to 40, 8 to 35, 8 to 30, 10 to 50, 10 to 45, 10 to 40, 10 to 35, or 10 to 30 amino acids) derived from the N-terminal region of a histone protein. In some cases, the cationic polypeptides of the present invention comprise 5 to 150 amino acids (e.g., 5 to 100, 5 to 50, 5 to 35, 5 to 30, 5 to 25, 5 to 20, 8 to 150, 8 to 100, 8 to 50, 8 to 40, 8 to 35, 8 to 30, 10 to 150, 10 to 100, 10 to 50, 10 to 40, 10 to 35, or 10 to 30 amino acids).
[0235] In some cases, the cationic polypeptide (e.g., a histone or HTP, e.g., H1, H2, H2A, H2AX, H2B, H3, or H4) of the cationic polypeptide composition comprises a post-translational modification (e.g., in some cases at one or more histidine, lysine, arginine, or other complementary residues). For example, in some cases, the cationic polypeptide is methylated (and / or susceptible to methylation / demethylation), acetylated (and / or susceptible to acetylation / deacetylation), crotonylated (and / or susceptible to crotonylation / decrotonylation), ubiquitinylated (and / or susceptible to ubiquitination / deubiquitination), phosphorylated (and / or susceptible to phosphorylation / dephosphorylation), sumoylated (and / or susceptible to sumoylation / desumoylation), farnesylated (and / or susceptible to farnesylation / defarnesylation), sulfated (and / or susceptible to sulfation / desulfation), or otherwise post-translationally modified. In some cases, the cationic polypeptide (e.g., a histone or HTP, e.g., H1, H2, H2A, H2AX, H2B, H3, or H4) of the cationic polypeptide composition is a substrate of p300 / CBP (see, e.g., representative HTPs below, e.g., SEQ ID NOS: 129-130). In some cases, the cationic polypeptide (e.g., a histone or HTP, e.g., H1, H2, H2A, H2AX, H2B, H3, or H4) of the cationic polypeptide composition contains one or more thiol residues (e.g., which may include cysteine and / or methionine residues) that are sulfated or susceptible to sulfation (e.g., as a substrate for thiosulfate sulfurtransferase). In some cases, the cationic polypeptide (e.g., a histone or HTP, e.g., H1, H2, H2A, H2AX, H2B, H3, or H4) of the cationic polypeptide composition is amidated at the C-terminus. Histones H2A, H2B, H3, and H4 (and / or HTP) can be mono-, di-, or tri-methylated at any of their lysines to promote or repress transcriptional activity and alter nuclear-specific export kinetics.
[0236] Cationic polypeptides can be synthesized with the desired modification or modified by in vitro reactions. Alternatively, cationic polypeptides (e.g., histones or HTPs) can be expressed in a cell population, and the desired modified protein can be isolated / purified. In some cases, the cationic polypeptide composition of the nanoparticles of the present invention comprises a methylated HTP, for example, an HTP sequence of H3K4(Me3) (including the amino acid sequence set forth as SEQ ID NO: 75 or 88). In some cases, the cationic polypeptide (e.g., histones or HTPs, e.g., H1, H2, H2A, H2AX, H2B, H3, or H4) of the cationic polypeptide composition comprises a C-terminal amide.
[0237] Examples of histones and HTPs For example, the following array: H2A SGRGKQGGKARAKAKTRSSR (SEQ ID NO: 62) [1-20] SGRGKQGGKARAKAKTRSSRAGLQFPVGRVHRLLRKGGG (SEQ ID NO: 63) [1-39] MSGRGKQGGKARAKAKTRSSRAGLQFPVGRVHRLLRKGNYAERVGAGAPVYLAAVLEYLTAEILELAGNAARDNKKTRIIPRHLQLAIRNDEELNKLLGKVTIAQGGVLPNIQAVLLPKKTESHHKAKGK (SEQ ID NO: 64) [1-130] H2AX CKATQASQEY (SEQ ID NO: 65) [134-143] KKTSATVGPKAPSGGKKATQASQEY (SEQ ID NO: 66) [KK 120-129] MSGRGKTGGKARAKAKSRSSRAGLQFPVGRVHRLLRKGHYAERVGAGAPVYLAAVLEYLTAEILELAGNAARDNKKTRIIPRHLQLAIRNDEELNKLLGGVTIAQGGVLPNIQAVLLPKKTSATVGPKAPSGGKKATQASQEY (SEQ ID NO: 67) [1-143] H2B PEPA-K(cr)-SAPAPK (SEQ ID NO: 68) [1-11 H2BK5(cr)] [cr: crotonylation] PEPAKSAPAPK (SEQ ID NO: 69) [1-11] AQKKDGKKRKRSRKE (SEQ ID NO: 70) [21-35] MPEPAKSAPAPKKGSKKAVTKAQKKDGKKRKRSRKESYSIYVYKVLKQVHPDTGISSKAMGIMNSFVNDIFERIAGEASRLAHYNKRSTITSREIQTAVRLLLPGELAKHAVSEGTKAVTKYTSSK (SEQ ID NO: 71) [1-126]
[0238] H3 ARTKQTAR (SEQ ID NO: 72) [1-8] ART-K(Me1)-QTARKS (SEQ ID NO: 73) [1-8 H3K4(Me1)] ART-K(Me2)-QTARKS (SEQ ID NO: 74) [1-8 H3K4(Me2)] ART-K(Me3)-QTARKS (SEQ ID NO: 75) [1-8 H3K4(Me3)] ARTKQTARK-pS-TGGKA (SEQ ID NO: 76) [1-15 H3pS10] ARTKQTARKSTGGKAPRKWC-NH2 (SEQ ID NO: 77) [1-18 WC, amide] ARTKQTARKSTGG-K(Ac)-APRKQ (SEQ ID NO: 78) [1-19 H3K14(Ac)] ARTKQTARKSTGGKAPRKQL (SEQ ID NO: 79) [1-20] ARTKQTAR-K(Ac)-STGGKAPRKQL (SEQ ID NO: 80) [1-20 H3K9(Ac)] ARTKQTARKSTGGKAPRKQLA (SEQ ID NO: 81) [1-21] ARTKQTAR-K(Ac)-STGGKAPRKQLA (SEQ ID NO: 82) [1-21 H3K9(Ac)] ARTKQTAR-K(Me2)-STGGKAPRKQLA (SEQ ID NO: 83) [1-21 H3K9(Me1)] ARTKQTAR-K(Me2)-STGGKAPRKQLA (SEQ ID NO: 84) [1-21 H3K9(Me2)] ARTKQTAR-K(Me2)-STGGKAPRKQLA (SEQ ID NO: 85) [1-21 H3K9(Me3)] ART-K(Me1)-QTARKSTGGKAPRKQLA (SEQ ID NO: 86) [1-21 H3K4(Me1)] ART-K(Me2)-QTARKSTGGKAPRKQLA (SEQ ID NO: 87) [1-21 H3K4(Me2)] ART-K(Me3)-QTARKSTGGKAPRKQLA (SEQ ID NO: 88) [1-21 H3K4(Me3)] ARTKQTAR-K(Ac)-pS-TGGKAPRKQLA (SEQ ID NO: 89) [1-21 H3K9(Ac), pS10] ART-K(Me3)-QTAR-K(Ac)-pS-TGGKAPRKQLA (SEQ ID NO: 90) [1~21 H3K4(Me3), K9(Ac), pS10] ARTKQTARKSTGGKAPRKQLAC (SEQ ID NO: 91) [1-21 Cys] ARTKQTAR-K(Ac)-STGGKAPRKQLATKA (SEQ ID NO: 92) [1-24 H3K9(Ac)] ARTKQTAR-K(Me3)-STGGKAPRKQLATKA (SEQ ID NO: 93) [1-24 H3K9(Me3)] ARTKQTARKSTGGKAPRKQLATKAA (SEQ ID NO: 94) [1-25] ART-K(Me3)-QTARKSTGGKAPRKQLATKAA (SEQ ID NO: 95) [1-25 H3K4(Me3)] TKQTAR-K(Me1)-STGGKAPR (SEQ ID NO: 96) [3-17 H3K9(Me1)] TKQTAR-K(Me2)-STGGKAPR (SEQ ID NO: 97) [3-17 H3K9(Me2)] TKQTAR-K(Me3)-STGGKAPR (SEQ ID NO: 98) [3-17 H3K9(Me3)] KSTGG-K(Ac)-APRKQ (SEQ ID NO: 99) [9-19 H3K14(Ac)] QTARKSTGGKAPRKQLASK (SEQ ID NO: 100) [5-23] APRKQLATKAARKSAPATGGVKKPH (SEQ ID NO: 101) [15-39] ATKAARKSAPATGGVKKPHRYRPG (SEQ ID NO: 102) [21-44] KAARKSAPA (SEQ ID NO: 103) [23-31] KAARKSAPATGG (SEQ ID NO: 104) [23-34] KAARKSAPATGGC (SEQ ID NO: 105) [23-34 Cys] KAAR-K(Ac)-SAPATGG (SEQ ID NO: 106) [H3K27(Ac)] KAAR-K(Me1)-SAPATGG (SEQ ID NO: 107) H3K27(Me1)] KAAR-K(Me2)-SAPATGG (SEQ ID NO: 108) [H3K27(Me2)] KAAR-K(Me3)-SAPATGG (SEQ ID NO: 109) [H3K27(Me3)] AT-K(Ac)-AARKSAPSTGGVKKPHRYRPG (SEQ ID NO: 110) [21-44 H3K23(Ac)] ATKAARK-pS-APATGGVKKPHRYRPG (SEQ ID NO: 111) [21-44 pS28] ARTKQTARKSTGGKAPRKQLATKAARKSAPATGGV (SEQ ID NO: 112) [1-35] STGGV-K(Me1)-KPHRY (SEQ ID NO: 113) [31-41 H3K36(Me1)] STGGV-K(Me2)-KPHRY (SEQ ID NO: 114) [31-41 H3K36(Me2)] STGGV-K(Me3)-KPHRY (SEQ ID NO: 115) [31-41 H3K36(Me3)] GTVALREIRRYQ-K(Ac)-STELLIR (SEQ ID NO: 116) [44-63 H3K56(Ac)] ARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKPHRYRPGTVALRE (SEQ ID NO: 117) [1-50] TELLIRKLPFQRLVREIAQDF-K(Me1)-TDLRFQSAAI (SEQ ID NO: 118) [H3K79(Me1)] EIAQDFKTDLR (SEQ ID NO: 119) [73-83] EIAQDF-K(Ac)-TDLR (SEQ ID NO: 120) [73-83 H3K79(Ac)] EIAQDF-K(Me3)-TDLR (SEQ ID NO: 121) [73-83 H3K79(Me3)] RLVREIAQDFKTDLRFQSSAV (SEQ ID NO: 122) [69-89] RLVREIAQDFK-(Me1)-TDLRFQSSAV (SEQ ID NO: 123) [69-89 H3K79(Me1), amide] RLVREIAQDFK-(Me2)-TDLRFQSSAV (SEQ ID NO: 124) [69-89 H3K79(Me2), amide] RLVREIAQDFK-(Me3)-TDLRFQSSAV (SEQ ID NO: 125) [69-89 H3K79(Me3), amide] KRVTIMPKDIQLARRIRGERA (SEQ ID NO: 126) [116-136] MARTKQTARKSTGGKAPRKQLATKVARKSAPATGGVKKPHRYRPGTVALREIRRYQKSTELLIRKLPFQRLMREIAQDFKTDLRFQSSAVMALQEACESYLVGLFEDTNLCVIHAKRVTIMPKDIQLARRIRGERA (SEQ ID NO: 127) [1-136]
[0239] H4 SGRGKGG (SEQ ID NO: 128) [1-7] RGKGGKGLGKGA (SEQ ID NO: 129) [4-12] SGRGKGGKGLGKGGAKRHRKV (SEQ ID NO: 130) [1-21] KGLGKGGAKRHRKVLRDNWC-NH2 (SEQ ID NO: 131) [8-25 WC, amide] SGRG-K(Ac)-GG-K(Ac)-GLG-K(Ac)-GGA-K(Ac)-RHRKVLRDNGSGSK (SEQ ID NO: 132) [1-25 H4K5,8,12,16(Ac)] SGRGKGGKGLGKGGAKRHRK-NH2 (SEQ ID NO: 133) [1-20 H4 PRMT7 (protein arginine methyltransferase 7) substrate, M1] SGRG-K(Ac)-GGKGLGKGGAKRHRK (SEQ ID NO: 134) [1 to 20 H4K5(Ac)] SGRGKGG-K(Ac)-GLGKGGAKRHRK (SEQ ID NO: 135) [1 to 20 H4K8(Ac)] SGRGKGGKGLG-K(Ac)-GGAKRHRK (SEQ ID NO: 136) [1 to 20 H4K12(Ac)] SGRGKGGKGLGKGGA-K(Ac)-RHRK (SEQ ID NO: 137) [1-20 H4K16(Ac)] KGLGKGGAKRHRKVLRDNWC-NH2 (SEQ ID NO: 138) [1-25 WC, amide] MSGRGKGGKGLGKGGAKRHRKVLRDNIQGITKPAIRRLARRGGVKRISGLIYEETRGVLKVFLENVIRDAVTYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG (SEQ ID NO: 139) [1-103] This includes, but is not limited to:
[0240] Thus, the cationic polypeptide of the cationic polypeptide composition of the present invention can comprise an amino acid sequence having the amino acid sequence set forth in any of SEQ ID NOS: 62-139. In some cases, the cationic polypeptide of the cationic polypeptide composition of the present invention comprises an amino acid sequence having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 98% or more, 99% or more, or 100% sequence identity) to the amino acid sequence set forth in any of SEQ ID NOS: 62-139. In some cases, the cationic polypeptide of the cationic polypeptide composition of the present invention comprises an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 98% or more, 99% or more, or 100% sequence identity) to the amino acid sequence set forth in any of SEQ ID NOS: 62-139. The cationic polypeptide can comprise any advantageous modification, and many such contemplated modifications, such as methylation, acetylation, crotonylation, ubiquitinylation, phosphorylation, sumoylation, farnesylation, sulfation, etc., are discussed above.
[0241] In some cases, the cationic polypeptide of the cationic polypeptide composition comprises an amino acid sequence having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 98% or more, 99% or more, or 100% sequence identity) to the amino acid sequence set forth in SEQ ID NO: 94. In some cases, the cationic polypeptide of the cationic polypeptide composition comprises an amino acid sequence having 95% or more sequence identity (e.g., 98% or more, 99% or more, or 100% sequence identity) to the amino acid sequence set forth in SEQ ID NO: 94. In some cases, the cationic polypeptide of the cationic polypeptide composition comprises the amino acid sequence set forth in SEQ ID NO: 94. In some cases, the cationic polypeptide of the cationic polypeptide composition comprises a sequence represented by H3K4(Me3) (SEQ ID NO: 95), which includes the first 25 amino acids of human histone 3 protein and is trimethylated at lysine 4 (e.g., in some cases amidated at the C-terminus).
[0242] In some aspects, the cationic polypeptides (e.g., histones or HTPs, e.g., H1, H2, H2A, H2AX, H2B, H3, or H4) of the cationic polypeptide compositions contain cysteine residues that can facilitate conjugation (e.g., to form branched histone structures in some cases) to cationic (or, in some cases, anionic) amino acid polymers, linkers, NLSs, and / or other cationic polypeptides. For example, cysteine residues can be used for cross-linking (conjugation) via sulfhydryl chemistry (e.g., disulfide bonds) and / or amine-reactive chemistry. In some cases, the cysteine residue is an internal cysteine residue. In some cases, the cysteine residue is located at the N-terminus and / or C-terminus. In some cases, the cationic polypeptide (e.g., a histone or HTP, e.g., H1, H2, H2A, H2AX, H2B, H3, or H4) of the cationic polypeptide composition comprises a mutation (e.g., an insertion or substitution) that adds a cysteine residue. Examples of cysteine-containing HTPs include: CKATQASQEY (SEQ ID NO: 140) - from H2AX ARTKQTARKSTGGKAPRKQLAC (SEQ ID NO: 141) - from H3 ARTKQTARKSTGGKAPRKWC (SEQ ID NO: 142) KAARKSAPATGGC (SEQ ID NO: 143) from H3 KGLGKGGAKRHRKVLRDNWC (SEQ ID NO: 144) from H4 MARTKQTARKSTGGKAPRKQLATKVARKSAPATGGVKKPHRYRPGTVALREIRRYQKSTELLIRKLPFQRLMREIAQDFKTDLRFQSSAVMALQEACESYLVGLFEDTNLCVIHAKRVTIMPKDIQLARRIRGERA (SEQ ID NO: 145) from H3 This includes, but is not limited to:
[0243] In some embodiments, the cationic polypeptide of the cationic polypeptide composition (e.g., a histone or HTP, e.g., H1, H2, H2A, H2AX, H2B, H3, or H4) is conjugated to the cationic (and / or anionic) amino acid polymer of the core of the nanoparticle of the invention. By way of example, a histone or HTP can be conjugated to a cationic amino acid polymer (e.g., a cationic amino acid polymer comprising poly(lysine)) via a cysteine residue in which, for example, a pyridyl disulfide group of a lysine of the polymer is replaced by a disulfide bond to a cysteine of the histone or HTP.
[0244] Modification / branching structure In some aspects, the cationic polypeptide of the cationic polypeptide composition of the present invention has a linear structure. In some aspects, the cationic polypeptide of the cationic polypeptide composition of the present invention has a branched structure.
[0245] For example, in some cases, a cationic polypeptide (e.g., an HTP, e.g., an HTP with cysteine residues) is conjugated to the end (e.g., at its C-terminus) of a cationic polymer (e.g., poly(L-arginine), poly(D-lysine), poly(L-lysine), poly(D-lysine)), thereby forming an extended linear polypeptide. In some cases, one or more (two or more, three or more, etc.) cationic polypeptides (e.g., an HTP, e.g., an HTP with cysteine residues) are conjugated to the end (e.g., at their C-terminus) of a cationic polymer (e.g., poly(L-arginine), poly(D-lysine), poly(L-lysine), poly(D-lysine)), thereby forming an extended linear polypeptide. In some cases, the cationic polymer has a molecular weight in the range of 4,500 to 150,000 Da.
[0246] As another example, in some cases, one or more (two or more, three or more, etc.) cationic polypeptides (e.g., HTPs, e.g., HTPs with cysteine residues) are conjugated (e.g., at their C-termini) to the side chains of a cationic polymer (e.g., poly(L-arginine), poly(D-lysine), poly(L-lysine), poly(D-lysine)), thereby forming a branched structure (branched polypeptide). The formation of a branched structure by components of the nanoparticle core (e.g., components of the cationic polypeptide composition of the present invention) can, in some cases, increase the amount of core compaction (e.g., compaction of the nucleic acid payload) that can be achieved. Thus, in some cases, it is desirable to use components that form branched structures. A wide variety of branched structures are of interest and can be produced (e.g., using cationic polypeptides of the invention, e.g., HTPs, e.g., HTPs with cysteine residues; peptoids, polyamides, etc.). Examples of branched structures include, but are not limited to, brush polymers, webs (e.g., spider webs), graft polymers, star polymers, comb polymers, polymer networks, dendrimers, etc.
[0247] In some cases, the branched structure comprises 2-30 cationic polypeptides (e.g., HTPs) (e.g., 2-25, 2-20, 2-15, 2-10, 2-5, 4-30, 4-25, 4-20, 4-15, or 4-10 cationic polypeptides), where each cationic polypeptide can be the same as or different from other cationic polypeptides in the branched structure. In some cases, the cationic polymer has a molecular weight in the range of 4,500-150,000 Da. In some cases, 5% or more (e.g., 10% or more, 20% or more, 25% or more, 30% or more, 40% or more, or 50% or more) of the side chains of the cationic polymer (e.g., poly(L-arginine), poly(D-lysine), poly(L-lysine), poly(D-lysine)) are conjugated to a cationic polypeptide (e.g., an HTP, e.g., an HTP with a cysteine residue) of the invention. In some cases, 50% or less (e.g., 40%, 30%, 25%, 20%, 15%, 10%, or 5% or less) of the side chains of a cationic polymer (e.g., poly(L-arginine), poly(D-lysine), poly(L-lysine), poly(D-lysine)) are conjugated to a cationic polypeptide of the invention (e.g., an HTP, e.g., an HTP with cysteine residues). Thus, the HTP may be branched from the backbone of the polymer, e.g., the cationic amino acid polymer.
[0248] In some cases, the formation of branched structures can be facilitated using building blocks, such as peptoids (polypeptoids), polyamides, dendrimers, etc. For example, in some cases, peptoids (e.g., polypeptoids) are used as building blocks of nanoparticle cores to generate web (e.g., spider web) structures that can facilitate condensation of the nanoparticle cores.
[0249] One or more of the native or modified polypeptide sequences herein may be modified with terminal or intermittent arginine, lysine, or histidine sequences. In one embodiment, each polypeptide is incorporated into the nanoparticle core at equal amine molar concentrations. In this embodiment, the C-terminus of each polypeptide may be modified with 5R (five arginines). In some embodiments, the C-terminus of each polypeptide may be modified with 9R (nine arginines). In some embodiments, the N-terminus of each polypeptide may be modified with 5R (five arginines). In some embodiments, the N-terminus of each polypeptide may be modified with 9R (nine arginines). In some cases, H2A, H2B, and / or H4 histone fragments (e.g., HTP) are each crosslinked in tandem with a cathepsin B proteolytic cleavage domain, which is FKFL, or a cathepsin D proteolytic cleavage domain, which is RGFFP. In some cases, H2A, H2B, and / or H4 histone fragments (e.g., HTP) can be tandemly cross-linked by 5R (five arginines), 9R (nine arginines), 5K (five lysines), 9K (nine lysines), 5H (five histidines), or 9H (nine histidines) cationic spacer domains. In some cases, one or more H2A, H2B, and / or H4 histone fragments (e.g., HTP) are disulfide-cross-linked at their N-termini to protamine.
[0250] To illustrate how to generate branched histone structures, a representative preparation method is presented. One example of such a method involves the covalent modification of equimolar ratios of histone H2AX [134-143], histone H3 [Cys 1-21], histone H3 [Cys 23-34], histone H4 [WC 8-25], and the NLS from the SV40 T-Ag antigen in a reaction with 10% pyridyl disulfide-modified poly(L-lysine) [MW = 5400, 18,000, or 45,000 Da; n = 30, 100, or 250]. In a typical reaction, 29 μL of an aqueous solution of 700 μM Cys-modified histone / NLS (20 nmoles) can be added to 57 μL of 0.2 M phosphate buffer (pH 8.0). Second, 14 μL of 100 μM pyridyl disulfide-protected poly(lysine) solution can be added to the histone solution to make the ratio of pyridyl disulfide groups to cysteine residues 1:2, and the final volume can be brought to 100 μL. This reaction can be carried out at room temperature for 3 hours. The reaction can be repeated four times, and the degree of conjugation can be determined via the absorbance of pyridine-2-thione at 343 nm.
[0251] As another example, covalent modification of histone H3[Cys1-21] peptide and histone H3[Cys23-34] peptide at molar ratios of 0:1, 1:4, 1:3, 1:2, 1:1, 1:2, 1:3, 1:4, or 1:0 can be performed in reactions involving 10% pyridyl disulfide-modified poly(L-lysine) or poly(L-arginine) [MW = 5400, 18,000, or 45,000 Da; n = 30, 100, or 250]. In a typical reaction, 29 μL of an aqueous solution of 700 μM Cys-modified histone (20 nmoles) can be added to 57 μL of 0.2 M phosphate buffer (pH 8.0). Second, 14 μL of 100 μM pyridyl disulfide-protected poly(lysine) solution can be added to the histone solution to make the ratio of pyridyl disulfide groups to cysteine residues 1:2, and the final volume can be brought to 100 μL. This reaction can be carried out at room temperature for 3 hours. The reaction can be repeated four times, and the degree of conjugation can be determined via the absorbance of pyridine-2-thione at 343 nm.
[0252] In some cases, the anionic polymer is conjugated to a targeting ligand.
[0253] Nuclear localization sequence (NLS) In some aspects, the cationic polypeptide (e.g., histone or HTP, e.g., H1, H2, H2A, H2AX, H2B, H3, or H4) of the cationic polypeptide composition comprises (and / or is conjugated to) one or more (e.g., two or more, three or more, or four or more) nuclear localization sequences (NLSs). Thus, in some cases, the cationic polypeptide composition of the nanoparticles of the present invention comprises a peptide comprising an NLS. In some cases, the histone protein (or HTP) of the nanoparticles of the present invention comprises one or more (e.g., two or more, three or more) naturally occurring nuclear localization signals (NLSs). In some cases, the histone protein (or HTP) of the nanoparticles of the present invention comprises one or more (e.g., two or more, three or more) NLSs that are heterologous to the histone protein (i.e., an NLS that does not occur naturally as part of the histone / HTP; e.g., the NLS may be added by humans). In some cases, the HTP comprises an NLS at the N- and / or C-terminus.
[0254] In some embodiments, the cationic amino acid polymers of the cationic polymer composition (e.g., poly(arginine) (PR), poly(lysine) (PK), poly(histidine) (PH), poly(ornithine), poly(citrulline), poly(D-arginine) (PDR), poly(D-lysine) (PDK), poly(D-histidine) (PDH), poly(D-ornithine), poly(D-citrulline), poly(L-arginine) (PLR), poly(L-lysine) (PLK), poly(L-histidine) (PLH), poly(L-ornithine), or poly(L-citrulline)) comprise (and / or are conjugated to) one or more (e.g., two or more, three or more, or four or more) NLSs. In some cases, the cationic amino acid polymers comprise an NLS at the N- and / or C-terminus. In some cases, the cationic amino acid polymer comprises an internal NLS.
[0255] In some embodiments, the anionic amino acid polymer of the anionic polymer composition (e.g., poly(glutamic acid) (PEA), poly(aspartic acid) (PDA), poly(D-glutamic acid) (PDEA), poly(D-aspartic acid) (PDDA), poly(L-glutamic acid) (PLEA), or poly(L-aspartic acid) (PLDA)) comprises (and / or is conjugated to) one or more (e.g., two or more, three or more, or four or more) NLSs. In some cases, the anionic amino acid polymer comprises an NLS at the N- and / or C-terminus. In some cases, the anionic amino acid polymer comprises an internal NLS.
[0256] Any convenient NLS can be used (e.g., capable of binding to histones, HTPs, cationic amino acid polymers, anionic amino acid polymers, etc.). Examples include, but are not limited to, class 1 and class 2 "monokyaku NLSs," as well as class 3-5 NLSs (see, e.g., Figure 6, reprinted from Kosugi et al., J Biol Chem. 2009 Jan 2;284(1):478-85). In some cases, the NLS has the formula: (K / R)(K / R)X 10-12 (K / R) 3-5 In some cases, the NLS has the formula: K(K / R)X(K / R).
[0257] In some embodiments, the cationic polypeptide of the cationic polypeptide composition comprises one or more (e.g., two or more, three or more, or four or more) NLSs. In some cases, the cationic polypeptide is not a histone protein or histone fragment (e.g., is not an HTP). Thus, in some cases, the cationic polypeptide of the cationic polypeptide composition is an NLS-containing peptide.
[0258] In some cases, the NLS-containing peptide comprises a cysteine residue that facilitates conjugation with cationic (or in some cases anionic) amino acid polymers, linkers, histone proteins in the case of HTPs, and / or other cationic polypeptides (e.g., in some cases, as part of a branched histone structure). For example, the cysteine residue can be used for cross-linking (conjugation) via sulfhydryl chemistry (e.g., disulfide bonds) and / or amine-reactive chemistry. In some cases, the cysteine residue is a cysteine residue. In some cases, the cysteine residue is located at the N-terminus and / or C-terminus. In some cases, the NLS-containing peptide of the cationic polypeptide composition comprises a mutation (e.g., insertion or substitution) that adds a cysteine residue (e.g., compared to the wild-type amino acid sequence).
[0259] Examples of NLSs that can be used as NLS-containing peptides (or NLSs conjugated to any convenient cationic polypeptide, e.g., HTPs or cationic polymers or cationic amino acid polymers or anionic amino acid polymers) are: PKKKRKV (SEQ ID NO: 151) (T-ag NLS) PKKKRKVEDPYC (SEQ ID NO: 152) - SV40 T-Ag-derived NLS PKKKRKVGPKKKRKVGPKKKRKVGPKKKRKVGC (SEQ ID NO: 153) (NLS SV40) CYGRKKRRQRRR (SEQ ID NO: 154) - N-terminal cysteine of cysteine TAT CSIPPEVKFNKPFVYLI (SEQ ID NO: 155) DRQIKIWFQNRRMKWKK (SEQ ID NO: 156) PKKKRKVEDPYC (SEQ ID NO: 157) - C-terminal cysteine of SV40 T-Ag-derived NLS PAAKRVKLD (SEQ ID NO: 158) [cMyc NLS] These include, but are not limited to, the following (some of which contain cysteine residues):
[0260] For non-limiting examples of NLSs that can be used, see, e.g., Kosugi et al., J Biol Chem. 2009 Jan 2;284(1):478-85, and see, e.g., Figure 6 of the present disclosure.
[0261] Mitochondrial localization signal In some embodiments, the cationic polypeptide (e.g., histone or HTP, e.g., H1, H2, H2A, H2AX, H2B, H3, or H4), anionic polymer, and / or cationic polymer of the nanoparticles of the invention comprise (and / or are conjugated to) one or more (e.g., two or more, three or more, or four or more) mitochondrial localization sequences. Any convenient mitochondrial localization sequence may be used. Examples of mitochondrial localization sequences include, but are not limited to, PEDEIWLPEPESVDVPAKPISTSSMMMP (SEQ ID NO: 149), the mitochondrial localization sequence of SDHB, mono / di / triphenylphosphonium, or other phosphonium, VAMP 1A, VAMP 1B, the N-terminal 67 amino acids of DGAT2, and the N-terminal 20 amino acids of Bax.
[0262] delivery As mentioned above, in some aspects, the methods of the present invention include introducing a delivery vehicle (e.g., nanoparticles, delivery molecules, etc.) into a target cell, which in some cases can be achieved by contacting the target cell with the delivery vehicle. If the target cell is in vivo, introducing can be achieved by administering the delivery vehicle to an individual. The delivery vehicles of the present invention (e.g., nanoparticles, delivery molecules, etc.) can be delivered to any desired target cell, for example, any desired eukaryotic cell.
[0263] In some cases, the target cell is an in vitro cell (e.g., the cell is in culture), e.g., the cell can be a cell of an established tissue culture cell line. In some cases, the target cell is an ex vivo cell (e.g., the cell is a primary cell (or a younger passage progeny cell) isolated from an individual, e.g., a patient). In some cases, the target cell is in vivo, and thus is inside (or part of) an organism.
[0264] For example, the components described herein as the payload of a delivery vehicle may be introduced into a subject (i.e., administered to an individual) via any convenient route (examples include, but are not limited to, systemic, topical, parenteral, subcutaneous (sc), intravenous (iv), intracranial (ic), intraspinal, intraocular, intradermal (id), intramuscular (im), intralymphatic (il), or intraspinal fluid). The components / delivery vehicles may be introduced by injection (e.g., systemic injection, direct local injection, local injection at or near the tumor and / or tumor resection site, etc.), catheter, etc. Examples of methods for local delivery (e.g., delivery to the site of a tumor and / or cancer) include delivery by, e.g., bolus injection, e.g., by syringe, e.g., into or near a joint, tumor, or organ; delivery by, e.g., continuous infusion, e.g., by cannulation, e.g., with convection (see, e.g., U.S. Patent Application Publication No. 2007 / 0254842, incorporated herein by reference).
[0265] The number of times that a treatment is administered to a subject may vary. Introduction of a delivery vehicle into an individual may be a one-time event; however, in certain circumstances, such treatment may induce improvement for a limited period of time and require a series of repeated treatments. In other circumstances, multiple administrations of a delivery vehicle may be required before an effect is observed. As those skilled in the art will readily understand, the exact protocol will depend on the disease or condition, the stage of the disease, and the parameters of the individual being treated.
[0266] A "therapeutically effective amount" or "therapeutic dose" is an amount sufficient to produce a desired therapeutic result (i.e., achieve therapeutic efficacy). A therapeutically effective amount may be administered in one or more administrations. A therapeutically effective amount of a delivery vehicle is an amount that, when administered to an individual, is sufficient to palliate, ameliorate, stabilize, inhibit, prevent, slow the progression of, or delay a disease state / disorder for purposes of the present invention.
[0267] A typical therapeutic intervention would create resistance to HIV infection in addition to eliminating any retroviral DNA integrated into the host genome. Because T cells are directly affected by HIV, hybrid blood-targeting strategies targeting CD34+ / CD45+ cells may be explored. For example, an effective therapeutic intervention could involve simultaneously targeting HSCs and T cells and eliminating (and delivering replacement sequences for) CCR5-Δ32 and gag / rev / pol genes via multiple inducible nucleases (e.g., within a single particle).
[0268] In some cases, the target cell is a mammalian cell (e.g., a rodent cell, a mouse cell, a rat cell, an ungulate cell, a bovine cell, a sheep cell, a pig cell, a horse cell, a camel cell, a rabbit cell, a canine (dog) cell, a feline (cat) cell, a primate cell, a non-human primate cell, a human cell). Any cell may be targeted, and in some cases, specific targeting of a particular cell depends on the presence of a targeting ligand (e.g., as part of the surface coating of the nanoparticle, as part of the delivery molecule), where the targeting ligand provides for targeted binding to a particular cell. For example, cells that can be targeted include bone marrow cells, hematopoietic stem cells (HSCs), long-term HSCs, short-term HSCs, hematopoietic stem / progenitor cells (HSPCs), peripheral blood mononuclear cells (PBMCs), myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells (e.g., via targeting of CD19, CD20, CD22), NKT cells, NK cells, dendritic cells, monocytes, granulocytes, erythrocytes, megakaryocytes, mast cells, basophils, eosinophils, neutrophils, macrophages (e.g., via SIRPα-mimetic peptides), C cells, and the like. D47 targeting), erythroid progenitor cells (e.g., HUDEP cells), megakaryocyte-erythroid progenitor cells (MEP), common myeloid progenitor cells (CMP), multipotent progenitor cells (MPP), hematopoietic stem cells (HSC), short-term HSC (ST-HSC), IT-HSC, long-term HSC (LT-HSC), endothelial cells, neurons, astrocytes, pancreatic cells, pancreatic islet beta cells, muscle cells, skeletal muscle cells, cardiomyocytes, hepatocytes, adipocytes, intestinal cells, colonocytes, and gastric cells.
[0269] Examples of various applications (e.g., for targeting neurons, pancreatic cells, hematopoietic stem cells, and multipotent progenitor cells, etc.) have been discussed above, e.g., in the context of targeting ligands. For example, hematopoietic stem cells and multipotent progenitor cells can be targeted for in vivo gene editing (e.g., insertion). Editing even 1% of bone marrow cells in vivo (approximately 15 billion cells) would still target more cells (approximately 10 billion cells) than ex vivo therapy. As another example, pancreatic cells (e.g., pancreatic islet β cells) can be targeted to treat, for example, pancreatic cancer, treat diabetes, etc. As another example, somatic cells in the brain, e.g., neurons, can be targeted (e.g., to treat indications such as Huntington's disease, Parkinson's disease (e.g., LRRK2 mutations), and ALS (e.g., SOD1 mutations)). In some cases, this can be achieved via direct intracranial injection.
[0270] As another example, endothelial cells and cells of the hematopoietic system (e.g., megakaryocytes and / or any progenitor cells that are prototypical megakaryocytes, e.g., megakaryocyte-erythroid progenitors (MEPs), common myeloid progenitors (CMPs), multipotent progenitors (MPPs), hematopoietic stem cells (HSCs), short-term HSCs (ST-HSCs), IT-HSCs, long-term HSCs (LT-HSCs) (see, e.g., Figures 7-8)) can be targeted by the nanoparticles of the invention (or viral or non-viral delivery vehicles of the invention) to treat von Willebrand disease. For example, cells carrying a mutation in the gene encoding von Willebrand factor (VWF) (e.g., endothelial cells, megakaryocytes, and / or any progenitor cells that are prototypical for megakaryocytes, e.g., MEPs, CMPs, MPPs, HSCs, e.g., ST-HSCs, IT-HSCs, and / or LT-HSCs) can be targeted (in vitro, ex vivo, in vivo) to edit (and correct) the mutated gene, e.g., by introducing a replacement sequence (e.g., via delivery of donor DNA). In some of the above cases (e.g., for the treatment of von Willebrand disease, for targeting cells carrying a mutation in the gene encoding VWF), the targeting ligand of the invention binds to E-selectin.
[0271] The methods and compositions of the present invention can be used to treat any number of diseases linked to known mutations, such as mutations in the genome. For example, the methods and compositions of the present invention can be used to treat sickle cell disease, β-thalassemia, HIV, myelodysplastic syndromes, JAK2-mediated polycythemia vera, JAK2-mediated primary myelofibrosis, JAK2-mediated leukemia, and various blood disorders. In addition, the methods and compositions of the present invention can be used in the generation of B cell antibodies, immunotherapy (e.g., delivery of checkpoint blockade agents), and stem cell differentiation.
[0272] In some embodiments, the targeting ligand binds to KLS CD27+ / IL-7Ra- / CD150+ / CD34- hematopoietic stem / progenitor cells (HSPCs). For example, the β-globin (HBB) gene may be directly targeted to correct the altered E7V substitution with an appropriate donor DNA molecule (insert donor composition). As an example, a CRISPR / Cas RNA-guided polypeptide (e.g., Cas9, CasX, CasY, Cpf1) can be delivered with an appropriate guide RNA so that it binds to a locus within the HBB gene, creates a break in the genome, and induces the insertion of a sequence from the introduced first donor DNA (target donor composition). The resulting target site provides a target for a site-specific recombinase that catalyzes the insertion of a desired nucleotide sequence from the second donor DNA. In some cases, a donor DNA molecule (single- or double-stranded) may be introduced (as part of the payload) and released for 14-30 days, while the guide RNA / CRISPR / Cas protein complex (ribonucleoprotein complex) may be released for 1-7 days.
[0273] In some embodiments, a targeting ligand binds to CD4+ or CD8+ T cells, hematopoietic stem / progenitor cells (HSPCs), or peripheral blood mononuclear cells (PBMCs) to modify the T cell receptor. For example, gene editing tools (described elsewhere herein) can be introduced to modify the T cell receptor. The T cell receptor can be directly targeted and replaced with a corresponding homology-directed repair donor DNA molecule for a new T cell receptor. As one example, a CRISPR / Cas RNA-guided polypeptide (e.g., Cas9, CasX, CasY, Cpf1) can be delivered with an appropriate guide RNA so that it binds to a locus within the HBB gene, creates a break in the genome, and induces the insertion of a sequence from the introduced first donor DNA (target donor composition). The resulting target site provides a target for a site-specific recombinase that catalyzes the insertion of a nucleotide sequence of interest from the second donor DNA. It will be apparent to one of skill in the art that other CRISPR guide RNAs and donor sequences, and / or other expression vectors targeting β-globin, CCR5, T cell receptors, or other genes of interest may be used in accordance with the present disclosure.
[0274] In some cases, the methods of the present invention are used to target loci encoding T cell receptors (TCRs), in some cases having as many as 1,000,000 base pairs, with approximately 100 domains and constant regions separated from the V(D)J region by approximately 100,000 base pairs or more. In some cases, insertion of donor DNA occurs within the nucleotide sequence encoding the T cell receptor (TCR) protein. In some such cases, the sequence of donor DNA (of the insert donor composition) inserted into the genome encodes amino acids in the CDR1, CDR2, or CDR3 regions of the TCR protein. See, e.g., Dash et al., Nature. 2017 Jul 6;547(7661):89-93. Epub 2017 Jun 21 and Glanville et al., Nature. 2017 Jul 6;547(7661):94-98. Epub 2017 Jun 21.
[0275] In some cases, the methods of the present invention are used to insert genes so that they are under the control of (operably linked to) specific enhancers as a failsafe against genome manipulation. If the insertion fails, the enhancer leading to the subsequent gene is destroyed, making it unlikely that any possible indels will be expressed. If the gene insertion is successful, a new gene may be inserted with a stop codon at its end, particularly useful for multipartite genes, e.g., TCR loci. In some cases, the methods of the present invention may be used to insert chimeric antigen receptors (CARs) or other constructs into T cells or to generate specific antibodies or antibody replacements (e.g., nanobodies, shark antibodies, etc.) in B cells.
[0276] In some cases, the sequence of donor DNA (of the insert donor composition) inserted into the genome encodes a chimeric antigen receptor (CAR). In some such cases, insertion of the donor DNA results in operably linking the nucleotide sequence encoding the CAR to an endogenous T cell promoter (i.e., expression of the CAR is placed under the control of the endogenous promoter). In some cases, the sequence of donor DNA (of the insert donor composition) inserted into the genome includes a nucleotide sequence operably linked to a promoter and encodes a chimeric antigen receptor (CAR) (and thereby places the inserted CAR under the control of the promoter that was present on the donor DNA).
[0277] In some cases, the sequence of donor DNA (of the insert donor composition) inserted into the genome comprises a nucleotide sequence encoding a membrane-bound, extracellularly presented cell-specific targeting ligand. In some cases, insertion of the donor DNA results in operably linking the nucleotide sequence encoding the cell-specific targeting ligand to an endogenous promoter. In some cases, the sequence of donor DNA (of the insert donor composition) inserted into the genome comprises a promoter operably linked to the sequence encoding the membrane-bound, extracellularly presented cell-specific targeting ligand (and thereby, after insertion of the sequence, expression of the membrane-bound targeting ligand is under the control of the promoter present on the donor DNA).
[0278] In some aspects, insertion of the donor DNA sequence (of the insert donor composition) occurs within a nucleotide sequence encoding a T cell receptor (TCR) α or δ subunit. In some cases, insertion of the donor DNA sequence (of the insert donor composition) occurs within a nucleotide sequence encoding a TCR β or γ subunit. In some cases, the methods and / or compositions of the invention comprise two donor DNAs. In some such cases, insertion of one of the donor DNA sequences (of the insert donor composition) occurs within a nucleotide sequence encoding a T cell receptor (TCR) α or δ subunit, and insertion of the other of the donor DNA sequences (of the insert donor composition) occurs within a nucleotide sequence encoding a T cell receptor (TCR) β or γ subunit.
[0279] In some aspects, the insertion of the donor DNA sequence (of the Insert Donor composition) occurs within a nucleotide sequence encoding the constant region of a T cell receptor (TCR) α or δ subunit. In some cases, the insertion of the donor DNA sequence (of the Insert Donor composition) occurs within a nucleotide sequence encoding the constant region of a T cell receptor (TCR) β or γ subunit. In some cases, the methods and / or compositions of the invention comprise two donor DNAs. In some such cases, the insertion of one of the donor DNA sequences (of the Insert Donor composition) occurs within a nucleotide sequence encoding the constant region of a T cell receptor (TCR) α or δ subunit, and the insertion of the other of the donor DNA sequences (of the Insert Donor composition) occurs within a nucleotide sequence encoding the constant region of a T cell receptor (TCR) β or γ subunit.
[0280] In some aspects, the insertion of the donor DNA sequence (of the Insert Donor composition) occurs within a nucleotide sequence that functions as a promoter for the T cell receptor (TCR) α or δ subunit. In some cases, the insertion of the donor DNA sequence (of the Insert Donor composition) occurs within a nucleotide sequence that functions as a promoter for the T cell receptor (TCR) β or γ subunit. In some cases, the methods and / or compositions of the invention comprise two donor DNAs. In some such cases, the insertion of one of the donor DNA sequences (of the Insert Donor composition) occurs within a nucleotide sequence that functions as a promoter for the T cell receptor (TCR) α or δ subunit, and the insertion of the other of the donor DNA sequences (of the Insert Donor composition) occurs within a nucleotide sequence that functions as a promoter for the T cell receptor (TCR) β or γ subunit.
[0281] In some aspects, insertion of the donor DNA sequence (of the insert donor composition) occurs within a nucleotide sequence encoding a T cell receptor (TCR) α or γ subunit. In some cases, insertion of the donor DNA sequence (of the insert donor composition) occurs within a nucleotide sequence encoding a TCR β or δ subunit. In some cases, the methods and / or compositions of the invention comprise two donor DNAs. In some such cases, insertion of one of the donor DNA sequences (of the insert donor composition) occurs within a nucleotide sequence encoding a T cell receptor (TCR) α or γ subunit, and insertion of the other of the donor DNA sequences (of the insert donor composition) occurs within a nucleotide sequence encoding a T cell receptor (TCR) β or δ subunit.
[0282] In some aspects, insertion of the donor DNA sequence (of the Insert Donor composition) occurs within a nucleotide sequence encoding the constant region of a T cell receptor (TCR) α or γ subunit. In some cases, insertion of the donor DNA sequence (of the Insert Donor composition) occurs within a nucleotide sequence encoding the constant region of a T cell receptor (TCR) β or δ subunit. In some cases, the methods and / or compositions of the invention comprise two donor DNAs. In some such cases, insertion of one of the donor DNA sequences (of the Insert Donor composition) occurs within a nucleotide sequence encoding the constant region of a T cell receptor (TCR) α or γ subunit, and insertion of the other of the donor DNA sequences (of the Insert Donor composition) occurs within a nucleotide sequence encoding the constant region of a T cell receptor (TCR) β or δ subunit.
[0283] In some aspects, insertion of the donor DNA sequence (of the Insert Donor composition) occurs within a nucleotide sequence that functions as a promoter for the T cell receptor (TCR) α or γ subunit. In some cases, insertion of the donor DNA sequence (of the Insert Donor composition) occurs within a nucleotide sequence that functions as a promoter for the T cell receptor (TCR) β or δ subunit. In some cases, the methods and / or compositions of the invention comprise two donor DNAs. In some such cases, insertion of one of the donor DNA sequences (of the Insert Donor composition) occurs within a nucleotide sequence that functions as a promoter for the T cell receptor (TCR) α or γ subunit, and insertion of the other of the donor DNA sequences (of the Insert Donor composition) occurs within a nucleotide sequence that functions as a promoter for the T cell receptor (TCR) β or δ subunit.
[0284] In some aspects, insertion of a sequence of donor DNA (of an Insert Donor composition) results in operably linking the inserted sequence with the endogenous promoter of T cell receptor (TCR) α, β. In some cases, the inserted sequence includes a nucleotide sequence encoding a protein that is operably linked to a promoter of TCR α, β, γ, or δ, such that after insertion, the protein-encoding sequence remains operably linked to (remains under the control of) the promoter present in the donor DNA. In some cases, insertion of the sequence results in operably linking the inserted sequence (e.g., a nucleotide sequence encoding a protein, e.g., a CAR, TCR α, TCR β, TCR γ, or TCR δ sequence) with a CD3 or CD28 promoter. In some cases, the inserted sequence of donor DNA (of an Insert Donor composition) includes a nucleotide sequence encoding a protein that is operably linked to a promoter (e.g., a T cell-specific promoter). In some cases, insertion of the donor DNA sequence (of the Insert Donor composition) results in operable linkage of the inserted sequence with an endogenous promoter (e.g., a stem cell-specific or somatic cell-specific endogenous promoter). In some cases, the inserted donor DNA sequence (of the Insert Donor composition) includes a nucleotide sequence encoding a reporter protein (e.g., a fluorescent protein for assessing gene editing efficiency, such as GFP, RFP, YFP, CFP, near-infrared and / or far-red reporter proteins, etc.). In some cases, the inserted sequence includes a nucleotide sequence encoding an intronless protein (e.g., a nucleotide sequence encoding all or a portion of a TCR protein).
[0285] In some cases, the methods of the invention (and / or compositions of the invention) can be used for the insertion of sequences for applications, such as the insertion of fluorescent reporters (e.g., fluorescent proteins, e.g., green fluorescent protein (GFP) / red fluorescent protein (RFP) / near-red / far-red fluorescent proteins, etc.) into the C- and / or N-terminus of any encoded protein of interest, e.g., a transmembrane protein.
[0286] Co-Delivery (Not Limited to Nanoparticles of the Invention) As described above, one advantage of delivering multiple payloads as part of the same package (delivery vehicle) is that the efficiency of each payload is not reduced. In some embodiments, the first donor DNA, one or more site-specific nucleases (or one or more nucleic acids encoding same), the second donor DNA, and the site-specific recombinase (or nucleic acid encoding same) are payloads of the same delivery vehicle. In some embodiments, the donor DNA and / or one or more gene editing tools (e.g., as described elsewhere herein) are delivered in combination with a protein (and / or DNA or mRNA encoding same) and / or a non-coding RNA that increases genome editing efficiency (e.g., may be delivered as part of the same package / delivery vehicle, where the delivery vehicle does not need to be a nanoparticle of the present disclosure). In some embodiments, the one or more gene editing tools are delivered in combination with a protein (and / or DNA or mRNA encoding same) and / or a non-coding RNA that controls cell division and / or differentiation (e.g., may be delivered as part of the same package / delivery vehicle, where the delivery vehicle does not need to be a nanoparticle of the present disclosure). For example, in some cases, one or more gene editing tools are delivered in combination with a protein (and / or DNA or mRNA encoding same) and / or a non-coding RNA that controls cell division (e.g., may be delivered as part of the same package / delivery vehicle, where the delivery vehicle need not be a nanoparticle of the present disclosure). In some cases, one or more gene editing tools are delivered in combination with a protein (and / or DNA or mRNA encoding same) and / or a non-coding RNA that controls differentiation (e.g., may be delivered as part of the same package / delivery vehicle, where the delivery vehicle need not be a nanoparticle of the present disclosure). In some cases, one or more gene editing tools are delivered in combination with a protein (and / or DNA or mRNA encoding same) and / or a non-coding RNA that biases cellular DNA repair machinery (e.g., may be delivered as part of the same package / delivery vehicle, where the delivery vehicle need not be a nanoparticle of the present disclosure).
[0287] As noted above, in some cases, the delivery vehicle need not be a nanoparticle of the present disclosure. For example, in some cases, the delivery vehicle is viral, and in some cases, the delivery vehicle is non-viral. Examples of non-viral delivery systems include materials that can be used to co-condense multiple nucleic acid payloads, or combinations of protein and nucleic acid payloads. Examples include: (1) lipid-based particles, such as zwitterionic or cationic lipids, and exosomes or exosome-derived vesicles; (2) inorganic / hybrid composite particles, such as co-condensed ionic complexes with nucleic acid and / or protein payloads, and cationic ionic states of Ca, Mg, Si, Fe, and physiological anions, such as O. 2- , OH, PO4 3- , SO4 2- (3) carbohydrate delivery vehicles, e.g., cyclodextrin and / or alginate; (4) polymeric and / or copolymeric conjugates, e.g., poly(amino acid)-based electrostatic conjugates, poly(amido-amine), and cationic poly(B-amino ester); and (5) virus-like particles (e.g., protein and nucleic acid-based). Examples of viral delivery systems include, but are not limited to, AAV, adenoviral, retroviral, and lentiviral delivery systems.
[0288] Example payloads for co-delivery In some aspects, the payload components described herein may be delivered in combination with one or more of SCF (and / or DNA or mRNA encoding SCF), HoxB4 (and / or DNA or mRNA encoding HoxB4), BCL-XL (and / or DNA or mRNA encoding BCL-XL), SIRT6 (and / or DNA or mRNA encoding SIRT6), a nucleic acid molecule (e.g., siRNA and / or LNA) that inhibits miR-155, a nucleic acid molecule (e.g., siRNA, shRNA, microRNA) that reduces expression of ku70, and a nucleic acid molecule (e.g., siRNA, shRNA, microRNA) that reduces expression of ku80 (e.g., siRNA, shRNA, microRNA).
[0289] See Figure 9 for examples of microRNAs that can be delivered together (delivered as RNA or as DNA encoding the RNA).For example, the following microRNAs may be used to: block differentiation of pluripotent stem cells to the ectodermal lineage: miR-430 / 427 / 302; block differentiation of pluripotent stem cells to the endodermal lineage: miR-109 and / or miR-24; drive differentiation of pluripotent stem cells to the endodermal lineage: miR-122 and / or miR-192; drive differentiation of ectodermal progenitor cells to a keratinocyte fate: miR-203; drive differentiation of neural crest stem cells to a smooth muscle fate: miR-145; drive differentiation of neural stem cells to a glial cell fate and / or neural stem cells to a nigromacular fate: miR-146; miR-9 and / or miR-124a to drive differentiation towards a neuronal fate; miR-199a to block differentiation of mesodermal progenitor cells towards a chondrocyte fate; miR-296 and / or miR-2861 to drive differentiation of mesodermal progenitor cells towards an osteoblast fate; miR-1 to drive differentiation of mesodermal progenitor cells towards a cardiac fate; miR-133 to block differentiation of mesodermal progenitor cells towards a cardiac fate; miR-214, miR-206, miR-1 and / or miR-26a to drive differentiation of mesodermal progenitor cells towards a skeletal muscle fate; To block the differentiation of mesodermal progenitor cells to a skeletal muscle fate: miR-133, miR-221, and / or miR-222; to drive...
Claims
1. 1. A method for inserting a donor sequence into the genome of a cell, comprising: (a) a nuclease composition comprising one or more sequence-specific nucleases or one or more nucleic acids encoding said one or more sequence-specific nucleases, wherein said one or more sequence-specific nucleases cleave the genome; (b) a targeted donor composition comprising a first donor DNA comprising a nucleotide sequence to be inserted into the genome, wherein insertion of the nucleotide sequence provides a target sequence for a site-specific recombinase at an insertion site within the genome; (c) a recombinase composition comprising the site-specific recombinase or a nucleic acid encoding the site-specific recombinase, wherein the site-specific recombinase recognizes the target sequence; and (d) an Insert Donor composition comprising a second donor DNA comprising a nucleotide sequence to be inserted into the genome as a result of recognition of the target sequence by the site-specific recombinase. The method comprises introducing into a cell a delivery vehicle with a payload comprising:
2. 2. The method of claim 1, wherein insertion of the nucleotide sequence of the first donor DNA of the targeted donor composition provides a first target sequence for the site-specific recombinase at a first site within the genome and a second target sequence for the site-specific recombinase at a second site within the genome.
3. 2. The method of claim 1, wherein the nuclease composition cleaves the genome at two locations and the target donor composition comprises two of the first donor DNAs, each of which comprises a nucleotide sequence to be inserted into the genome, thereby providing a first target sequence for the site-specific recombinase at a first site within the genome and a second target sequence for the site-specific recombinase at a second site within the genome.
4. 4. The method of claim 2 or 3, wherein the first site and the second site in the genome are spaced apart by 1,000,000 base pairs or less.
5. 4. The method of claim 2 or 3, wherein the first site and the second site in the genome are spaced apart by 100,000 base pairs or less.
6. 4. The method of claim 2 or 3, wherein the length of the nucleotide sequence of the Insert Donor composition to be inserted into the genome is between 10 base pairs (bp) and 100 kilobase pairs (kbp).
7. 7. The method of any one of claims 1 to 6, wherein the second donor DNA comprises two target sequences for the site-specific recombinase, the two target sequences flanking the nucleotide sequence to be inserted into the genome.
8. The method according to any one of claims 1 to 7, wherein the target sequence for the site-specific recombinase is selected from an attB site, an attP site, an attL site, an attR site, a loxP site and an FRT site.
9. The method of any one of claims 1 to 8, wherein the site-specific recombinase is selected from ΦC31, ΦC31 RDF, Cre and FLP.
10. 10. The method of any one of claims 1 to 9, wherein at least one of the one or more sequence-specific nucleases is selected from meganucleases, homing endonucleases, zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs).
11. The method of any one of claims 1 to 9, wherein at least one of the one or more sequence-specific nucleases is a CRISPR / Cas effector protein class 2.
12. 12. The method of claim 11, wherein the CRISPR / Cas effector protein class 2 is selected from Cas9 and cpf1.
13. 13. The method of claim 11 or 12, wherein the nuclease composition comprises one or more CRISPR / Cas guide nucleic acids or one or more nucleic acids encoding the CRISPR / Cas guide nucleic acids.
14. The method of any one of claims 1 to 13, wherein the delivery vehicle is non-viral.
15. The method of any one of claims 1 to 14, wherein the delivery vehicle is a nanoparticle.
16. The method of claim 15 , wherein the nanoparticle comprises, in addition to the payload, a core comprising an anionic polymer composition, a cationic polymer composition, and a cationic polypeptide composition.
17. 17. The method of claim 16, wherein the anionic polymer composition comprises an anionic polymer selected from poly(glutamic acid) and poly(aspartic acid).
18. 18. The method of claim 16 or 17, wherein the cationic polymer composition comprises a cationic polymer selected from poly(arginine), poly(lysine), poly(histidine), poly(ornithine), and poly(citrulline).
19. The method of any one of claims 16 to 18, wherein the nanoparticle further comprises a shed layer encapsulating the core.
20. 20. The method of claim 19, wherein the shed layer is an anionic or cationic coat.
21. 21. The method of claim 19 or 20, wherein the decidual layer comprises one or more of silica, peptoid, polycysteine, calcium, calcium oxide, hydroxyapatite, calcium phosphate, calcium sulfate, manganese, manganese oxide, manganese phosphate, manganese sulfate, magnesium, magnesium oxide, magnesium phosphate, magnesium sulfate, iron, iron oxide, iron phosphate, and iron sulfate.
22. The method of any one of claims 19 to 21, wherein the nanoparticles further comprise a surface coat surrounding the shed layer.
23. 23. The method of claim 22, wherein the surface coat comprises a cationic or anionic anchor domain that electrostatically interacts with the decidual layer.
24. 24. The method of claim 22 or 23, wherein the surface coat comprises one or more targeting ligands.
25. 25. The method of claim 24, wherein the one or more targeting ligands are selected from a peptide, an ScFv, an F(ab), a nucleic acid aptamer, or a peptoid.
26. The surface coat is selected from the group consisting of rabies virus glycoprotein (RVG) fragments, ApoE-transferrin, lactoferrin, melanoferritin, ovotransferritin, L-selectin, E-selectin, P-selectin, sialylated peptides, polysialylated O-linked peptides, TPO, EPO, PSGL-1, ESL-1, CD44, death receptor 3 (DR3), LAMP1, LAMP2, Mac2-BP, stem cell factor (SCF), CD70, SH2 domain-containing protein 1A (SH2D1A), exendin 4, GLP1, RGD, transferrin ligand, FGF fragments, succinic acid, bisphosphonates, hematopoietic stem cell chemotactic lipids, sphingosine, ceramide, sphingosine-1-phosphate, ceramide-1-phosphate, IL2, CD80, CD86, CD8ε, peptide-HLA-A * 24. The method of claim 22 or 23, comprising one or more targeting ligands selected from the group consisting of: 2402, and active targeting fragments thereof.
27. The surface coat is selected from the group consisting of CD3, CD8, CD4, CD28, CD90, CD45f, CD34, CD80, CD86, CD19, CD20, CD22, CD47, CD3 epsilon, CD3 gamma, CD3 delta; constant regions of TCR alpha, TCR beta, TCR gamma and / or TCR delta; 4-1BB, OX40, OX40L, CD62L, ARP5, CCR5, CCR7, CCR10, CXCR3, CXCR4, CD94 / NKG2, NKG2A, NK 24. The method of claim 22 or 23, comprising one or more targeting ligands that result in binding to a target selected from G2B, NKG2C, NKG2E, NKG2H, NKG2D, NKG2F, NKp44, NKp46, NKp30, DNAM, XCR1, XCL1, XCL2, ILT, LIR, Ly49, IL2R, IL7R, IL10R, IL12R, IL15R, IL18R, TNFα, IFNγ, TGF-β and α5β1.
28. The surface coat is selected from the group consisting of bone marrow cells, hematopoietic stem cells (HSC), hematopoietic stem / progenitor cells (HSPC), peripheral blood mononuclear cells (PBMC), myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, NKT cells, NK cells, dendritic cells, monocytes, granulocytes, erythrocytes, megakaryocytes, mast cells, basophils, eosinophils, neutrophils, macrophages, erythroid progenitor cells, megakaryocyte-erythroid progenitor cells (MEP), common myeloid progenitor cells (CMP), and multiple myeloid progenitor cells.
24. The method of claim 22 or 23, comprising one or more targeting ligands that provide for binding to a target cell selected from: highly potent progenitor cells (MPPs), hematopoietic stem cells (HSCs), short term HSCs (ST-HSCs), IT-HSCs, long term HSCs (LT-HSCs), endothelial cells, neurons, astrocytes, pancreatic cells, pancreatic islet beta cells, liver cells, muscle cells, skeletal muscle cells, cardiac myocytes, hepatocytes, adipocytes, intestinal cells, colon cells and gastric cells.
29. The method of any one of claims 1 to 14, wherein the delivery vehicle is a targeting ligand conjugated to the payload, the targeting ligand providing binding to a cell surface protein.
30. 15. The method of any one of claims 1 to 14, wherein the delivery vehicle is a targeting ligand conjugated to a charged polymer polypeptide domain, the targeting ligand providing binding to a cell surface protein, and the charged polymer polypeptide domain being condensed with a nucleic acid payload and / or electrostatically interacting with a protein payload.
31. 31. The method of claim 29 or 30, wherein the targeting ligand is a peptide, ScFv, F(ab), nucleic acid aptamer or peptoid.
32. The method of claim 30, wherein the polypeptide domain that is the charged polymer has a length of 3 to 30 amino acids.
33. 33. The method of any one of claims 30-32, wherein the delivery vehicle further comprises an anionic polymer that interacts with the payload and the charged polymer polypeptide domain.
34. 34. The method of claim 33, wherein the anionic polymer is selected from poly(glutamic acid) and poly(aspartic acid).
35. The method of any one of claims 29 to 34, wherein the targeting ligand is 5 to 50 amino acids in length.
36. 36. The method of any one of claims 29 to 35, wherein the targeting ligand provides binding to a cell surface protein selected from G protein-coupled receptor (GPCR) family B, a receptor tyrosine kinase (RTK), a cell surface glycoprotein, and an intercellular adhesion molecule.
37. The targeting ligand is selected from the group consisting of rabies virus glycoprotein (RVG) fragment, ApoE-transferrin, lactoferrin, melanoferritin, ovotransferritin, L-selectin, E-selectin, P-selectin, sialylated peptides, polysialylated O-linked peptides, TPO, EPO, PSGL-1, ESL-1, CD44, death receptor 3 (DR3), LAMP1, LAMP2, Mac2-BP, stem cell factor (SCF), CD70, SH2 domain-containing protein 1A (SH2D1A), exendin, exendin-S11C, GLP1, RGD, transferrin ligand, FGF fragment, α5β1 ligand, IL2, Cde3ε, peptide-HLA-A * 2402, CD80, CD86, succinic acid, bisphosphonates, hematopoietic stem cell chemotactic lipids, sphingosine, ceramide, sphingosine-1-phosphate, ceramide-1-phosphate, and active targeting fragments thereof.
38. The targeting ligand is selected from the group consisting of CD3, CD28, CD90, CD45f, CD34, CD80, CD86, CD19, CD20, CD22, CD47, CD3 epsilon, CD3 gamma, CD3 delta; the constant regions of TCR alpha, TCR beta, TCR gamma and / or TCR delta; 4-1BB, OX40, OX40L, CD62L, ARP5, CCR5, CCR7, CCR10, CXCR3, CXCR4, CD94 / NKG2, NK 36. The method of any one of claims 29 to 35, which results in binding to a target selected from G2A, NKG2B, NKG2C, NKG2E, NKG2H, NKG2D, NKG2F, NKp44, NKp46, NKp30, DNAM, XCR1, XCL1, XCL2, ILT, LIR, Ly49, IL-2, IL-7, IL-10, IL-12, IL-15, IL-18, TNFα, IFNγ, TGF-β and α5β1.
39. The targeting ligand is selected from the group consisting of bone marrow cells, hematopoietic stem cells (HSCs), long-term HSCs, short-term HSCs, hematopoietic stem / progenitor cells (HSPCs), peripheral blood mononuclear cells (PBMCs), myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, NKT cells, NK cells, dendritic cells, monocytes, granulocytes, erythrocytes, megakaryocytes, mast cells, basophils, eosinophils, neutrophils, macrophages, erythroid progenitor cells (e.g., HUDEP cells), megakaryocyte-erythroid progenitor cells 36. The method of any one of claims 29 to 35, wherein the method results in binding to a cell selected from the group consisting of: common myeloid progenitor cells (MEPs), common myeloid progenitor cells (CMPs), multipotent progenitor cells (MPPs), hematopoietic stem cells (HSCs), short term HSCs (ST-HSCs), IT-HSCs, long term HSCs (LT-HSCs), endothelial cells, neurons, astrocytes, pancreatic cells, islet beta cells, muscle cells, skeletal muscle cells, cardiac myocytes, hepatocytes, adipocytes, intestinal cells, colon cells and gastric cells.
40. 40. The method of any one of claims 1 to 39, wherein insertion of the nucleotide sequence of the second donor DNA into the genome results in operable linkage of the inserted sequence with an endogenous promoter.
41. 41. The method of claim 40, wherein the endogenous promoter is selected from the group consisting of: (i) a T cell specific promoter; (ii) a CD3 promoter; (iii) a CD28 promoter; (iv) a stem cell specific promoter; (v) a somatic cell specific promoter; (vi) a T cell receptor (TCR) alpha, beta, gamma or delta promoter; (v) a B cell specific promoter; (vi) a CD19 promoter; (vii) a CD20 promoter; (viii) a CD22 promoter; (ix) a B29 promoter; and (x) a T cell or a B cell V(D)J specific promoter.
42. 40. The method of any one of claims 1 to 39, wherein the nucleotide sequence of the Insert Donor Composition to be inserted comprises a sequence encoding a protein operably linked to a promoter.
43. 43. The method of claim 42, wherein the promoter is selected from the group consisting of: (i) a T cell specific promoter; (ii) a CD3 promoter; (iii) a CD28 promoter; (iv) a stem cell specific promoter; (v) a somatic cell specific promoter; (vi) a T cell receptor (TCR) alpha, beta, gamma or delta promoter; (v) a B cell specific promoter; (vi) a CD19 promoter; (vii) a CD20 promoter; (viii) a CD22 promoter; (ix) a B29 promoter; and (x) a T cell or a B cell V(D)J specific promoter.
44. 44. The method of any one of claims 1 to 43, wherein the nucleotide sequence of the second donor DNA inserted into the genome encodes: (i) a T cell receptor (TCR) protein; (ii) an IgA, IgD, IgE, IgG or IgM protein; or (iii) a kappa or lambda chain of an IgA, IgD, IgE, IgG or IgM protein.
45. 44. The method of any one of claims 1 to 43, wherein the nucleotide sequence of the second donor DNA inserted into the genome encodes the CDR1, CDR2 or CDR3 region of a T cell receptor (TCR) protein.
46. 44. The method of any one of claims 1 to 43, wherein the nucleotide sequence of the second donor DNA inserted into the genome encodes a chimeric antigen receptor (CAR).
47. 47. The method of claim 46, wherein insertion of the nucleotide sequence encoding the CAR results in operably linking the nucleotide sequence encoding the CAR to an endogenous T cell specific promoter.
48. 44. The method of any one of claims 1 to 43, wherein the nucleotide sequence of the second donor DNA inserted into the genome encodes a multivalent surface receptor.
49. 49. The method of claim 48, wherein the cell is a T cell.
50. 50. The method of claim 48 or 49, wherein the multivalent surface receptor is a bispecific or trispecific chimeric antigen receptor (CAR) or a T cell receptor (TCR).
51. 44. The method of any one of claims 1 to 43, wherein the nucleotide sequence of the second donor DNA inserted into the genome encodes a cell-specific targeting ligand that is membrane-bound and presented extracellularly.
52. 44. The method of any one of claims 1 to 43, wherein the nucleotide sequence of the second donor DNA that is inserted into the genome encodes a reporter protein.
53. 53. The method of claim 52, wherein the reporter protein is a fluorescent protein.
54. 54. The method of claim 52 or 53, wherein the nucleotide sequence encoding the reporter protein is operably linked to a cell-specific or tissue-specific promoter.
55. 54. The method of claim 52 or 53, wherein the nucleotide sequence encoding the reporter protein is operably linked to a constitutive promoter.
56. 56. The method of any one of claims 1 to 55, wherein the nucleotide sequence of the second donor DNA to be inserted into the genome comprises a nucleotide sequence encoding a protein without introns.
57. 57. The method of claim 56, wherein the nucleotide sequence without introns encodes all or a portion of a TCR protein or an immunoglobulin.
58. the method comprising introducing a first and a second of the delivery vehicles into the cell; (1) the nucleotide sequence of the second donor DNA of the first delivery vehicle that is inserted into the genome encodes a T cell receptor (TCR) α or δ subunit, and the nucleotide sequence of the second donor DNA of the second delivery vehicle that is inserted into the genome encodes a TCR β or γ subunit; or (2) the nucleotide sequence of the second donor DNA of the first delivery vehicle that is inserted into the genome encodes a T cell receptor (TCR) α or γ subunit, and the nucleotide sequence of the second donor DNA of the second delivery vehicle that is inserted into the genome encodes a TCR β or δ subunit; or (3) The method of any one of claims 1 to 57, wherein the nucleotide sequence of the second donor DNA of the first delivery vehicle that is inserted into the genome encodes a kappa chain of an IgA, IgD, IgE, IgG, or IgM protein, and the nucleotide sequence of the second donor DNA of the second delivery vehicle that is inserted into the genome encodes a lambda chain of an IgA, IgD, IgE, IgG, or IgM protein.
59. the method comprising introducing a first and a second of the delivery vehicles into the cell; the nucleotide sequence of the second donor DNA of the first delivery vehicle that is inserted into the genome encodes a constant region of a T cell receptor (TCR) α or δ subunit; the nucleotide sequence of the second donor DNA of the second delivery vehicle that is inserted into the genome encodes a constant region of a TCR β or γ subunit; 58. The method of any one of claims 1 to 57.
60. the method comprising introducing a first and a second of the delivery vehicles into the cell; (1) the nucleotide sequence of the second donor DNA of the first delivery vehicle is inserted within a nucleotide sequence that functions as a promoter for a T cell receptor (TCR) alpha or delta subunit, and the nucleotide sequence of the second donor DNA of the second delivery vehicle is inserted within a nucleotide sequence that functions as a promoter for a TCR beta or gamma subunit; or (2) the nucleotide sequence of the second donor DNA of the first delivery vehicle is inserted within a nucleotide sequence that functions as a promoter for a T cell receptor (TCR) α or γ subunit, and the nucleotide sequence of the second donor DNA of the second delivery vehicle is inserted within a nucleotide sequence that functions as a promoter for a TCR β or δ subunit; or (3) The method of any one of claims 1 to 57, wherein the nucleotide sequence of the second donor DNA of the first delivery vehicle is inserted within a nucleotide sequence that functions as a promoter of a kappa chain of an IgA, IgD, IgE, IgG, or IgM protein, and the nucleotide sequence of the second donor DNA of the second delivery vehicle is inserted within a nucleotide sequence that functions as a promoter of a lambda chain of an IgA, IgD, IgE, IgG, or IgM protein.
61. The method of any one of claims 1 to 60, wherein the cell is a mammalian cell.
62. The method of any one of claims 1 to 61, wherein the cell is a human cell.
63. (a) a nuclease composition comprising one or more sequence-specific nucleases or one or more nucleic acids encoding the one or more sequence-specific nucleases; (b) a target donor composition comprising a first donor DNA comprising a target sequence for a site-specific recombinase; (c) a recombinase composition comprising the site-specific recombinase or a nucleic acid encoding the site-specific recombinase, wherein the site-specific recombinase recognizes the target sequence; and (d) an Insert Donor composition comprising a second donor DNA comprising a nucleotide sequence of interest for insertion into the genome of the target cell. Including; (a), (b), (c) and (d) are payloads as part of the same delivery vehicle; composition.
64. 64. The composition of claim 63, wherein the delivery vehicle is a nanoparticle.
65. 65. The composition of claim 64, wherein the nanoparticle comprises a core comprising (a), (b), an anionic polymer composition, a cationic polymer composition, and a cationic polypeptide composition.
66. 66. The composition of claim 64 or 65, wherein the nanoparticle comprises a targeting ligand that binds the nanoparticle to a cell surface protein.
67. 67. The composition of claim 66, wherein the cell surface protein is CD47.
68. 68. The composition of claim 67, wherein the targeting ligand is a SIRPα protein mimetic.
69. 69. The composition of claim 68, wherein the nanoparticle further comprises an endocytosis-inducing ligand.
70. 70. The composition of any one of claims 63 to 69, wherein the payload forms one or more deoxyribonucleoprotein complexes or one or more ribo-deoxyribonucleoprotein complexes.
71. 71. The composition of any one of claims 63-70, wherein the delivery vehicle is a targeting ligand conjugated to a polypeptide domain that is a charged polymer, the targeting ligand providing binding to a cell surface protein, and the polypeptide domain that is a charged polymer electrostatically interacting with one or more of the payloads.
72. 72. The composition of claim 71, wherein the delivery vehicle further comprises an anionic polymer that interacts with one or more of the payload and the polypeptide domain that is the charged polymer.
73. 71. The composition of any one of claims 63 to 70, wherein the delivery vehicle is a targeting ligand associated with one or more of the payloads, the targeting ligand providing binding to a cell surface protein.
74. 71. The composition of any one of claims 63-70, wherein the delivery vehicle comprises a targeting ligand coated water-in-oil-in-water emulsion particle, an oil-in-water emulsion micelle particle, a multilamellar water-in-oil-in-water emulsion particle, a multilamellar particle, or a DNA origami nanobot.
75. 72. The method of any one of claims 66 to 71, wherein the targeting ligand is a peptide, ScFv, F(ab), nucleic acid aptamer or peptoid.
76. The composition of any one of claims 63 to 70, wherein the delivery vehicle is non-viral.
